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ABSTRACT 
Clostridium difficile (C. difficile) is a leading cause of healthcare-associated infections 
(HAIs) and an important public health threat. Recently, the prevalence C. difficile PCR 
ribotype 002 in the UK has been noted, yet the drivers for this increased prevalence 
remain unclear. The aim of this study was to characterise C. difficile PCR ribotype 002 
(CD002) isolates from different time lineages and assess any phenotypic and genotypic 
traits that may help explain the emergence of this ribotype.   
 
A total of 60 clinical isolates of CD002 (isolated between 2007-2014 in the UK and across 
Europe) were used in this study. Antimicrobial susceptibilities to a range of antimicrobial 
agents were assessed using the agar dilution method. Maximum specific growth rate 
(µmax) was measured by batch culture growth curves, and cytotoxin production (log10 
relative units (RU)) was evaluated in a Vero cell cytotoxicity assay. Factors associated 
with C. difficile persistence: sporulation capacity, spore adherence capability, and 
biofilm formation capacity were characterised using standard techniques. For selected 
strains, phenotypic microarrays (PMs) were used to elucidate nutrient utilisation 
profiles, and competition for glucose between isolates from different CD002 lineages 
was investigated in a single-stage fermenter. Using 1D SDS gel electrophoresis, followed 
by Liquid Chromatography-Tandem Mass spectrometry (LC-MS/MS), the whole cell 
proteomes of three CD002 isolates were compared.  
 
All CD002 were susceptible to metronidazole, vancomycin, fidaxomicin, 
chloramphenicol, linezolid, tetracycline (MICs ≤ 2 mg/L), and resistant to trimethoprim 
(MICs >128 mg/L) and ciprofloxacin (MICs ≥8 mg/L). Resistance to clindamycin (27% 
n=16), erythromycin (3.3%, n=2), moxifloxacin, nitrofurantoin and rifampicin (1.7%), was 
present. All but one C. difficile isolate demonstrated intermediate resistance to 
ampicillin and penicillin (MICs >1mg/L). One UK isolate of the UK 2007-8 lineage was 
classified as multidrug-resistant (MDR). The µmax of non-UK 2012-14 strains was 
significantly higher (0.92 h-1, p<0.001) than that of strains from the UK (2007-2014). 
Cytotoxin titres did not differ significantly between lineages (median titres 2-3 RU). The 
sporulation formation capacities for recent CD002 (UK and Non- UK) were significantly 
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higher (p<0.001) than those of the older isolates. Spore adherence capability did not 
differ significantly between CD002 lineages. Recent CD002 (UK 2011-13 & Non-UK 2012-
14) strains formed significantly more profuse biofilms in vitro than the older strains 
(p<0.001). The recent CD002 (UK 2011-13 & Non-UK 2012-14) appeared to have more 
expanded nutrient utilisation profiles than older CD002 isolates, and one recent UK 
strain outcompeted a recent Non-UK strain for glucose. Analysis of whole-cell 
proteomes revealed similarities and differences between strains that suggest a minimal 
adaptation of the proteome in CD002 has occurred over time.  
 
To conclude, the study uncovered some differences between the different lineages of 
CD002. The increased sporulation, higher µmax, greater biofilm formation, abundance of 
spores in mature biofilms, and the utilisation of several nutrient substrates, 
demonstrated by recent C. difficile PCR ribotype 002, suggests that they may have a 
competitive advantage over other ribotypes, therefore increasing their prevalence in 
recent years. However, whether these factors, have a greater in vivo implication for this 
ribotype, remains to be determined. 
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1 INTRODUCTION 
 
1.1 CLOSTRIDIUM DIFFICILE 
1.1.1 Historical Background 
The bacterium Clostridium difficile was first reported in 1935, when Hall and O’ Toole isolated 
a new obligate anaerobe, from the meconium and stools of new-born infants(Hall & O’toole, 
1935). They named this organism Bacillus difficilis (In Latin ‘difficile stands for ‘difficult’) to 
reflect the difficulty involved in its isolation and characterisation(Bartlett, 2008). Hall and 
O’Toole further evaluated the organism’s ability to cause disease in an experiment using 
rabbits and guinea pigs. B. difficilis was found to be highly pathogenic to animals studied,  as 
cultures or filtrates caused marked oedema and eventually death following 48h subcutaneous 
injection(Hall & O’toole, 1935). They suggested that an exotoxin released by the organism 
was responsible for its pathogenicity. Consequently, Hall and O’Toole postulated that toxins 
produced by the organism played a role in conditions such as the formation of occult blood 
and febrile convulsions of the new-born(Snyder, 1937). Two years later, Snyder performed a 
follow-up study and found B. difficilis in 10% of infant faecal samples. Snyder’s study further 
confirmed the bacterium characteristics described in Hall and Toole’s study. B. difficilis was 
later renamed Clostridium difficile and placed in the genus of Clostridium spp (Kuipers & 
Surawicz, 2008). Since then, it has been proposed to be re-classified as Peptoclostridium 
difficile (Yutin & Galperin, 2013). More recently, a further reclassification to a novel genus, 
Clostridioides, was proposed, to reflect the organism’s phenotypic, chemotaxonomic and 
phylogenetic characteristics which differ from other members of the genus Clostridium. As a 
result, it has been officially reclassified from Peptoclostridium difficile to Clostrioides difficile 
 2 
 
(Lawson et al .,2016). However, for the purpose of this thesis the more familiar and popular 
name, Clostridium difficile, is retained. 
1.1.2 Clostridium difficile as a pathogen 
Following initial reports, Smith & King reviewed eight cases of C. difficile of human infections. 
C. difficile was found to exist as a commensal rather than a pathogen in all the cases reviewed. 
As a result, the authors concluded that C. difficile was not pathogenic to man(Smith & King, 
1962). Subsequently, C. difficile was not regarded as a pathogenic organism until an 
experiment using germ-free rats by Hammarström and colleagues (1969) demonstrated the 
organism's pathogenic ability. The authors reported the development of transient diarrhoea 
in rats mono-contaminated with C. difficile, which occasionally led to death (Hammarström 
et al., 1969). Little was known about the organism until the late 1970s when three 
coincidental independent reports provided evidence to show that C. difficile was the 
etiological agent for the development of antimicrobial-associated pseudomembranous colitis 
(PMC) (Bartlett et al.,1978; George et al., 1978; Tedesco et al., 1974).  
In 1974, Tedesco et al found a significant link between clindamycin administration and the 
development of PMC in patients(Tedesco et al., 1974).  In the same year, Green reported the 
presence of cytotoxin in the stools of guinea pigs that developed diarrhoea after receiving 
penicillin treatment(Green, 1974). Three years later, Bartlett and colleagues described 
clindamycin–induced colitis in hamsters and reported an unidentified toxin-producing 
Clostridium species present in the faeces of symptomatic animals(Bartlett et al.,1977). This 
organism was subsequently identified as C. difficile. Larson and colleagues later reported the 
presence of a cytotoxin in the faeces of four out of five patients with histologically proven 
PMC(Larson et al., 1978). Other studies soon followed and this provided confirmation that C. 
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difficile was a cause of antibiotic-associated diarrhoea and PMC in man(Bartlett et al., 1978, 
1977; Larson et al., 1978; Tedesco et al., 1974). 
1.1.3  Morphology  
C. difficile is a Gram-positive, rod-shaped, spore-forming, and obligatory anaerobic bacterium, 
which is a member of the family phylum Firmicutes(Lawson et al., 2016). As a member of 
Firmicutes, C. difficile possesses low G+C content chromosomal DNA, and a cell wall 
peptidoglycan that contains meso-DAP (a diagnostic di-amino acid) (Lawson et al., 2016).C. 
difficile can exist in two forms; as vegetative cell and an endospore (Fig 1-1). Vegetative cells 
of C. difficile are 3- 16.9 µm in length, 0.5 - 1.9µm in width and produce oval-shaped sub-
terminal spores that are highly resistant to a variety of physical and chemical conditions, thus 
prolonging C. difficile survival in the environment (Hafiz & Oakley, 1976). C. difficile is a 
heterotrophic organism with an optimal growth temperature of 37˚C, most strains are motile 
and possess peritrichous flagella and multiple fimbriae(Lawson et al., 2016; Sebaihia et al., 
2006). Colonies of C. difficile on blood agar plates following 48 hours incubation in anaerobic 
conditions at 37℃ appear typically large (2-5 mm), flat, rhizoidal edge and slightly grey in 
colour with a matt to a glossy surface(Lawson et al., 2016). One characteristic feature that 
differentiates C. difficile from other species of clostridia is its ability to decarboxylate 
parahydroxyphenylacetic acid to produce para-cresol (p-cresol), which gives C. difficile its 
characteristic pig-like smell (Hafiz & Oakley, 1976). Recent evidence suggests that p-cresol 
production contributes to the virulence of C. difficile in vivo (Passmore et al., 2018). 
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Figure 1-1 Phase-contrast micrograph of a C. difficile spore preparation. Showing phase-bright 
endospores (white arrow) and vegetative cells (black arrow) (Dembek et al., 2013) 
 
1.1.4 C. difficile Infection (CDI) 
Since the identification of C. difficile as a pathogen, it is recognised as one of the leading 
causes of healthcare-associated infections worldwide (Planche & Karunaharan, 2017). In 
2013, C. difficile became classified as an urgent public health threat by the US Centre for 
Disease Control and Prevention (CDC, 2013). The annual incidence of nosocomial C. difficile 
infection (CDI) in the USA is almost 500,000 cases, resulting in 29,000 deaths, with estimated 
costs of over $4.8 billion in acute care facilities (Lessa et al., 2015). Several studies showed an 
increased incidence, severity and recurrence rate in CDI, surpassing methicillin-resistant 
Staphylococcus aureus (MRSA) as the most common hospital-acquired infection in the 
USA(Gupta & Khanna, 2014; McGlone et al., 2012; Miller et al., 2011). In the UK, the annual 
number of cases which had been increasing steeply since 2001, declined significantly from 
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2007- 2014 (Figure 1-2) and has now plateaued (Planche & Karunaharan, 2017). This is 
attributed to the introduction of the Clostridium difficile Ribotyping Network (CDRN) in 2007, 
as well as the mandatory surveillance and reporting of CDI cases (Both Trust and Non- Trust 
Apportioned) in England(Public Health England, 2018). 
 
 
Figure 1-2 Clostridium difficile laboratory report data for England, both mandatory and 
voluntary reporting data (Planche & Karunaharan, 2017). 
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1.2 VIRULENCE FACTORS AND PATHOGENESIS OF C. DIFFICILE  
1.2.1 Toxin A and B  
C. difficile produces two main toxin virulence factors, toxin A (TcdA), an enterotoxin, and toxin 
B (TcdB), a cytotoxin. These exotoxins TcdA and TcdB have a molecular mass of 308kDa and 
270kDa respectively. Both toxins belong to the large clostridial toxin (LCT) family together 
with C. sordellii lethal and haemorrhagic toxin and C. novyii alpha-toxin(Braun et al., 1996). C. 
difficile exists naturally as either toxigenic (toxin-producing) or non-toxigenic strains, and both 
are capable of colonising their host. 
TcdA and TcdB are encoded on a 19.6-kb pathogenicity locus (PaLoc), together with three 
other regulatory genes tcdC, tcdE, and tcdR (Figure 1-3). The two toxin genes are closely 
aligned, separated by an intervening sequence (tcdE). The toxins are greatly expressed during 
the late-log and stationary phases of growth due to environmental stimuli(Di Bella et al., 
2016). Baines et al reported that some hypervirulent strains produce toxins earlier in their 
growth cycle, but peak toxin titres were not greater than strains of other ribotypes (e.g. 
001)(Baines et al., 2008). 
tcdE is an accessory gene, with homology to phage holin proteins and is positioned in between 
tcdA and tcdB on the PaLoc(Wee et al., 2001). The role of TcdE in CDI pathogenesis is poorly 
understood. Prior studies provided conflicting evidence on the role of TcdE, in facilitating the 
release of toxins into the extracellular environment(Govind & Dupuy, 2012; Olling et al., 2012; 
Wee et al., 2001). Subsequently, Govind and colleagues validated the role of TcdE as they 
demonstrated its capacity to release of TcdA and TcdB in C. difficile R20291(Govind et al., 
2015). The authors suggested that the disparity in evidence from earlier studies(Govind & 
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Dupuy, 2012; Olling et al., 2012) may be attributed to the use of different strains by both 
studies. 
tcdR encodes an alternative RNA polymerase sigma factor, and the major positive regulator 
of toxin expression that responds to the environmental stimuli(Di Bella et al., 2016; Girinathan 
et al., 2017; Voth & Ballard, 2005). It is located next to tcdB on the PaLoc and increases during 
stationary phase(Voth & Ballard, 2005). A recent study suggested that the role of tcdR may 
be strain-specific, as a mutation in this gene affected both sporulation and toxin production 
in C. difficile R20291 strain, but not in C. difficile 630Δerm strain (Girinathan et al., 2017). 
tcdC is located next to tcdA on the PaLoc and transcribed differently from toxin genes, it is 
highly expressed in the early exponential phase, and its expression declines as growth moves 
to stationary phase(Bakker et al., 2012; Hundsberger et al., 1997). This decline is shown to be 
consistent with the increase in toxin production, suggesting that tcdC negatively regulates 
toxin production for both toxin genes(Merrigan et al., 2010; Vohra & Poxton, 2011).  
 
The relative significance of the two toxins in CDI pathogenesis has long been a debate. Initial 
reports indicated that TcdA was the only toxin associated with the development of disease 
and therefore the major virulence factor(Lyerly et al., 1985). Subsequently, Lyras et al refuted 
this claim when their study revealed that TcdB, was 100-1000 fold more toxic to cultured cells 
than TcdA, suggesting that TcdB and not TcdA was essential for virulence(Lyras et al., 2009). 
Contrastingly, Kuehne et al indicated that both toxins play an important role in the 
development of CDI(Kuehne et al., 2010).In that study, TcdA+ TcdB- were as likely as wild type 
strains expressing both toxins to cause disease in animal models, suggesting that both toxins 
contribute equally to the pathogenesis (though toxin B makes a larger contribution to 
virulence)(Kuehne et al., 2010). It is noteworthy that some ribotypes have deletions in their 
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PaLoc that abrogate the production of Toxin A or Toxin B (e.g. RT 017, RT033 & RT047)but not 
their capacity to cause disease (al-Barrak et al., 1999; Alfa et al., 2000; Kim et al., 2008; Pituch 
et al., 2001; Toyokawa et al., 2003; Wang et al.,2018). 
1.2.1.1 Regulation and Expression of C. difficile toxins A and B 
The regulation and expression of C. difficile toxins A and B are influenced by a variety of 
environmental stimuli that are activated by the synthesis of the tcdR gene. Short chain fatty 
acids (such as butyric acid) and subinhibitory concentrations of antibiotics are known to 
induce toxin production(Aldape et al., 2013; Chilton et al., 2012; Karlsson et al., 2000). 
Conversely, several amino acids (such as cysteine) within the bacterial environment repress 
toxin production through the action of a GTP-sensing transcriptional pleiotropic repressor 
CodY (Dineen et al.,2010; Karlsson et al., 2000; Nawrocki et al., 2016). Additionally, rapidly 
metabolisable carbohydrates such as glucose have been shown to inhibit the production of 
toxins through the action of the global transcriptional regulator, carbon catabolite 
control/repressor protein (CcpA) (Antunes et al., 2012; Fletcher et al., 2018). The sigma factor 
sigD, that is associated with the expression of motility genes, promotes toxin expression 
through binding to a SigD dependent promoter sequence(Mackin et al., 2013). The signalling 
molecule cyclicdi-guanosyl-5’monophosphate(c-di-GMP), associated with adhesion, 
aggregation and biofilm formation has been shown to repress the transcription of toxin 
encoding genes and tcdR(Mackin et al., 2013). The master sporulation regulator, Spo0A, has 
recently been shown to regulate toxin expression, but only in some strains of C. 
difficile(Mackin et al., 2013; Pettit et al., 2014). Also, quorum sensing studies show that toxin 
synthesis is regulated by an accessory gene regulator (agr) quorum-signalling system, which 
is mediated through the action of a novel thiolactone quorum signalling peptide (Figure 1-
3)(Darkoh et al., 2015; Mackin et al., 2013). Several studies indicated that many of these 
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factors are strain-dependent, which suggests that toxin regulatory mechanisms have evolved 
independently to modulate the pathogenesis of CDI(Baban et al., 2013; Girinathan et al., 
2017; Lyon et al., 2016; Mackin et al., 2013). 
1.2.1.1 Mechanism of action C. difficile toxin A and B  
TcdA and TcdB display a high degree of similarity at the amino acid level, suggesting that they 
may have arisen from a gene duplication event (von Eichel-Streiber et al.,1992). Both toxins 
harbour four functional domains: a catalytic glycosyltransferase domain, cysteine protease 
domain (responsible for autocatalytic processing), a translocation domain that mediates the 
entry of the toxin into the cell and a C-terminal receptor binding domain, consisting of a series 
of repeating oligopeptides (also known as CROP: combined repetitive oligopeptides) that is 
truncated in toxin B (Albesa-Jové et al., 2010; Pruitt et al., 2009; Pruitt et al., 2010; Pruitt & 
Lacy, 2012). 
C. difficile toxins are taken up into the cells by receptor recognition and binding to the C- 
terminal domain, which triggers endocytosis of the toxins into the cellular endosome. The 
endosome is then acidified, resulting in a structural conformational change of the toxin, 
consequently, leading to the formation of a pore, and translocation into the cell cytosol 
(Figure1-4)(Pruitt et al., 2010). Once inside the cell, a host cytoplasmic inositol 
hexakisphosphate (InsP6) induces autocatalytic cleavage, mediated by a C. difficile aspartate 
protease(Pruitt et al., 2009). This cleaving event results in the release of glycosyltransferase 
domain into the host cell cytosol where glycosylation of the Rho family of GTPases (Rho, Rac, 
and Cdc42) occurs. Subsequently, there is a disruption of the actin cytoskeleton, inhibition of 
cell division, membrane trafficking and eventual alteration of the intestinal epithelial. This 
results in increased intestinal permeability and fluid accumulation which subsequently 
manifests as diarrhoea, a hallmark symptom of CDI (Smits et al.,2016)
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Figure 1-3 The pathogenicity locus of Clostridium difficile The schematic of the 19.kb C. difficile PaLoc, showing the two major toxins; TcdA and TcdB (encoded 
by tcdA and tcdB genes), the negative and positive regulatory genes tcdC and tcdR and the putative holin-like protein tcdE gene. Other regulators (sigma D 
(SigD), cyclicdi-guanosyl-5’monophosphate(c-di-GMP), the nutritional repressor CodY (known as GTP-sensing transcriptional pleiotropic repressor CodY), 
catabolite control protein A (CcpA), Stage 0 sporulation protein A (Spo0A) and quorum sensing (QS)(Thiolactone) that affect toxin gene transcription mostly 
act via expression of the tcdR gene(Adapted from, Voth & Ballard, 2005). 
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Figure 1-4  Mechanism of TcdA and TcdB entry into the cells. TcdA and TcdB consist of four domains; catalytic glycosyltransferase domain 
(GTD)(grey), cysteine protease domain(orange), translocation domain(green)and the C-terminal receptor binding domain(yellow). Toxins bind 
to the cell membrane via the C- terminal and are internalised by receptor-mediated endocytosis. Once Internalised, the acidic environment 
results in a conformation change to the toxins that allows insertion into the endosomal membrane and pore formation. Subsequently, 
autoproteolytic processing of the toxins occurs, and GTD is released into the cytosol by inositol hexakisphosphate InsP6. GTD glycosylated the 
Rho family of GTPase that results in damage to the actin cytoskeleton and cell integrity(Adapted from Pruitt & Lacy, 2012).
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1.2.1.2 The emergence of Hypervirulent C. difficile  
In the early 2000s, the epidemic of CDI significantly increased due to the emergence and 
predominance of a hypervirulent strain, causing several outbreaks and increasing disease 
severity (Loo et al., 2005; Pepin et al., 2005; Pépin et al., 2004). This strain was characterised 
as restriction endonuclease analysis group BI, pulse-field gel electrophoresis type NAP1, and 
polymerase chain reaction ribotype 027, designated BI/NAP1/027(Killgore et al., 2008; 
McDonald et al., 2005). This strain has been recovered from patients in many countries across 
Europe, North America, Asia, South America and Australia(Collins et al., 2013; Hernández-
Rocha et al., 2012; Kuijper et al., 2006; Quesada-Gómez et al., 2010; Riley et al., 2009; Tae et 
al., 2009). In addition, BI/NAP1/027 has been associated with increased purported toxin 
production, high sporulation rates and fluoroquinolone resistance (Akerlund et al., 2008; He 
et al., 2013; McDonald et al., 2005; Warny et al., 2005). Initial studies suggested that 
mutations (∆117 frameshift mutation and 18bp deletion) observed in the tcdC gene is 
responsible for the elevated toxin production demonstrated by BI/NAP1/027 strains (Curry et 
al., 2007; MacCannell et al., 2006; Warny et al., 2005). However conflicting reports did not 
support the role of tcdC as a significant repressor of toxin production. Contrary to initial 
studies, Merrigan and colleagues found no significant difference in the amounts of toxin 
produced by both hypervirulent and non-hypervirulent strains in the exponential phase, 
suggesting that TcdC played a modulatory rather than a repressive one (Merrigan et al., 2010). 
Subsequently, studies by Vohra and Poxton supported these findings as increasing levels of 
tcdC transcription also coincided with increased transcription of toxin genes(Vohra & Poxton, 
2011). Furthermore, Cartmen et al reported no association with tcdC and toxin production in 
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both hypervirulent strain (R20291) and wild type (C. difficile 630). Suggesting that tcdC is not 
the major repressor of toxin production(Cartman et al., 2012). 
The emergence of other hypervirulent strains and has since been reported. These include 
strains of PCR ribotypes 017, 018 and 078, which have been linked to outbreaks of CDI 
(Barbanti & Spigaglia, 2016; Berger et al., 2019; Cairns et al., 2017, 2015; Goorhuis et al., 2008; 
Hung et al., 2016). PCR ribotype 078 (Toxinotype V), produces toxin A and B, as well as the 
binary toxin, while PCR ribotype 018 only produces toxin A and B. Although strains of PCR 
ribotype 017 (Toxinotype VIII) harbour almost the entire tcdA gene, prior studies revealed a 
1.8 kb deletion in the repeating region (3’ end)(Figure 1-5(Imwattana et al., 2019)), and a 
point mutation in the 5’ end that abrogates the production of the toxin A(Drudy et al., 
2007;Von Eichel-Streiber et al., 1999). In addition, strains of this ribotype do not produce the 
binary toxin and possess no mutations in the tcdC gene. Isolates belonging to ribotype 017 
and 018 and are reportedly multi-drug resistant (MDR), as they are resistant to more than 
two or antimicrobial classes (Barbanti & Spigaglia, 2016; Freeman et al., 2018; Isidro et al., 
2018; Spigaglia et al., 2010). 
 14 
 
 
 
 Figure 1-5 A diagram showing the variations in the Paloc of C.difficile strains. A)The PaLoc of  toxin A positive and toxin B positive C.difficile strains. B)The 
Paloc of C.difficile ribotype 017 (A- B+ ) strains showing the nonsense mutation near the 5’ terminal of the tcdA and the 1.8 kb deletion near the 3’ end that  
abrogates the production of TcdA. The arrows indicate open reading frames and the direction of transcription. (Adapted from Imwattana et al., 2019). 
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1.2.2 C. difficile binary toxin (CDT) 
Some C. difficile strains, particularly ribotype 027 and 078, produce a third toxin, known as a 
C. difficile binary transferase (CDT)(Lyon et al., 2016).CDT was first described in 1988 as a 
member of binary ADP-ribosylating toxin family, specifically iota-like subfamily of binary 
toxins which includes C. perfringens iota and C. spiroforme toxin (Barth et al., 2004; Popoff et 
al., 1988).  
CDT is encoded by two genes cdtA (50kDa), and cdtB, (100kDa), that are located on a 4.3 kb 
genomic region referred to as Cdt locus (CDTLoc)(Carter et al., 2007). This region contains 
both toxin genes and a regulatory protein cdtR (Figure 1-6), recently cdtR has been shown to 
regulate the production of TcdA and TcdB in epidemic 027 strains (Lyon et al., 2016). Strains 
lacking this toxin have a conserved 68-bp sequence in place of the CDT Locus (Carter et al., 
2007). As with all binary toxins, CDT comprises an enzymatic (CdtA) and a binding (CtdB) 
component. CdtB binds to a cellular receptor, leading to the internalization of CdtA into the 
cytosol. This, in turn, catalyses the ADP- ribosylation of actin, leading to disruption of the actin 
cytoskeleton, excessive fluid loss, cell rounding and eventual cell death(Carter et al., 2007). 
The exact role of this toxin in disease pathogenesis is controversial, with animal studies 
providing conflicting evidence. Geric and colleagues suggested that the binary toxin is not 
essential for disease, but maybe important for colonisation, as supernatants from four A-/B-
/CDT+ strains resulted in colonisation and not disease or death in hamsters(Geric et al., 2006). 
Contrastingly, Kuehne et al indicated that knock out strains of epidemic strain R20291 with 
only CDT gene were virulent in a hamster model (Kuehne et al., 2014). In addition, Schwan et 
al reported that CDT aids adherence to intestinal epithelial cells by the formation of 
microtubule protrusions (Schwan et al., 2009).CDT has been shown to be more prevalent in 
 16 
 
strains isolated from animals, with the CDT structural genes being found in approximately 
23% to 100% of these isolates(Carter et al., 2007). In addition, several cases of CDI were 
reported in France that was linked to TcdA- TcdB- CDT+, suggesting that this toxin may play an 
important role in disease pathogenesis(Eckert et al., 2015). A retrospective study by Bacci et 
al indicated that human infections with CDT-producing strains of C. difficile yielded greater 
mortality when compared to infections caused by strains that did not produce CDT (regardless 
of ribotype) suggesting that the binary toxin contributes to the severity of CDI(Bacci et 
al.,2011).  
 
 
Figure 1-6 The CDT locus of C. difficile, showing the toxin and regulatory genes (cdtA, cdtB and 
cdtR)(Carroll & Bartlett, 2011). 
 
1.2.3 Adhesion factors 
The colonisation of the colon is a key factor in the full manifestation of CDI. C. difficile 
colonisation of the gut is facilitated by adhesion to the mucosal epithelium, making this step 
crucial to disease pathogenesis. The ability of C. difficile to adhere to the human gut was first 
reported in by Borriello, who detected the presence of C. difficile cells under the microscope, 
in a washed biopsy sample from patients with PMC(Borriello, 1979). Subsequently, several 
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non-toxin related virulence factors that play a key role in adherence and colonisation have 
been identified and partially characterised.    
1.2.3.1 Surface layer proteins (SLP)  
The S-layer proteins (SLP) are proteinaceous layers produced by many bacteria including C. 
difficile. They are mainly composed of two protein subunits commonly referred to as high 
molecular weight and low molecular weight proteins which display inter-strain variability in 
C. difficile (Calabi et al., 2002). These proteins are encoded by slpA and formed from the post-
translational cleavage by the protease Cwp84 (Dang et al., 2010). There is evidence to show 
that these proteins play a role in colonisation, acting as adhesins assisting the interaction 
between C. difficile cells and the gut cells (Calabi et al., 2002). In a recent study, antibodies 
against SlpA were able to inhibit the adherence of C. difficile to cultured cells (Merrigan et al., 
2013).In addition to adherence, several studies show that SLPs play an important role in 
immune recognition and inflammatory response(Bianco et al., 2011; Fagan et al., 2011; Ryan 
et al., 2011). Thus far, the best-characterised S-layer proteins are Cwp84 (84kDa) and Cwp66. 
As initially stated, Cwp84 is involved in the processing of the S-layer while Cwp66 (66kDa) is 
implicated in adherence (de la Riva et al., 2011). Cwp66 contains two domains, each carrying 
three imperfect repeats and one showing a correlation with the autolysin CwIB in Bacillus 
subtilis(Waligora et al., 2001). Studies suggest that the adhesive capability of Cwp66 in C. 
difficile may be heat shock-mediated. As reduced adherence of heat-shocked C. difficile to 
cultured cells was observed in the presence of antibodies against Cwp66 (Waligora et al., 
2001).  
1.2.3.2 Other Adhesion Factors  
C. difficile strains are known to possess flagella for motility, although this is a variable trait 
among clonal isolates (Pituch et al., 2002). The two best characterised C. difficile flagellar 
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proteins include FliC (structural monomer) and FliD (cap protein), both of these have been 
shown to participate in the attachment to the intestinal mucus(Tasteyre et al., 2002). 
Currently, the role of flagella in disease pathogenesis is debatable and appears to be strain-
dependent (Baban et al., 2013; Dingle et al., 2011). Some studies suggest that flagella play an 
important role in adherence to intestinal epithelial cells including hypervirulent strain 
(ribotype 027). Conversely, other studies have indicated that the absence of the flagella in 
non-epidemic strains (630∆erm) had little or no effect on adherence, rather mediated 
increased adherence to cells (Baban et al., 2013; Dingle et al., 2011). Flagella have also been 
shown to play a role in the development of C. difficile biofilms (Ðapa et al., 2013).  
 
Some strains of C. difficile have fimbriae which are polar, 4-9nm in width and up to 6µm long 
(Borriello et al., 1988). Earlier studies investigated the importance of fimbriae in disease 
pathogenesis, however, no correlation was established between the presence of fimbriae in 
a strain and its ability to cause disease(Borriello et al., 1988; Taha et al., 2007). A recent 
analysis of Type IV pilus genes in the epidemic strain ribotype 027 (R20291) revealed the 
presence of nine pilin and putative pilin-like genes. Immunization studies using proteins 
produced by 6 of these genes yielded immunological responses in animals (Maldarelli et al., 
2014).  
 
A 58kDa heat shock protein, GroEL, is expressed by C. difficile in response to various 
environmental stress. GroEL was found in the membrane as well as the extracellular space 
following heat-shock (Hennequin et al., 2001). Additionally, the importance of GroEL was 
demonstrated, when GroEL specific antibodies and purified GroEL protein inhibited C. difficile 
adherence to eukaryotic cells in vitro (Hennequin et al., 2001). Vaccination with recombinant 
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GroEL, reduced gut colonization in infected mice, thus supporting the importance of this 
protein in intestinal adhesion (Péchiné et al.,  2013). 
1.2.4 Sporulation 
C. difficile forms highly resistant metabolically dormant endospores as a result of exposure to 
unfavourable conditions such as temperature, nutrient limitation, and extremes of pH (Rupnik 
et al., 2009).The spore is formed within the mother cell, which ensures its preservation until 
spores encounter favourable conditions for germination and outgrowth. C. difficile spores are 
ubiquitous, especially in the nosocomial environment, where they persist on hospital surfaces 
for long periods (Vedantam et al., 2012). The ability of spores to persist in the environment is 
believed to be a key factor in the acquisition and transmission of CDI.  
It is hypothesised that spores ingested by a susceptible host, are able to survive the low pH 
environment in the stomach and reach the small intestine where germination occurs upon 
exposure to bile salts(Paredes-Sabja et al., 2014). There are several bile salts that induce the 
germination of C. difficile, however, sodium taurocholate is the most effective, glycine and 
thioglycolate serve as co-germinants (Crobach et al., 2018; Sorg & Sonenshein, 2008). An 
earlier study indicated that patients with CDI can excrete high levels of spores to the 
environment for 1 to 4 weeks after CDI treatment (Sethi et al., 2010). Additionally, an in vitro 
study by Paredes-Sabja & Sarker (2012) demonstrated the adherence of C. difficile spores to 
the surface of the intestine. Spores, which are not affected by antimicrobial therapies 
commonly used in the treatment of CDI, can then germinate and recolonise the host 
gastrointestinal tract before the normal microflora recovers after antibiotic treatment, 
causing a relapse of infection (Hopkins & Wilson, 2018; Paredes-Sabja & Sarker, 2012). 
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There is some debate regarding the association between strains of the hypervirulent ribotype 
027, and the greater production of spores. Several studies noted that some clinical C. difficile 
isolates, especially those of the hypervirulent ribotype 027, germinated more efficiently and  
formed more spores in vitro  than non-epidemic ribotypes(Akerlund et al., 2008; Merrigan et 
al., 2010; Moore et al., 2013; Vohra & Poxton, 2011), however, subsequent studies reported 
no association(Burns et al., 2011; Heeg et al., 2012). 
1.2.4.1  Sporulation pathway in C. difficile   
Sporulation is an ancient process of bacterial cell differentiation largely conserved among 
Clostridiales and Bacillales (Dembek et al., 2015; Higgins & Dworkin, 2012). Sporulation in C. 
difficile, like other spore-forming bacterial organisms, is a complex process that results in the 
formation of a resistant spore from a vegetative cell. This process is largely regulated by 
external signals which trigger a signalling cascade of sigma factors to initiate sporulation 
(Fimlaid et al., 2013). Little is known about the signals that trigger C. difficile sporulation, 
however, studies suggest that it could be related to environmental stimuli such as nutrient 
starvation, quorum sensing, and other unidentified stress factors (Higgins & Dworkin, 2012). 
Although the sporulation pathway in C. difficile has been extensively studied, the molecular 
mechanisms that govern their composition and formation remain poorly understood. 
Sporulation studies in Bacillus subtilis (B. subtilis) provides insight into the sporulation 
pathway in C. difficile (Fimlaid et al., 2013).   
The entry into sporulation of B. subtilis is controlled by Spo0A, a master regulatory protein 
which becomes activated by a phosphorelay cascade (Higgins & Dworkin, 2012). Accordingly, 
Spo0A activates downstream regulators which initiate the sporulation process and repress 
vegetative cell functions. Activated Spo0A triggers an asymmetric division, yielding two 
distinct cells, a pre-spore (also known as forespore), and the mother cell (Figure1-7) (Pereira 
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et al., 2013). Soon after division, sporulation-specific RNA sigma factors required for gene 
expression in the forespore and mother cell are sequentially activated. The four-cell type-
specific sigma factors (σF, σE, σG, and σK) are alternated between the two cells. Sigma F and E 
control the early stages of development in the two cells and are replaced by sigma G and K in 
the later stages of development (Fimlaid et al., 2013; Pereira et al., 2013). Sigma F is activated 
in the forespore, while sigma E is activated in the mother cell. Sigma E activates production 
of spore coat proteins and communicates with the forespore for the activation of sigma G. 
Sigma G initiates the signalling cascade that results in the activation of sigma K, this leads to 
the assembly of the spore outer coat (Pereira et al., 2013).   
 
During the asymmetric division, a septum is formed which divides the prespore from the 
mother cell. Whilst the septum is being formed, the chromosome replicates to form an axial 
filament (Dembek et al., 2015; Fimlaid et al., 2013). The remaining section of the chromosome 
is actively transported into the forespore and segregated from the mother cell with the 
completion of the septum formation. This results into two distinct cells, both with a complete 
chromosome. The mother cell surrounds the forespore and compresses the membrane off in 
the way to completely engulf the forespore. Following this, the chromosome in the forespore 
is reconstructed into a circular structure, a thick cell wall and the protective protein coat is 
formed, this completes the full synthesis of the spore. Subsequently, the mother cell is lysed 
(programmed cell death), liberating the mature spore (Pereira et al., 2013).   
 
Although the sporulation activities in B. subtilis are quite similar to those in other Clostridium 
species, recent studies have highlighted some differences (Pereira et al., 2013). The main 
periods of activity for the four cell-type sigma factors are highly conserved in C. difficile 
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relative to B. subtilis (Pereira et al., 2013). The main observable difference with B. subtilis was 
that sigma E activity was partially independent of sigma F and sigma G or K did not require 
sigma E or sigma G. Pereira et al suggested that the connection between the forespore and 
mother cell lines of gene expression in C. difficile were weaker compared to those observed 
in B. subtilis (Pereira et al., 2013). 
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Figure 1-7 Schematic of the main morphogenetic stages in the process of sporulation. Mother cell 
(MC) and forespore (FS) (Adapted from Pereira et al., 2013) 
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1.2.5 Biofilms 
Biofilms are complex communities of microorganisms enclosed in a self–produced 
extracellular matrix composed primarily of exopolysaccharides(Costerton et al., 1999). The 
transition of a bacterial cell from planktonic to biofilm growth occurs as a survival strategy in 
response to environmental stresses such as nutrient starvation (Semenyuk et al., 2014). 
Numerous studies have established the link between biofilms and many human 
infections(Costerton et al., 1999; Delcaru et al., 2016; Høiby et al., 2010; Sonesson et al., 
2017). However, biofilm formation by individual gut species, particularly anaerobic species, is 
poorly understood (Dapa & Unnikrishnan, 2013). The formation of C. difficile biofilms has 
been shown to be modulated by central regulators such as Spo0A and LuxS and by adhesion 
factors such as flagella and the cysteine protease Cwp84 (Dapa & Unnikrishnan, 2013; Dawson 
et al., 2012; Pantaléon et al., 2015). 
 
The role of biofilms in CDI has not been fully established. Nevertheless, there is evidence to 
show that C. difficile forms microbial communities in the host gastrointestinal tract (Lawley 
et al., 2012). Using murine studies, the adherence of C. difficile to mucus and intestinal cell 
lines with the formation of cellular aggregates was revealed(Lawley et al., 2012). This 
suggested that C. difficile can form part of intestinal biofilms, thus facilitating recurrent 
infections through the germination of C. difficile. Initially, the presence of spores in C. difficile 
biofilms was debatable but recent studies revealed the abundance of spores in biofilms of the 
organism (Crowther et al., 2014; Dawson et al., 2012; James et al., 2018; Semenyuk et al., 
2014). 
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However, the gastrointestinal tract biofilms are composed of complex mixtures of gut 
microorganisms, therefore pure culture studies of C. difficile biofilms may elicit data that is of 
limited relevance to the complex situation likely to be observed in vivo. Consequently, 
complex gut model biofilms have been developed in order to study the interplay between the 
gut microflora, C. difficile (spores and vegetative forms), and antimicrobial agents during 
simulated CDI(Crowther et al., 2014b). An in vitro gut model study by Crowther and colleagues 
observed dormant C. difficile spores in the sessile gut communities, in comparison to their 
planktonic counterpart(Crowther et al., 2014a). The authors simulated recurrent CDI, 
following the cessation of antimicrobial therapy in the gut model and suggested that intestinal 
biofilms may serve as a potential reservoir for C. difficile spores. Additionally, consistent with 
other biofilms, C. difficile in biofilms have been shown to have reduced susceptibility to 
vancomycin, which is one of the first-line therapies for CDI (Ðapa et al., 2013). 
 
1.2.5.1   Biofilm formation in C. difficile  
Like many other bacteria, the formation and development of biofilms in C. difficile are 
characterised by three important processes; initiation, maturation and disassembly 
(Kostakioti et al., 2013; Vlamakis et al., 2013). The process begins with the formation of a 
heterogeneous community through the attachment of planktonic cells to a surface, leading 
to the formation of microcolonies (Semenyuk et al., 2014). After initial attachment, the 
bacterial population increases as a result of cell division and density-dependent cell-cell 
communication known as quorum sensing is initiated. The resident bacteria become enclosed 
in an extracellular polymeric substance (EPS) that can be made up of polysaccharides, amino 
acids, and nucleic acids. The EPS serves as a protective barrier for the organisms. 
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Subsequently, there is development and maturation of the biofilm architecture, this stage is 
also aided by cell-cell communication between microbial colonies. The next phase is the 
development and maturation of the biofilm architecture, and this is facilitated by cell-cell 
communication. As cells mature, biofilms release D-amino acids, consequently leading to the 
dissolution of mature biofilms, and the released bacteria can colonise new surfaces (Vlamakis 
et al., 2013).   
 
1.3 RISK FACTORS FOR CDI 
1.3.1 Prior hospitalisation 
C. difficile is usually nosocomially acquired, as a result, most cases arise due to hospitalisation 
or use of long-term care facilities. The prevalence of C. difficile spores in the nosocomial 
environment is considered a great risk factor as patients are more likely to become colonised 
or develop CDI in the hospital setting. Studies have described a high rate of C. difficile 
colonization (10-35%) among hospitalised patients and 4-20% of residents in long- term care 
facilities(Barbut & Petit, 2001; Kuijper et al., 2006; Simor et al., 2002).In addition, isolation of 
C. difficile from stool samples of the hospital inpatients is reported to be proportional to the 
length of hospital stay (Kuijper et al., 2006). 
1.3.2 Antibiotic exposure  
The major risk factor in the development of CDI is the prior use of one or more courses of 
antibiotics for the treatment of an infection. Reportedly, most antibiotics have potential to 
induce CDI, some antibiotics such as clindamycin, cephalosporins, aminopenicillins and 
fluoroquinolones are associated with a relatively higher risk of C. difficile infection (Rupnik et 
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al., 2009). Several studies have demonstrated that by restricting the use of these antibiotics, 
the rates of CDI significantly reduced (Carling et al., 2003; Kallen et al., 2009; Gaynes et al., 
2004; Valiquette et al., 2007). The use of antimicrobial agents is known to disrupt the 
protective host microbiota, leading to the loss of colonization resistance by the host, as a 
result, patients become susceptible to infections caused by opportunistic bacterial pathogens 
(Johanesen et al., 2015). Studies have shown that antibiotics in the gut facilitate the 
germination and outgrowth of C. difficile spores, increased toxin production and the 
expression of colonization factors that all aid in full manifestation of CDI (Adams et al., 2007; 
Aldape et al., 2013; Chilton et al., 2012; Heinlen & Ballard, 2010; Saxton et al., 2009). 
1.3.3 Age  
The risk and severity of CDI increase with age due to the reduction in health status. In one 
study, it was revealed that the risk of CDI during an outbreak was 10 times great in the elderly 
(<65years of age) than the younger population (Depestel & Aronoff, 2013). Although CDI is 
mostly reported in the elderly population, there is an increasing incidence of CDI in the 
younger population (Baker et al., 2010; Benson et al., 2007; Dumyati et al., 2012; Khanna et 
al., 2012). A population-based study by Khanna et al showed a striking increase of CDI among 
the younger population over the last 20 years, with most cases arising from the community 
setting(Khanna et al., 2012). However, the drivers of increased CDI prevalence among the 
younger population in the community are yet to be identified.  
1.3.4 Proton pump inhibitors (PPIs) 
The use of proton pump inhibitors has been linked to the development of CDI, however 
this remains a controversial risk factor as many studies appear to conflicting (Aseeri et al., 
2008; Cunningham et al., 2003; Dial et al., 2004; Janarthanan et al., 2012; Kim et al., 2010; 
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Kwok et al., 2012; Linsky et al., 2010; McDonald et al., 2015; Ro et al., 2016). A potential 
mechanism for this phenomenon is the reduction of gastric acid secretion by PPIs in the 
stomach. Which results increased stomach pH that facilitates the passage of ingested C. 
difficile that can colonise the gut and cause disease (Gupta & Khanna, 2014). It is not 
exactly clear how gastric acid suppression may increase the risk of CDI, however, it has 
been proposed that spores may be stimulated to germinate by bile salts while increased 
pH may allow the survival of vegetative cells (Dial et al., 2006). The link between PPI 
exposure and CDI was demonstrated by Hung and colleagues in an animal study. Hung and 
colleagues observed an increase in the severity of C. difficile associated colitis in mice after 
PPI exposure, suggesting that PPIs play an important role in CDI (Hung et al., 2013). It is 
reported, that incessant use of PPIs in the community (being one of the most prescribed 
medications for acid – related disorders) is particularly significant to a subset of 
community-acquired CDI without prior antibiotic exposure (Chitnis et al., 2013). Suggesting 
that, the disruption of the microbiota, following PPI exposure, may be sufficient to cause 
disease(Clooney et al., 2016; Imhann et al., 2016; Seto et al., 2014).  
 
1.4 CLINICAL MANIFESTATIONS OF CDI 
C. difficile can cause a spectrum of clinical manifestations, ranging from asymptomatic 
carriage to life-threatening infections that can be fatal (Smits et al., 2016). 
1.4.1 Asymptomatic Colonisation 
Asymptomatic C. difficile colonisation is a condition whereby C. difficile is detected in 
individuals without clinical symptoms of CDI (Furuya-Kanamori et al., 2015). Evidence from 
earlier studies shows that asymptomatic C. difficile colonisation provides a protective effect 
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against CDI through an immune-mediated response(Kyne et al., 2000, 2001). Recently, it was 
proposed that asymptomatic carriage may lead to C. difficile co-colonisation with other 
members of the gut microbiota, and therefore serve as a protective factor for CDI (Vincent et 
al., 2016). The prevalence of asymptomatic C. difficile colonisation varies depending on age 
and geographical location. According to reports from several studies, approximately 17.5% of 
healthy adults are colonised by C. difficile, with 1-5 % being colonised by toxigenic strains(Eyre 
et al., 2013; Galdys et al., 2014; Ozaki et al., 2004; Terveer et al., 2017). Prevalence of up to 
50% is found in elderly patients in long term care facilities, health-care workers and patients 
with underlying diseases (e.g. cystic fibrosis) (Arvand et al., 2012; Bauer et al., 2014; Hell et 
al., 2012; Riggs et al., 2007). In addition, a high prevalence of colonisation has been reported 
in neonates, and healthy infants of up to 2 years of age, as they have been considered 
insensitive to free C. difficile toxins due to their lack of the mature toxin- binding necessary 
for disease causation(Jangi & Lamont, 2010; Rousseau et al., 2012; Schäffler & Breitrück, 
2018). It is suggested that asymptomatic carriers serve as reservoirs for disease transmission 
in the environment(Eyre et al., 2013; Riggs et al., 2007). Riggs et al suggested that 
asymptomatic carriage of epidemic and non-epidemic C. difficile strains have the potential to 
contribute disease transmission in long term care facilities(Riggs et al., 2007).  
1.4.2  Mild or moderate CDI 
C. difficile is the cause of approximately 25-30% of all cases of antibiotic-associated diarrhoea 
(AAD)(Bartlett & Gerding, 2008). While a large proportion of the remainder is due to an 
osmotic imbalance within the large intestine(Walk & Young, 2008). In this scenario, the 
bacteria responsible for breaking down fermentable starch are eliminated by antimicrobial 
therapy, as a result, dietary sugar is not being metabolised (Walk & Young, 2008). 
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Consequently, there is an increased intestinal permeability and fluid accumulation that results 
in diarrhoea. 
For mild to moderate CDI patients experience watery diarrhoea occurring between 1-2 hours, 
within 2 weeks after antimicrobial therapy (Goudarzi et al., 2013). Other clinical 
manifestations include abdominal cramps, sub-febrile temperature, nausea and leucocytosis 
(Postma et al.,2015). Overall, fever, leucocytosis and abdominal cramps occur in about 15%, 
50%, and 22% of cases, respectively(Bartlett & Gerding, 2008). Elevated creatinine, elevated 
lactate and hypoalbuminemia are the common laboratory findings in mild-moderate CDI 
cases. Physical examination demonstrates lower abdominal tenderness (Potsma et al., 2015).  
Evidence of CDI colitis includes abdominal pain, nausea, malaise, anorexia, watery diarrhoea, 
and in some cases, a trace of blood in the stool(Postma et al., 2015). In addition, low-grade 
fever, dehydration, pyrexia and leukocytosis may be present. The sigmoidoscopic 
examination may reveal a nonspecific diffuse or patchy erythematous colitis without 
pseudomembranes (Bartlett & Gerding 2008). 
1.4.3 Severe CDI 
Pseudomembranous colitis (PMC) is one of the severe forms of CDI, and C. difficile causes 95% 
of PMC(Farooq et al., 2015). Unlike mild or moderate CDI, PMC is characterised by the 
formation of pseudomembranes in the colorectal mucosa. Clinical symptoms include 
abdominal cramp, dehydration, hypoalbuminemia, watery diarrhoea, rising inflammatory 
cells, serum proteins and mucus (Vaishnavi, 2010). Sigmoidoscopic examination reveals 2-
10mm yellow plaques in the colorectal mucosa (Figure 1-8) and in rare cases the terminal 
ileum. 
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Figure 1-8 The appearance of the colon from a patient with pseudomembranous colitis, with 
yellow plaques in the colorectal mucosa (Adapted from Natural health news, 2017). 
 
Fulminant colitis is considered the most serious form of CDI occurring in approximately 3-8% 
of cases.The increase in fulminant colitis has been attributed to the emergence of 
hypervirulent C. difficile strain BI/NAP-1/027(Dallal et al., 2002; Nakamura et al., 2014; Oguri 
et al., 2019; Tagashira et al., 2013).Fulminant colitis results in the development of symptoms, 
multiple organ failure and increased mortality (Goudarzi et al., 2013).Patients with fulminant 
colitis experience severe lower abdominal pain, watery diarrhoea, abdominal distention, 
hypovolemia and lactic acidosis. Some symptoms are accompanied by fever and marked 
leukocytosis (up to 40,000 WBC/μL). Occasionally, little or no diarrhoea may be experienced 
due to paralytic ileus resulting from colon dilatation (Potsma et al., 2015). Advanced 
complications of fulminant colitis may result in bowel perforation and toxic megacolon. 
Patients with signs and symptoms of bowel perforation may experience abdominal rigidity, 
tenderness and reduced bowel sound. Abdominal radiography may also reveal free 
abdominal air (Postma et al., 2015). Patients with toxic megacolon experience clinical signs of 
severe systemic toxicity (e.g. fever, tachycardia, leukocytosis, anaemia) and colonic dilation 
Yellow Plaques  
 31 
 
(i.e. diameter >6cm) (Vaishnavi, 2010). Surgical interventions are often required to prevent 
further complications and death. 
1.4.4 Recurrent CDI (RCDI) 
One of the characteristic features of CDI is its propensity to recur. Recurrences occur in 
approximately 20-30% of primary CDI cases, and 40-60% of recurrent cases (McFarland et al., 
2002; Paredes-Sabja & Sarker, 2012). Recurrence may be either due to relapse or reinfection 
and this has been demonstrated using several enhance typing methodologies, including 
whole-genome sequencing (WGS)(Eyre et al., 2014; Marsh et al., 2012). Approximately 10- 
40% of patients experience recurrent symptoms of CDAD within 8 weeks after successful 
initial therapy (Vancomycin or metronidazole)(McFarland et al., 1999). Recurrence is often 
associated with treatment failure where C. difficile has not been successfully eradicated from 
the gut following the cessation of antibiotic therapy, and patients become infected with the 
same strain or another strain(Marsh et al., 2012). Many studies show that fewer recurrences 
occur after treatment with oral vancomycin, however, recent studies indicated that oral 
fidaxomicin is more effective in the treatment of recurrent CDI(Cornely et al., 2012; Eyre et 
al., 2014; Chilton et al., 2016; Louie et al., 2012).In vitro CDI gut model studies suggest that 
fidaxomicin becomes sequestered into biofilms, persists on spores by adhering to the 
exosporium and therefore inhibits outgrowth and proliferation by remaining active in the gut 
for longer than vancomycin(Chilton et al., 2016, 2014). Recurrent CDI is a significant 
socioeconomic burden as it increases the length of hospital stay and overall cost of 
hospitalization. The pathogenesis of recurrent CDI is not clear, however, studies suggest that 
recurrence may be due to an impaired immune response to C. difficile toxins or and alteration 
of the colonic microbiota (Cornely et al., 2012; Louie et al., 2012). 
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1.5   DIAGNOSIS  
1.5.1 Clinical diagnosis 
Due to the incidence and severity of CDI, rapid and accurate diagnosis has been sought after 
for timely patient management and prevention of nosocomial transmission. Accurate 
diagnosis of CDI relies on the combination of both clinical and laboratory 
diagnosis(Napolitano & Edmiston, 2017). The  Society for Healthcare and Epidemiology of 
America (SHEA) guidelines on CDI diagnosis recommend that laboratory testing should be 
performed when one or either of the following clinical presentation are observed; the 
presence of diarrhoea (≥3 unformed stools in a 24 hour period) or a radiographic evidence of 
ileus or toxic megacolon or histopathologic findings indicating the presence of 
pseudomembranous colitis(Bartlett & Gerding, 2008; Cohen et al., 2010; Debast et al., 2014; 
Rao & Higgins, 2016). 
1.5.2 Laboratory diagnosis  
There is currently no single diagnostic test that is used for CDI, instead several methods exist, 
and are divided into three groups: test for C. difficile products (glutamate dehydrogenase 
(GDH), TcdA and or TcdB); culture methods for the detection of toxin-producing C. difficile 
(Cell culture cytotoxicity neutralisation assay (CCNA) and toxigenic culture (TC)) and Nucleic 
acid amplification test (NAAT) for C. difficile genes (detecting 16S rRNA, toxin genes or genes 
encoding GDH)(Crobach et al., 2016).  
1.5.2.1 Cytotoxin detection 
Cytotoxin detection techniques (CCNA and TC), are considered the gold standard technique 
for CDI diagnosis, and both methods detect the presence of C. difficile toxins in stool samples 
(Timothy et al., 2011).CCNA is performed by inoculating the monolayer of an appropriate cell 
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line (i.e. Vero cells) with stool filtrates, which is then observed at 24 and 48h intervals, for the 
presence of C. difficile toxin. This is demonstrated by a cytopathic effect (CPE)(Delme´e, 2001) 
along with neutralisation of the CPE with a C. sordellii antitoxin. Toxigenic culture (TC) is 
similar to CCNA, however, faecal samples are cultured on a selective differential medium 
(usually cefoxitin, cycloserine egg yolk agar) first, which in theory will inhibit the growth of 
other faecal organisms other than C. difficile (Wren, 2010). The recovered isolate is then 
tested for the ability to produce toxin. In addition, toxigenic culture only gives information on 
whether the C. difficile strain can produce toxin. While both methods are reportedly sensitive 
(94%-100), they appeared to be laborious and time-consuming, which limited their 
practicality for diagnostic testing (Burnham & Carroll, 2013). 
1.5.2.2 Enzyme Immunoassays (EIA) 
Enzyme immunoassays (EIAs) have been adopted by most laboratories because of their 
simplicity, and faster turnaround times (Burnham & Caroll, 2013). Toxin A/B EIAs directly 
detect free toxins in stools, while GDH EIAs, detects glutamate dehydrogenase (GDH), a 
metabolic enzyme that is produced by both toxigenic and non-toxigenic strains (Crobach et 
al., 2016). Although both methods are economical, their sensitivity and specificity are very 
low. Compared to CCNA and TC, the pooled sensitivity of EIAs ranged between 57- 83%, 
however, their specificity was reported to be 99% (Crobach et al., 2016). The pooled 
sensitivity of GDH EIAs compared to CCNA and TC is 94-96% respectively (Crobach et al., 
2016). However, they cannot make a distinction between the presences of toxigenic or non- 
toxigenic strains and are thus less specific to detect disease.  
1.5.2.3 Nucleic Acid amplification tests (NAAT) 
The use of NAATs for the detection of C. difficile from stool specimens was reported in 1993 
(Gumerlock et al., 1993). Since then, a variety of NAATs targeting genes encoding TcdB, TcdA, 
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and/or the binary toxin genes have been developed (Burnham &Carroll, 2013). Available 
NAATs, include PCR assays, helicase dependent amplification assays and loop-mediated 
isothermal amplification assay. NAATs are reportedly as sensitive as CCNA and TC (95-96% 
respectively) and more specific (compared to CCNA and TC 94% and 98 % respectively) than 
GDH EIA as the only detect toxigenic strains of C. difficile.  Although NAATs are superior to 
other diagnostic methods for CDI, this testing method only detects the presence of toxin 
genes. As a result, it will also detect asymptomatic carriers of toxigenic C. difficile (Crobach et 
al., 2016; Peng et al., 2018). 
1.5.2.4 Two-step algorithms  
Owing to the large variation in sensitivity and specificity of the various diagnostic test for CDI, 
the ability to accurately distinguish between C. difficile colonization and disease is difficult 
(Smits et al., 2016). Consequently, the European Society for Clinical Microbiology and 
Infectious Diseases (ESCMID) recommends a two-step algorithm (Figure 1-9), with either 
NAAT or GDH-EIA tests (First Step) to maximise diagnostic accuracy(Polage et al., 2015). 
Samples with a negative result from either NAATs or GDH-EIA tests can be reported as 
negative for CDI, but samples with a positive result are further tested by a toxin-EIA as a 
second step (Crobach et al.2016). Samples confirmed positive by the second toxin- EIA test 
and then reported as CDI positive (Peng et al., 2018). 
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Figure 1-9 Algorithms for CDI testing as recommended by ESCMID guidelines. a) GDH or 
NAAT- Tox A/B algorithm, b) GDH and Tox A/B- NAAT/TC algorithm (Crobach et al., 2016). 
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1.6 TREATMENT OF CDI  
1.6.1 Metronidazole 
Metronidazole, a nitroimidazole compound has been recommended as a treatment for CDI 
since the late 1990s (Gerding et al., 2008) It is the first choice therapy for treatment for mild 
to moderate CDI due to its good antimicrobial activity against C. difficile strains (Debast et al., 
2014; Owens et al., 2008). Metronidazole, a prodrug, executes bactericidal activity by 
reduction of the 5-nitro group of the imidazole ring to become cytotoxic to bacterial 
cells(Edwards, 1993). In anaerobic organisms, metronidazole is reduced by microbial 
nitroreductases to a cytotoxic nitro radical, which binds non-specifically to bacterial DNA, 
resulting in damage characterised by helix disruption and strand breakage(Löfmark et al., 
2010).  
Although resistance to metronidazole is currently rare, prior studies have identified treatment 
failure and relapse post-metronidazole therapy(Musher et al., 2005). Reduced susceptibility 
(MIC >2mg/l) and resistance to metronidazole in C. difficile strains (with MIC values of ≥8 to 
32mg/l) have been reported in different regions of the world (Baines et al., 2008; Freeman et 
al., 2015).A recent pan- European surveillance (ClosER) study, reported metronidazole 
resistance in 0.11% (MIC <8µg/ml) of strains investigated (Freeman et al., 2015).  A recent 
investigation in Eastern China showed that 15.6% of strains recovered from hospitalised 
patients (between 2012-2015) were metronidazole resistant, including one non-toxigenic 
isolate (MIC>256µg/ml)(Jin et al., 2017). Meanwhile, in the Middle East, 5-5.3% of clinical 
isolates tested between 2010 and 2011 in Iran are reportedly resistant to metronidazole and 
18.3% of strains in Israel were metronidazole resistant (Adler et al., 2015; Goudarzi et al., 
2013; Shayganmehr et al., 2015). 
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Some studies indicated that C. difficile exhibits hetero-resistance to metronidazole (Peláez et 
al., 2008). In vitro studies suggest that sub-inhibitory concentrations of metronidazole had a 
role in selecting and maintaining colonies with increased MICs(Moura et al., 2013; Peláez et 
al., 2008), making this phenomenon a matter of concern in the treatment of CDI. C. difficile 
mechanism of reduced susceptibility and resistance to metronidazole is yet to be elucidated 
Metronidazole resistance studies, in Helicobacter pylori and Bacteroides fragilis, identified the 
presence of nim genes (nimA-G) associated with resistance (Albert et al., 2005; Baines et al., 
2008; Gal & Brazier, 2004; Kaakoush et al., 2009). Recent studies on RT027 and RT010 strains 
suggest that the mechanism of resistance may be multifactorial, involving alterations in 
different metabolic pathways, such as the activity of nitroreductases, iron uptake and DNA 
repair (Chong et al., 2014; Moura et al., 2014). Data obtained from recent in vitro studies 
demonstrated that subinhibitory concentrations of metronidazole can enhance biofilm 
formation of RT010, suggesting that biofilms may play a role in C. difficile resistance to 
metronidazole(Vuotto et al., 2016).  
1.6.1 Vancomycin 
Vancomycin, a glycopeptide is a first-line therapy for moderate to severe CDI (Debast et al., 
2014). Vancomycin exerts bactericidal activity by the inhibition of peptidoglycan synthesis 
(Arthur et al., 1996). Vancomycin is a large hydrophilic molecule which is orally administered 
due to its poor absorption in the gastrointestinal tract and achieves a high concentration in 
the stool(Gonzales et al., 2010; Spigaglia, 2016). Resistance to vancomycin has rarely been 
reported, however, the emergence of decreased susceptibility (MIC ≥ 4mg/L) has been 
reported in several studies(Freeman et al., 2015; Peláez et al., 2002). The resistance 
mechanism of C. difficile to vancomycin has not yet been reported, however, published 
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reports on vancomycin resistance in Enterococcus identified the acquisition of vanABDEG 
genes resulting in the production of peptidoglycan precursors with reduced affinity to 
glycopeptide antibiotics (Courvalin, 2006). These genes have not been identified in C. difficile, 
however C. difficile does possess vanRSGXYT putative proteins (VanG-like gene cluster), which 
is functional but somehow prevented from conferring resistance (Ammam et al., 2012; 
Ammam et al., 2013). Leeds et al identified mutations in the rpoC gene, CD2725, CD3659 and 
sdaB of C. difficile isolates with reduced susceptibility to vancomycin, and suggested that this 
may contribute to reduced susceptibility(Leeds et al., 2014). 
1.6.2 Fidaxomicin 
Fidaxomicin is a macrocyclic narrow spectrum, a bactericidal antimicrobial agent, used for the 
management of CDI with the risk of recurrences (Debast et al., 2014). Its mechanism of action 
results in the inhibition of protein synthesis. It has a minimal impact on the composition of 
the indigenous gut microbiota, particularly Bacteroides species, due to its narrow spectrum 
of activity (Artsimovitch et al., 2012; Louie et al., 2012). Fidaxomicin is very active against C. 
difficile isolates in vitro, exhibiting lower MICs (0.02-0.025mg/L) (Baines &Wilcox, 2015; 
Freeman et al., 2015). When administered orally, fidaxomicin is poorly absorbed in the gut, 
resulting in high faecal concentration (>1000µg/g) that exceed the MIC of C. difficile (Sears et 
al., 2012). Evidence of reduced susceptibility (MIC 2-4 mg/L) and resistance (MIC 16mg/L) of 
C. difficile to fidaxomicin has been reported (Finegold et al., 2004; Goldstein et al., 2011; Leeds 
et al., 2014). Whole-genome sequencing analysis of reduced susceptible isolates of C. difficile 
to fidaxomicin revealed mutations in the RNA polymerase β subunit (rpoB)gene and CD22120 
(marR homologue), indicating that these mutations contribute to reduced susceptibility 
(Leeds et al., 2014). 
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1.6.3 Potential Newer Antibiotics for CDI 
1.6.3.1 Rifaximin 
Rifaximin is a semisynthetic, nonabsorbable antibiotic that inhibits protein synthesis(Neff et 
al., 2013). It is primarily used for the treatment of traveller’s diarrhoea and hepatic 
encephalopathy (Neff et al., 2013). It has demonstrated excellent in vitro activity against C. 
difficile isolates(Marchese et al., 2000)and has also been shown to be as efficient as 
vancomycin in animal studies (Kokkotou et al., 2008). It has been shown to be effective in the 
treatment of first episodes and recurrent CDI (Basu et al., 2010; Garey et al.,  2009; Johnson 
et al., 2009; Rubin et al., 2011). Although promising, resistant strains of C. difficile have 
already been recovered from patients(Liao et al., 2012; Marchese et al., 2000). 
1.6.3.2 Cadazolid 
Cadazolid is a novel fluoroquinolone- oxazolidinone antibiotic which works by the inhibition 
of protein synthesis and weak inhibition of bacterial DNA synthesis as a second effect (Locher 
et al., 2014). This antibiotic has been shown to exhibit potent in vitro activity against clinical 
C. difficile isolates and vancomycin-resistant enterococci, a major risk factor for vancomycin-
treated patients(Chilton et al., 2014; Seiler et al., 2016). In addition, cadazolid reduced spore 
and toxin production as well as the recurrence of a simulated CDI, in an in vitro gut model 
study (Chilton et al., 2014).In phase II clinical trial, cadazolid was effective in the treatment of 
first episodes or recurrences of CDI when compared with vancomycin(Louie et al., 2015). The 
efficacy of cadazolid was further investigated in two phase III clinical trials but failed to reach 
its primary endpoint of non-inferiority to vancomycin, in one of the two phases 3 clinical trials. 
As a result, the further development of cadazolid as a treatment for CDI is highly 
unlikely(Gerding et al., 2019). 
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1.6.3.3 Ridinilazole 
Ridinilazole (formerly SMT-19969) is a narrow-spectrum antibiotic that inhibits DNA synthesis 
with poor oral bioavailability(Fehér et al., 2017). Ridinilazole is reportedly highly active against 
multiple isolates of C. difficile and has demonstrated efficacy in both in vitro gut and in vivo 
hamster models(Baines et al., 2015; Bassères et al., 2016; Freeman et al., 2016; Sattar et al., 
2015). The precise mechanism of action is not fully known, however, it has been shown to 
significantly reduce toxin production levels, and demonstrated anti-inflammatory activity in 
vitro on human intestinal cells(Baines et al., 2015; Bassères et al., 2016). Ridinilazole was 
superior to vancomycin in two phase II trials as it sustained clinical response in the treatment 
of CDI(Snydman et al., 2018; Vickers et al., 2017). A Phase III trial is currently ongoing.  
1.6.3.4 Tigecycline  
Tigecycline is a broad-spectrum glycylcycline antibiotic that inhibits protein synthesis (Feher 
et al., 2017). There is evidence to show that tigecycline is effective in the treatment of CDI 
(Fantin et al., 2015; Kim et al., 2014; Kundrapu et al., 2015; Larson et al., 2011). Tigecycline 
has proven to be efficient in the inhibition of toxin production and sporulation of C. difficile 
in vitro  (Aldape et al., 2015; Garneau et al., 2014). However, due to its wide spectrum activity, 
tigecycline may alter the intestinal microbiota significantly, thus there is a potential of 
facilitating primary and recurrent CDI(Bassis et al.,2014).  
1.6.4 Microbiome therapy  
1.6.4.1 Faecal microbiota transplantation 
Faecal microbiota transplantation (FMT) has emerged as a promising therapy for multiple 
recurrent CDI (Debast et al., 2014). Prior to FMT, donors are rigorously screened in order to 
prevent the transmission of communicable diseases(Bakken et al., 2011). Subsequently, the 
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faeces of a healthy donor (Figure 1-10) is introduced into the gut of patient with recurrent 
CDI through a nasogastric tube, colonoscopy or rectal enema (Lee et al., 2016; Youngster et 
al., 2014). The aim of FMT is to restore intestinal microbiota by re-colonising the gut with the 
population of commensal organisms that have been disrupted by antibiotics and rebuild 
colonisation resistance(Braun et al., 1996; Vincent et al., 2016).FMT has shown efficacy in the 
treatment of multiple recurrent CDI and fulminant CDI(Emanuelsson et al., 2014; Gravito-
Soares et al., 2017; Lagier et al., 2015; Lee et al., 2016; Tabbaa et al.,2018; Youngster et al., 
2014). Although FMT has been successful over the years, the long -term safety and efficacy of 
this therapy still remain unclear(Sbahi & Di Palma, 2016; Tabbaa et al., 2018).   
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Figure 1-10 C. difficile infection and the role of faecal microbiota transplantation. Ingestion of antibiotics results in disruption of the gut flora, 
2 Ingestion of spores, 3 Spores germinate resulting in dysbiosis of the gut flora, 4 Development of CDI, 5 FMT and 6 Restored 
microbiota(Geoghegan et al.,2017).
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1.6.4.2 Stool- substitute therapies   
Several studies have investigated the efficacy of stool- substitute therapies in the treatment 
of CDI. Khanna et al investigated the efficacy of a spore mixture (SER-109) to prevent 
recurrent CDI in a phase Ib clinical trial(Khanna et al., 2016). The spore mixture was derived 
from stool samples of healthy donors. After elimination of the rest of the microbiota with 
ethanol, the spore mixture comprised of Firmicutes spores. The aim of this therapy is to 
restore the microbiota diversity through the competition of strains with C. difficile in the gut. 
Promising results were achieved in the phase Ib trial as the gut microbiota diversity was 
increased, and 29 (96.7%) out of 30 patients with multiple recurrent CDI, had no further 
recurrences during the study period(Khanna et al., 2016). Despite initial results in phase Ib, 
SER-109 failed to meet the primary efficacy endpoint of reduced CDI occurrences after 8 
weeks in a phase II trial. Sere Therapeutics initiated another phase II clinical trial, and recent 
reports show that SER-109 was able to reduce the abundance of antibiotic resistance genes 
in recurrent CDI cases while increasing the microbiome diversity in subjects(Ford et al., 2018). 
In addition, higher doses of SER-109 resulted in an increase of secondary bile acids and the 
prevention of recurrent CDI in the gut model (Henn et al., 2018). A phase 3 clinical trial on the 
efficacy of SER-109, has been initiated by Seres therapeutics. 
In a small proof- of principle trial, representative species of the gut (33 purified bacterial 
strains, MER-1) derived from a single healthy donor stool sample was used in the treatment 
of two patients with recurrent CDI. The treatment was successful as patients remained free 
of recurrent CDI episodes for six months (Petrof et al., 2013). A clinical pilot study for MER-1 
was initiated in 2016 to assess the efficacy of this drug in comparison to vancomycin for the 
treatment of recurrent CDI. 
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An earlier study, reported the reduced risk of developing CDI in patients asymptomatically 
colonised with non- toxigenic C. difficile strain (NTCD)(Shim et al., 1998). Administration of 
non-toxigenic C. difficile strains has been reported to provide gastrointestinal colonization 
and prevent CDI in hamsters (Nagaro et al., 2013). NTCD strains are thought to compete with 
toxigenic CDI strains in the gut and thus prevent CDI. Advanced research is being done with 
the nontoxigenic C. difficile strains M3, with encouraging results in a recent phase II 
trial(Gerding et al., 2015). However, the possibility that NTCD strains may acquire toxin genes 
by toxigenic strains in vivo may be a matter of concern as this phenomenon has been 
demonstrated in vitro by Brouwer et al. (2013). The transconjugation of the pathogenicity 
locus, which contains toxin A and B genes from toxigenic strains to NTCD was accomplished 
in vitro however, it remains to be determined if this transfer would be possible in vivo or in 
laboratory conditions which closely reflect the conditions within the human colon(Brouwer 
et al., 2013).  
1.6.4.3 Probiotics  
As defined by the Food and Agriculture Organisation (FAO) of the United Nations (UN) and 
the World Health Organisation (WHO), probiotics are “live microorganisms which, when 
administered in adequate amounts, confer a health benefit to the host” (FAO/WHO, 2002). 
Probiotics have been suggested as both a prophylactic and treatment in CDI, however, studies 
have given variable results with regard their effectivity in the treatment of CDI (Lawrence et 
al., 2005; McFarland et al., 1994). Various species of probiotics have been studied, but the 
most common probiotics used are Saccharomyces boulardii and Lactobacillus rhamnosus (Lau 
& Chamberlain, 2016; Lawrence et al., 2005; McFarland et al., 1994). It has been reported 
that Saccharomyces boulardii, secretes a protease which digests toxin A and B molecules and 
its brush border membrane receptor(Castagliuolo et al., 1996; Castagliuolo et al., 1999). In 
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addition, this yeast has been shown to inhibit C. difficile adherence to Vero Cells in vitro  
(Tasteyre et al., 2002). The aim of probiotics as therapy is to re-populate the gut and prevent 
CDI through the action of colonisation resistance (Lau & Chamberlain 2016). Many studies 
that have investigated the effectiveness of probiotics in either the prevention or treatment 
of CDI, however, these results appear to be conflicting(Allen et al., 2013; Johnston et al., 2012; 
Susanne et al., 2012). Recent randomised control trials, demonstrated the effectiveness of 
this therapy, as probiotic supplementation led to a significant reduction in the risk of 
developing CDI in patients receiving antibiotics (Lau & Chamberlain 2016). Although argued 
by some that there is no harm in taking probiotics as a preventative measure; in a severely 
immunocompromised patient and infant’s, probiotics can still cause infection (Munoz et al., 
2005) 
1.6.5  Therapies based on toxins 
1.6.5.1 Tolevamer  
Tolevamer is a novel high molecular mass (>400kDa) non-antimicrobial anionic polymer 
proposed for the treatment of CDI. Tolevamer targets C. difficile toxins A and B and binds non- 
covalently to neutralise their activity. Unlike traditional antibiotics, a major advantage of this 
therapy is that tolevamer has no antimicrobial activity, as a result, there is no disruption of 
the normal gut microflora (Barker et al., 2006). The original tolevamer compound (GT160-
246) attenuated CDI severity and recurrences in preclinical studies(Kurtz et al., 2001). Despite, 
its demonstrated efficacy in the treatment of CDI Phase III clinical trials were ended 
prematurely as results showed that tolevamer was not as effective as vancomycin in treating 
CDI (Louie et al., 2006; Peppe et al., 2008).These results were further replicated in an in vitro 
gut model study(Baines et al., 2009). 
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1.6.6 Immunotherapy  
1.6.6.1 Clostridium difficile toxoid vaccine (ACAM-CDIFF) 
ACAM-CDIFF is a C. difficile toxoid vaccine against C. difficile toxin A and B, developed by 
Sanofi Pasteur. This vaccine stimulates an immune response through the production of serum 
IgG anti-toxin A and serum IgG anti-toxin B antibodies(Anosova et al., 2013; Anosova et al., 
2015). After a  positive immunological response was obtained in both phase I and II trials(de 
Bruyn et al., 2016; Foglia et al., 2012; Greenberg et al., 2012), a phase III randomised control 
trial was launched and is currently ongoing. 
1.6.6.2 Monoclonal antibodies (MAbs) 
Monoclonal antibodies (MAbs) against C. difficile cytotoxins have been proposed for the 
treatment of CDI. Initially, the efficacy of a single administration of MAbs for either toxin A or 
B was debatable (Corthier et al., 1991; Steele et al., 2013). Until enhanced efficacy and lower 
recurrences were observed when the two antibodies (toxin A; actoxumab and toxin B; 
bezlotoxumab) were administered together in a hamster model(Babcock et al., 2006).This 
combination was further compared to standard CDI treatment in a phase II trial, significantly 
lower recurrence rates were reported(Lowy et al., 2010). Despite good results with this 
combination, the efficacy of bexlotoxumab in preventing CDI recurrence was confirmed in 
phase III trials, however, its combination with actoxumab did not show any additional benefit 
(Wilcox et al., 2017). Based on these results the US Food and Drug Administration (FDA) 
recently approved bexlotoxumab, it was made available in the first quarter of 2017 (FDA, 
2016), it is now administered as standard therapy for CDI. 
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1.6.6.3 Passive immunization  
Previous studies have indicated the potential of colostrum hyper-immune bovine colostrum 
(HBC) as a therapy for CDI (Kelly et al., 1996; Steele et al., 2013). HBC was reportedly as 
effective as metronidazole in the treatment recurrent CDI in a discontinued randomised 
phase II study (Mattila et al., 2008). It was recently demonstrated to alleviate the symptoms 
of CDI in gnotobiotic piglets without disrupting the normal gut microbiota (Sponseller et al., 
2015). Meanwhile, a murine study demonstrated the ability of HBC to prevent and treat 
primary CDI and prevent recurrences(Hutton et al., 2017). 
1.6.7 Phage Therapy  
Phages are viruses that infect and replicate within bacteria and their use as therapeutic agents 
began shortly after their discovery in the 20th century(Twort, 1915). Previous studies have 
described isolated phages that can specifically lyse clinically relevant C. difficile ribotypes but 
their use in CDI treatment is still limited(Fortier & Moineau, 2007; Goh et al., 2005; Govind et 
al., 2006; Sekulovic et al., 2014).This mainly due to the lack of strict virulent phages that target 
C. difficile. A recent study examined the therapeutic potential of seven isolated C. difficile 
phages (CDHM 1-6) on multiple C. difficile ribotypes(Nale et al., 2016). CDHM3 was identified 
as the phage with broadest therapeutic potential as it was able to infect 31 out of 80 strains 
from 12 different ribotypes. Additionally, Nale and colleagues observed complete lysis of C. 
difficile in vitro following treatment with a four-phage cocktail (CDHM1, 2, 5, &6)(Nale et al., 
2016). Similarly, the same phage cocktail reduced C. difficile colonisation in a hamster model 
and in Galleria mellonella larva models(Nale et al., 2016a; Nale et al., 2016b; Shan et al., 
2018).  More recent studies using in vitro batch fermentation human colon models have 
provided useful insights into the specificity of C. difficile phages and shown that phages do 
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not have a deleterious impact on members of the gut microbiota(Meader et al., 2010; Meader 
et al., 2013; Nale et al., 2018).  
1.7 ANTIMICROBIAL SUSCEPTIBILITY AND RESISTANCE IN C. DIFFICILE  
1.7.1 Antibiotic resistance patterns  
The antimicrobial resistance patterns in C. difficile varies considerably according to different 
countries and different geographical location. The recent pan- European surveillance study 
that included 22 European countries, report resistance to rifampicin, moxifloxacin and 
clindamycin in multiple ribotypes(Freeman et al., 2018). In addition, antimicrobial 
susceptibility studies of C. difficile published between 2012 and 2015 from different countries 
show that most C. difficile isolates are resistant to clindamycin, cephalosporins, erythromycin 
and fluoroquinolones (Goudarzi et al., 2013; Obuch-Woszczatyński et al., 2014; Pirš et al., 
2013; Tenover et al., 2012). 
1.7.2 Antibiotics linked to induction of CDI   
Fluoroquinolones are a broad spectrum of antimicrobial agents strongly associated with the 
development of CDI (Spigaglia et al., 2010). The in vitro activity of the older fluoroquinolones, 
such as ciprofloxacin, has been reported to be moderate or poor against anaerobes, including 
C. difficile. Conversely, the third- and fourth-generation fluoroquinolones (e.g. moxifloxacin, 
levofloxacin) are characterised by improved activity against anaerobic bacteria(Redgrave et 
al., 2014). Fluoroquinolones are direct inhibitors of DNA synthesis; by binding to the enzyme-
DNA complex, they stabilize DNA strand breaks created by DNA gyrase and topoisomerase IV. 
Alterations in the quinolone – resistance determining region (QRDR) of either gyrA and/or 
gyrB genes, which encode the A and B subunits of enzymes responsible for bacterial DNA 
supercoiling and separation of the two DNA fragments after replication, are reportedly the 
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major mechanism of resistance identified in C. difficile (Baines & Wilcox, 2015). Several amino 
acid substitutions have been identified in both gyrA and gyrB genes, but the most common 
substitution identified in resistant strains is a point mutation Thr82Ile in GyrA(Ackermann et 
al., 2001; Dridi et al., 2002; Kuwata et al., 2015; Spigaglia et al., 2011). In the recent 3- year 
pan-European antimicrobial susceptibility surveillance study (ClosER), moxifloxacin resistance 
was particularly common among prevalent C. difficile ribotypes(RT027, RT001, RT017, RT018, 
RT356 and RT198), and characterised by MIC ≥32mg/L(Freeman et al., 2018; Freeman et al., 
2015). 
Penicillin’s including cephalosporins and aminopenicillins are broad-spectrum β-lactam 
antimicrobial agents that are well recognised for their propensity to induce CDI (Baines & 
Wilcox, 2015). Resistance to β-lactams (particularly cephalosporins) has been reported in C. 
diffficile, however, the mechanisms of resistance is yet to be elucidated(Baines et al., 2013; 
Isidro et al., 2018; Snydman et al., 2011). Genomic analysis of C. difficile 630 genomes 
revealed coding sequences for β-lactamase like proteins and penicillin-binding proteins (PBPs) 
that may be potentially involved in resistance to cephalosporins(Sebaihia et al., 2006). 
However, further studies are required to clarify their role. Studies on imipenem resistance in 
ribotype 017 isolates revealed two amino acid substitutions in the transpeptidase domain of 
the penicillin-binding protein (pbp3-Cys721Ser and pbp1-Ala555Thr)(Isidro et al., 2018a; Isidro 
et al., 2018b).They authors suggested this may contribute to imipenem resistance by reducing 
the affinity of imipenem binding to PBPs. 
Majority of C. difficile strains are resistant to members of the antimicrobial group macrolide-
lincosamide-streptogramin B (MLSB), particularly erythromycin and clindamycin (Solomon et 
al., 2011). Resistance to erythromycin (MIC ≥ 8mg/L) and clindamycin (MIC ≥16-256 mg/L) has 
been identified in multiple C. difficile ribotype, especially ribotype 001, 017, 018 and 027. 
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MLSBs are protein synthesis inhibitors which act by binding to the ribosome 30S subunit. 
Multiple resistance mechanisms have been identified, however, ribosomal methylation, 
mediated by erythromycin ribosomal methylase (erm) genes is the widespread mechanism of 
resistance (Patterson et al., 2007; Solomon et al., 2011; Spigaglia et al., 2011; Spigaglia et al., 
2005).MLSb resistance in C. difficile is encoded by the ermB gene, which is located on a 9.6 kb 
mobilisable nonconjugative element called Tn5398 (Farrow et al., 2001; Mullany et al., 1995). 
ErmB mediates resistance by methylation of bacterial 23S rRNA, leading to inhibition of 
antimicrobial activity. In addition, other transposable elements such as Tn5398-like 
derivatives, Tn6194 and Tn6215 and the cfr (chloramphenicol florfenicol resistance) gene 
have been implicated in C. difficile resistance to MLSB (Dingle et al., 2014; Wasels et al., 2015).  
1.7.3 Other antibiotics  
Tetracyclines are broad-spectrum antibiotics that consist of four fused cyclic rings and are 
effective against aerobic and anaerobic Gram-positive and Gram-negative bacteria (Chopra & 
Roberts, 2001). This family of antimicrobials are considered a low risk for CDI induction. Like 
MLSB antibiotics, tetracyclines are protein synthesis inhibitors that act at the ribosomal level, 
preventing the attachment of aminoacyl-tRNA to the ribosomal acceptor (A) site (Chopra & 
Roberts 2001). Published reports indicated that C. difficile resistance to tetracycline is 
primarily due to either energy-dependent efflux or ribosomal protection via tet genes(Dong 
et al., 2014; Mullany et al., 2012). The tet class of genes are usually carried on several 
transposable elements such as Tn5397, Tn916 or Tn916-like family and Tn6164.  Many studies 
have shown that resistant C. difficile strains carry the tetM gene on the conjugative 
transposon Tn5397(Dong et al., 2014; Jasni et al., 2010; Mullany et al., 2012)and in some 
cases the tetW and tetX genes (Fry et al., 2012; Spigaglia et al., 2008). Both TetM and TetW 
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are cytoplasmic proteins with homology to elongate factors (EF-Tu and EF-G) that protect 
ribosomes from the action of tetracyclines by reducing their susceptibility (Baines & Wilcox 
2015). Spigaglia and colleagues demonstrated the concurrent presence of tetM and tetW in 
three isolates of ribotype 048 and 012 (Spigaglia et al., 2011). 
Recently, linezolid a synthetic antibiotic belonging to a new class of antimicrobial agents, 
known as oxazolidinones has been reported to reduce toxin levels in C. difficile(Baines et al., 
2011). Linezolid is principally active against Gram-positive bacteria and is not currently used 
to treat CDI(Marín et al., 2015). The mechanism of action of linezolid is by inhibiting protein 
synthesis at the ribosomal level through interaction with 23s rRNA(Baines et al., 2011). 
Resistance to linezolid in Gram-positive bacteria is uncommon but has been reported mainly 
in clinical isolates of coagulase-negative staphylococci, Staphylococcus aureus, Enterococcus 
faecaelis, and Enterococcus faecium (Shen et al., 2013). One or more of 3 resistance 
mechanisms to linezolid in these organisms have been reported:  1) point mutations within 
the domain V region of 23S rRNA gene, 2) mutations/deletions in ribosomal proteins L3 (rplC 
gene) and L4 (rplD gene), and 3) methylation of position A2503 of 23SrRNA mediated by an 
rRNA methyltransferase(Long et al., 2010; Marín et al., 2015; Tewhey et al., 2014).C. difficile 
resistance to linezolid has been described in clinical isolates, although possible mechanisms 
of resistance in this species have not been elucidated (Ackermann et al., 2003; Freeman et 
al., 2016; Marín et al., 2015; Peláez et al., 2002). Sequencing results by Marín et al (2015) 
revealed the presence of the cfr gene in 7 out 9 C. difficile linezolid-resistant strains, 
suggesting that the presence of this gene may be the mechanism of resistance. However, the 
exact contribution of these genes in C. difficile resistance to linezolid is still unknown. 
Consistent with these reports, Freeman et al (2016), found a high level of linezolid resistance 
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(≥16mg/L) in RT001, RT017, RT027 & RT356, however, the mechanism of resistance in these 
isolates was not investigated. 
1.7.4 Multi-Drug Resistance in C. difficile  
Multidrug resistance (MDR), is defined as resistance to more than two antimicrobial classes.  
The emergence of multidrug resistance (MDR) among C. difficile isolates, particularly 
hypervirulent BI/NAP1/027, RT078, RT001/072 has been reported in many studies (Goudarzi 
et al., 2013; Senoh et al., 2015; Tenover et al.,  2012). Analysis performed by Spigaglia and 
colleagues in a European based study on 316 clinical isolates of C. difficile indicated that 55% 
of clinical isolates were MDR (Spigaglia et al., 2011).  Data extrapolated from 13 published 
studies indicated that MDR patterns among C. difficile isolates are characterised by resistance 
to clindamycin, fluoroquinolones, erythromycin and cephalosporins (Spigaglia et al., 2016). 
Recent reports indicated that MDR of C. difficile isolates in Europe is associated with emergent 
ribotypes, notably 017, 018, 198 and 356 (Freeman et al., 2015, 2018). These strains are 
resistant to clindamycin, erythromycin, moxifloxacin and rifampicin, however, in Korea and 
Japan, MDR strains of RT018 are resistant to clindamycin, erythromycin and moxifloxacin(Kim 
et al., 2012; Senoh et al., 2015). In Poland and the Czech Republic, MDR is associated with 
strains of RT176, which is resistance to erythromycin, moxifloxacin, ciprofloxacin and 
rifampicin(Krutova et al., 2015; Obuch-Woszczatyński et al., 2014).  
1.8  EPIDEMIOLOGY AND TYPING 
1.8.1 C. difficile Epidemiology in Europe  
In 2005, the European Study Group on Clostridium difficile (ESGCD) performed a 2-month 
survey of 38 hospitals in 14 different European countries. This survey was carried out to obtain 
an overview of the incidence of CDI in Europe. The mean incidence of CDI was 2.45 
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cases/10,000 patient days, but this figure varied widely among the participating hospitals 
(minimum to maximum range; 0.1-7.1)(Barbut et al., 2007; Freeman et al., 2010). PCR 
ribotype 001 was the most common toxigenic isolate (1.), followed by ribotype 014 (9%); PCR 
ribotypes 002, 012, 017, 020 and 027 contributed to 6% of all toxigenic isolates, whereas 
ribotype 078 was found in 3% of toxigenic isolates. The distribution of PCR ribotypes varied 
among the countries studied; however, PCR ribotype 002 was predominant in Switzerland 
(28.6%) France (12.1), and Italy (10.5 %). Higher incidence of CDI was observed in countries 
that had experienced recent outbreaks attributed to ribotype 027 strains (i.e. Netherlands, 
Belgium and France) than countries where 027 had not been reported (Italy, Turkey and 
Greece) (Barbut et al., 2007). Additionally, patients infected with ribotype 027 were more 
likely to have more severe diseases than patients who were infected by another PCR ribotype. 
 
In November of 2008, the European Society of Clinical Microbiology and Infectious Disease 
(ECDIS) Study Group performed the first pan-European Surveillance study. This study was 
sponsored by the European Centre of Disease Prevention and Control (ECDC) and was carried 
out in 69 hospitals in 28 countries in Europe (Bauer et al., 2011).  The incidence of C. difficile 
varied across hospitals (weighted mean 4.1 per 1000 patient’s days per hospital, range 0.0-
36.3). PCR ribotype 014/020 (16%), 001 (9%) and 078 (8%) were the most prevalent ribotypes. 
Additionally, ribotypes 001, 002, 012, 014, 015 018, 027 and 078 were the most common 
ribotypes seen across Europe (Public Health England, 2016). 
In November 2014, reports from a European multicentre, prospective, bi-annual point- 
prevalence study of C. difficile infection in hospitalised patients with diarrhoea (EUCLID study) 
were released. This study included 20 European countries, with 482 participating hospitals 
which were queried for their methods and testing policy for CDI. The reported cases of CDI 
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varied between countries with a mean of 7.0 cases per 10,000 patient bed days (Davies et al., 
2014). The diversity of C. difficile ribotypes across Europe was much greater in this study 
compared with prior European studies (Bauer et al., 2011; Freeman et al., 2010). The most 
common PCR ribotypes encountered in this study included: 027, 001/072, 014, 002,140, 010, 
020, 018, 015, and 005.The prevalence of 027 had risen more than threefold (from 5% to 18 
%) although striking intercountry variation was noted: high endemicity of ribotype 027 was 
shifted from the UK and Ireland in 2008 to Germany and eastern Europe in 2012-13 (Davies et 
al., 2014). In a recent study, ClosER (Clostridium difficile European Resistance), the most 
common RTs encountered were RT: 027(12%), 001/072 (9%), 078 and 014 (both 8 %). Ribotype 
prevalence differed markedly according to country, with some exhibiting predominant RTs, 
while others showed a diversity of types. Recent surveillance studies of C. difficile in children 
show that PCR ribotype 265 is predominantly found in children, in the Netherlands(van Dorp 
et al., 2017). 
Since the creation of the Clostridium difficile Ribotyping Network (CDRN) in the UK, the 
incidence of CDI has declined dramatically. According to CDRN reports (2008/2009), the 
prevalent C. difficile ribotypes in the UK were PCR ribotypes 027 (36%), 106 (13%) and 001 
(7%). Recently; the CDRN reported (2013-2015) a decrease in the once prevalent ribotypes 
(027, 106 and 001) while other ribotypes have emerged (078, 005, 014/020 and 015), 
including ribotype 002(Figure 1-11), which is now the most prevalent ribotype in the UK 
(Fawley et al., 2016; Health Protection Scotland, 2018; Public Health England, 2016; Public 
Health Wales, 2019). The drivers for its increased prevalence (CD002) remain unclear. The 
potential drivers may be associated with the organism, antimicrobial prescribing policies in 
the hospital or greater community-associated CDI importing into the nosocomial 
environment. 
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Figure 1-11 UK C. difficile RT prevalence 2007-2013 (Data supplied courtesy of CDRN). 
1.8.2 C. difficile Epidemiology in North America  
Since the early 2000s, there has been a significant increase in the incidence and severity of 
CDI in North America (Freeman et al., 2010; Lessa et al., 2012). Reports from 28 community 
hospitals in southern USA suggested that C. difficile had become the most common cause of 
healthcare-associated infection (replacing MRSA) (Miller et al., 2010). Additional reports 
indicated that hospital discharge of CDI cases in the United States had increased from 3.82 to 
8.75 per 1000 discharge from 2000 to 2008 respectively (Lessa et al., 2012).In Quebec, 
Canada, a retrospective study of all CDI cases revealed a fourfold increase in incidence from 
35.6 to 156.3 cases per 100,000 population from 1991 to 2003 (Pepin et al., 2004).  
The increased incidence of CDI in the United States and Canada has been largely attributed to 
the spread of emergent hypervirulent strain BI/NAP1/027 (ribotype 027) strain. This epidemic 
strain 027 has now been found in at least 40 states in the United States and all Canadian 
provinces (O’Connor et al., 2009). 
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1.8.3 C. difficile Epidemiology in Asia and Australia  
The distribution of C. difficile ribotypes in Asia and Australia is significantly different from 
Europe and North America. Although outbreaks in North America and Europe have been 
caused by C. difficile PCR ribotypes 027 and 078, they appear to have only caused sporadic 
cases of CDI in Asia (Singapore, Hong Kong, Korea and Japan)(Collins et al., 2013). Based on 
published data from different Asian countries, the most predominant ribotypes in this 
geographic region are 001, 002, 014, 017 and 018(Borren et al., 2017; Chow et al., 2017; 
Collins et al., 2013; Hung et al., 2016). 
In 2009, a surveillance study was carried out in Hong Kong, China. This study included 345 C. 
difficile toxigenic isolates from 307 patients in Hong Kong. C. difficile PCR ribotype 002 was 
the most predominant ribotype (9.4%), with a higher sporulation frequency (20.2%) and 
resistance to fluoroquinolones. Also, there was a significant increase the incidence rate (from 
0.53 to 0.95 per 1000 admissions) and positive detection rate of toxigenic C. difficile (from 
4.17% to 6.28% between 2004-2008 and 2009). This increase was temporally related to the 
predominance of CD002 (Cheng et al., 2011). Meanwhile, in Japan ribotype smz/018 (referred 
to as ribotype 018 in Europe) has persisted for over a decade as the most common prevalent 
C. difficile ribotype (Senoh et al., 2015). 
In 2012, a prevalence study involving 175 hospitals in Queensland, Australia was performed. 
The three most common ribotypes isolates were C. difficile PCR ribotype 002 (22.9%), 014 
(13.3%) and the binary toxin-positive PCR ribotype 244 (8.4%)(Huber et al., 2014). 
1.8.4 C. difficile in Animals  
C. difficile has been found as a commensal organism and pathogen to farm, wild and 
domesticated animals. Although no direct evidence of zoonotic transmission of C. difficile to 
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humans has been established, several studies identified, farm, domesticated and wild animals 
as potential reservoirs for C. difficile(Andrés-Lasheras et al., 2018; Bakri, 2018; Hensgens et 
al., 2012; Knetsch et al., 2018; Rodriguez-Palacios et al., 2007; Zhang et al., 2019). Several 
studies identified a considerable ribotype overlap between bovine, porcine, canine and 
human isolates of C. difficile, with certain strains being largely species-specific, while others 
were found across multiple species, including humans (Lessa et al., 2012; Pirš et al., 2013; Pirs 
et al., 2008; Rabold et al., 2018).In particular, PCR ribotype 078 has been increasingly 
identified as predominant strain in cattle and pigs in the United States and Europe and also 
as important pathogens in humans (Goorhuis et al., 2008). In the Netherlands, 4%- 11% of 
humans with CDI carried ribotype 078, between February 2005 and February 2008 the 
incidence of infection with this strain increased, making it the second most common ribotype 
isolated from humans in the Netherlands. Studies in the United States and Europe have 
indicated that certain C. difficile genotypes (ribotypes) may be found in farm animals 
(Hensgens et al., 2012; Janezic et al., 2014; Schneeberg et al., 2013) and retail meats and the 
same ribotypes are known to cause community-associated human infections. PCR ribotype 
078 is often reported as the major animal associated C. difficile typically found in pigs. 
However, PCR ribotypes (014/020 and 002) are also among the most prevalent animal-
associated C. difficile strains worldwide (Janezic et al., 2014). 
1.8.5 Community-acquired CDI (CA-CDI) 
Although CDI is historically regarded as a nosocomial infection, it has increasingly been 
recognised in the community as the cause of diarrhoea (Fawley et al., 2016; Furuya-Kanamori 
et al., 2017; Hensgens et al., 2012; Kotila et al., 2016; Lessa et al., 2015). Community-acquired 
CDI (CA-CDI) is defined as CDI occurring in the community or within 48 hours of admission to 
 58 
 
hospital, with no onset symptoms and no prior hospitalisation in the past 12 weeks(Khanna 
et al., 2012). Several studies reported that strains isolated from patients in the community 
(Ribotypes 002, 014/20, 018), are similar to strains isolated from patients in the nosocomial 
environment, suggesting a common source of infection or transmission between both 
settings (Eyre et al., 2013; Fawley et al., 2016; Furuya-Kanamori et al., 2017; Hensgens et al., 
2012). Nevertheless, certain ribotypes have been frequently implicated in CA-CDI cases across 
different geographical locations. In the United States, the estimated incidence of CA-CDI at 
30 to 120 cases per 100,000 persons per year (Lessa et al., 2015). Meanwhile, the incidence 
in the Netherlands is estimated at 390 to 730 per 100, 000 person per year (Bouwknegt, van 
Dorp, & Kuijper, 2015). The most commonly recovered ribotypes were 002 and 078, each 
identified in 11% of samples. These same ribotypes accounted for 7.6% and 3.4%, 
respectively, of CA-CDI in the US (Bouwknegt et al., 2015; Lessa et al., 2015), suggesting a 
zoonotic mode of transmission in the community, as these ribotypes have been recovered 
from animals (Bouwknegt et al., 2015; Janezic et al., 2014). In a recent study ribotype, 002 
was the most predominant ribotype, frequently associated with CA-CDI in Australia (Furuya-
kanamori et al., 2017). Recent Eurosurveillance data on CA-CDI cases in England (2011- 2013) 
identified RT 002(13.5%) as the most frequently occurring ribotype in CA- CDI cases (Fawley 
et al., 2016). While RT078 and RT027 were fourth and eighth most frequently identified 
ribotype in CA-CDI cases. More recently Dauby and colleagues (Dauby et al., 2017) reported 
a fatal incident of C. difficile bacteraemia in the community, the C. difficile strain recovered 
from the patient’s stools was identified as PCR ribotype 002 through multi-locus variable 
number tandem repeat analysis. Most patients who develop CA-CDI do not have typical risk 
factors for CDI, such as antibiotic treatment or recent hospitalisation (Hensgens et al., 2012; 
Wilcox et al., 2008). 
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1.8.6 Typing of C. difficile  
1.8.6.1 Pulse- field gel electrophoresis (PFGE) 
PFGE is one of the first molecular typing methods used for C. difficile. PFGE involves the 
resolution of large fragments of DNA generated from the digestion of genomic DNA using 
rare-cutting enzymes such as SmaI and SacII (Janezic & Rupnik, 2010; Killgore et al., 2008). 
The resultant banding patterns are referred to as pulsotypes. Initially, the attempt to apply 
PFGE to typing C. difficile was challenging as many isolates were un-typeable due to the 
sensitivity of their DNA degradation. However, this issue was resolved when a newly 
improved protocol (incorporating 200µM of thiourea) was introduced, eventually, un-
typeable isolates were designated(Fawley & Wilcox, 2002; Gal et al., 2005). It is considered 
the standard typing C. difficile in North America (Canada &USA)(Huber et al., 2013).  
1.8.6.2 PCR ribotyping 
PCR ribotyping is a strain typing method that is mostly used in Europe and Australia for 
epidemiological investigations to track transmission and identify emerging variants of C. 
difficile(Janezic & Rupnik, 2010). This method distinguishes strains based on the amplification 
of the 16S-23S rRNA intergenic spacer (ITS) region using primers that target the 3’ end of the 
16S RNA and 5’ end 23S RNA. The potential of this technique for typing C. difficile was initially 
described in 1993, however, the protocol was long and laborious(Gurtler, 1993). It was later 
modified by O'Neil and colleagues, who designed new primers closer to the ITS region in order 
to obtain smaller fragments for improved analysis on agarose gels(O’Neill et al., 1996). Using 
a modified PCR ribotyping technique, Stubbs et al identified 116 distinct ribotypes of C. 
difficile(Stubbs et al., 1999). This approach was later adopted for routine use by the UK 
Anaerobe Reference Laboratory, Cardiff. Subsequently, Bidet and colleagues further 
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optimised the PCR ribotyping technique using new, and more specific primers and obtained 
bands that are more stable and readable(Bidet et al., 1999). Although this technique exhibits 
good discriminatory power, it is not sufficient for the discrimination of strains of closely 
related ribotypes such as 027, 106 and 017 (Manzoor et al., 2011). There are now more than 
900 distinct PCR ribotypes that have been identified and the use of capillary electrophoresis 
has allowed further discrimination of closely related ribotypes (Dr Jane Freeman– personal 
communication). 
1.8.6.3 Toxinotyping 
Toxinotyping is used to differentiate C. difficile isolates based on variation in the PaLoc 
(Rupnik et al., 1998). The principle of toxinotyping is based on amplifying regions within PaLoc 
and restricting these regions with enzymes such as; EcoRI, AccI and HincII. The resultant 
pattern is then compared to the C. difficile reference strain VPI 10463 to determine the 
toxinotype (Rupnik et al., 1998).To date, 34 toxinotypes have been identified(Rupnik & 
Janezic, 2016). While a good correlation between this method and other typing methods such 
as; PFGE, ribotyping and serogrouping was found, it is not as discriminatory as some other 
techniques (Martin et al., 2008).   
1.8.6.4 Multi-Locus Sequence Typing (MLST) 
MLST is a technique that involves examining the DNA sequence variations within multiple 
housekeeping genes of microbial species after PCR amplification. Sequence variants of each 
housekeeping gene is assigned a distinct allele number and a combination of these numbers 
provides a sequence type (ST)(Knetsch et al., 2013). MLST was first described for C. difficile 
typing by Lemee and colleagues, who developed typing scheme that involved the analysis of 
seven housekeeping genes (aroE, ddl, dutA, tpi, recA, gmk and sodA) to study the genetic 
relationship and population structure of a group of C. difficile isolates(Lemee et al.,2004). 
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Allelic profiling allowed the definition of 34 different sequence types (STs). In a later scheme 
by Griffiths et al, a different set of seven housekeeping genes (adk, atpA, dxr, glyA, recA, sodA, 
and tpi) were used for epidemiological analysis of a diverse panel of C. difficile 
isolates(Griffiths et al., 2010). This was a more robust MLST scheme as it yielded 40 STs and 
allowed genotyping of C. difficile directly from stool specimens. The discriminatory power of 
MLST appears to be similar to PCR ribotyping, but not sufficient to delineate outbreak cases 
(Griffiths et al., 2010; Killgore et al 2008). MLST is recommended as an appropriate tool for 
phylogenetic studies of C. difficile (Knetsch et al., 2013). 
1.8.6.5 Multi-Locus variable number tandem repeat analysis (MLVA) 
MLVA has emerged as the most superior typing method for C. difficile due to its higher 
discriminatory power in monitoring transmission events involved in outbreaks (Eckertet al., 
2011; Manzoor et al., 2011; Marsh et al., 2006; van den Berg et al., 2007). This method uses 
PCR to amplify multiple variable number tandem repeat (VNTR) loci and determine the 
number of repeat sequences per loci by fragment analysis. The level of diversity within the 
genome is used to resolve phylogenetic relationships of isolates. Since the identification of 
this technique for typing of C. difficile, different methods have been published with the 
number of VNTR loci used ranging from 2-12 (Eckert et al., 2011; Manzoor et al., 2011; Wei 
et al., 2011). Wei et al suggested that a 10 loci MLVA scheme should be used to detect 
epidemic clones and a 4 loci scheme to detect outbreaks(Wei et al., 2011). MLVA was shown 
to be a highly discriminatory tool in the investigation of C. difficile outbreaks in France, 
Argentina and the UK (Eckert et al., 2011; Fawley & Wilcox, 2011; Goorhuis et al., 2009).In 
England, CDRN currently offers MLVA analysis of C. difficile using seven VNTR loci or an 
expanded panel of 12, as an enhanced service for investigating outbreaks. 
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1.8.6.6 Whole Genome Sequencing (WGS) 
Whole-genome sequencing (WGS) is a high-throughput typing method that differentiates 
strains based on single nucleotide polymorphisms (SNP), within the bacterial genome(Knetsch 
et al., 2013).WGS has proven to be advantageous in surveillance studies, outbreak 
identification, and the study of strain transmission events in several bacterial pathogens 
including C. difficile(Eyre et al., 2013; He et al., 2013, 2010; Köser et al., 2012).WGS was able 
to discriminate ribotype 027 isolates from the US and Europe into 25 distinct genotypes, as 
well as reveal distinct evolution lineages, and unique antibiotic resistance genes (He et al., 
2010). Eyre and colleagues used WGS to study the transmission events involved in many cases 
of C. difficile in Oxfordshire. The authors, reported that many cases of C. difficile infection 
thought to be genetically related were in fact genetically distinct, suggesting diverse sources 
of infection within the nosocomial environment (Eyre et al., 2013; Knetsch et al., 2013). 
Although this approach has proven successful, it is predominantly used retrospectively due to 
its cost, as a result, MLVA is usually performed to determine the genetic relatedness of strains 
in an outbreak.  
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1.9 AIMS AND OBJECTIVES  
C. difficile PCR ribotype 002 (CD002) is now the most commonly isolated C. difficile strain in 
the United Kingdom. According to statistics generated by the C. difficile Ribotyping Network 
for England and Northern Ireland (CDRN), its prevalence has increased incrementally over the 
past 7 years, yet the drivers for this increased prevalence remain unclear. The aim of this 
study is to characterise UK C. difficile PCR ribotype 002 (CD002) isolates from different time 
lineages and assess any phenotypic traits that may help explain the emergence of this 
ribotype. The objectives are the following: 
1. Determination of antimicrobial susceptibilities and resistance mechanisms of CD002 
isolates from different time lineages in vitro using standard techniques (Agar 
incorporation MICs and PCR/sequencing of resistance genes) 
2. Quantification of biofilm formation of CD002 isolates from different time lineages in 
different culture media using a crystal violet microtitre plate assay 
3. Evaluation of the cytotoxin production profiles, total sporulation capacities and spore 
adherence abilities of CD002 isolates from different time lineages using standard 
techniques (Vero cell cytotoxicity assay, batch culture growth experiments, spore 
adherence assay) 
4. Nutrient utilisation analysis of CD002 isolates using a nutrient microarray. 
5. Assessment of the comparative in vitro fitness using continuous flow fermentation 
techniques.   
6. Proteomics analysis CD002 isolates using gel electrophoresis and LC-MS/MS mass 
spectrometry analysis. 
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2 GENERAL MATERIALS AND METHODS 
 
2.1 BACTERIAL STRAINS AND CULTURE  
2.1.1 C. difficile Strains  
A total of 60 C. difficile ribotype 002 strains (provided by Prof. Mark Wilcox via the CDRN) 
isolated between 2007- 2014 from the UK and across Europe were used in this study. Thirty-
five of these strains were isolated from the UK while twenty-five from different geographical 
locations across Europe (Figure 2-1). Strains were grouped according to their time lineage; 
fourteen of the UK strains formed part of the older lineage of CD002 strains (UK 2007-2008), 
while twenty-two were part of the recent group of strains (UK 2011- 2013). For the non-UK 
isolates, only one strain isolated from Dublin in 2008 formed part of the old group, while 
twenty-three strains formed of the recent group of strains (Table 1& 2). C. difficile ATCC® 
700057 was used as a control strain in all experiments performed in this study. 
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Figure 2-1 Distribution of CD002 isolates evaluated in this study. Non-UK CD002 makers are correct to country but not exact geographical location (Contour 
colouration is not relevant to this study map acquired from www.nasa.gov.uk
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Table 2-1 UK CD002 isolates used in this study 
Strain Group Strain code Location Year of Isolation 
UK 2007-08  174 Leeds 2007 
173 Great Yarmouth 2007 
172 Luton 2007 
171 Cambridge 2007 
170 Preston 2007 
169 Exeter 2007 
168 Bournemouth 2007 
167 Liverpool 2007 
166 Carlisle 2008 
165 Manchester 2008 
163 Poole 2008 
162 Belfast 2008 
161 Peterborough 2008 
160 Salisbury 2008 
UK 2011-13 159 Exeter 2011 
158 Bournemouth 2012 
157 Taunton 2012 
156 Carlisle 2012 
154 Liverpool 2012 
39 Cumberland 2012 
40 Cumberland 2012 
53 Leeds 2012 
54 Leeds 2012 
66 Harrogate 2012 
68 Harrogate 2012 
71 Maidstone 2012 
153 Cambridge 2013 
151 London 2013 
150 Grimsby 2013 
149 Surrey 2013 
148 HPA South East 2013 
147 Hull 2013 
146 Bristol 2013 
145 Leeds 2013 
144 Durham 2013 
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Table 2-2 Strain selection of Non- UK CD002 isolates used in this study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.2 Control Strains  
C. difficile ATCC® 700057 was used as a control strain in all experiments performed in this 
study.  However, for some individual experiments, additional controls were included. In the 
antimicrobial susceptibility testing, four additional strains were used as controls. In the 
biofilm formation assay, a C. difficile strain of ribotype 078 (Strain 24) was used as an 
additional control due to its elevated biofilm production. In the cytotoxicity assay, a C. difficile 
Strain Group Strain code Location Year of Isolation 
Non- UK 2008 164 Dublin 2008 
Non- UK  2012-14 1 Ireland 2012 
4 Ireland 2012 
5 Ireland 2012 
6 Ireland 2012 
155 Ireland 2012 
139 Switzerland 2013 
141 Portugal 2013 
140 Poland 2013 
138 Latvia 2013 
142 Germany 2013 
143 Belgium 2013 
134 Austria 2013 
128 Sweden 2014 
137 Spain 2014 
126 Slovenia 2014 
131 Netherlands 2014 
133 Italy 2014 
136 Hungary 2014 
135 Greece 2014 
130 France 2014 
132 Finland 2014 
129 Denmark 2014 
127 Czech Rep 2014 
152 Dublin 2013 
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PCR ribotype 001 (P24) strain was cultured for 72 hours to produce a cytotoxin-positive 
control sample, which was neutralised by C. sordellii antitoxin (PL 6508, Prolab Diagnostics, 
Bromborough, UK). 
2.1.3 Media, buffers and solutions  
All reagents, liquid media, solid media and solutions used in this study are described in 
Appendix 1. 
2.1.4  C. difficile culture growth conditions  
All C. difficile cultures were incubated in an anaerobic work station (DG500, Don Whitley, 
United Kingdom) with a gas mixture of 80% nitrogen, 10% carbon dioxide, and 10% hydrogen 
(British Oxygen Company (BOC Gases), UK) at 37°C. 
2.1.5 Culture of C. difficile on solid media 
All strains were cultured onto Brazier’s Cefoxitin/Cycloserine Egg Yolk (CCEY) agar (LAB160, 
Lab M, Lancashire, UK) supplemented with 2% lysed defibrinated horse blood (SR0050C, 
Thermo-scientific) and incubated anaerobically at 37°C for 48 hours before any test was 
performed. All solid media were pre-reduced in an anaerobic workstation (DG500, Don 
Whitley, United Kingdom) for 24h at 37°C. 
2.1.6 Culture of C. difficile on liquid media 
Liquid media used for the culture of C. difficile isolates were prepared according to the 
manufacturers’ instructions. This included: Schaedler’s anaerobe broth (CM0497, Oxoid), and 
Brain heart infusion (BHI) Broth (CM1135, Oxoid). All liquid media were pre-reduced for 24 
hours at 37°C in the anaerobic work station prior to inoculation.  
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2.1.7 Preparation and harvesting of C. difficile spores  
C. difficile was inoculated onto Braziers CCEYL agar and incubated anaerobically at 37°C for 
48 hours. Single pure colonies of C. difficile were cultured on to pre-reduced Columbia blood 
agar (CBA) plate and incubated anaerobically at 37°C for 7 days. Subsequently, CBA plates 
were recovered from the anaerobic cabinet, and all growth was removed from CBA using a 
sterile swab and immersed into a 5ml solution of 50% ethanol. The cell suspension was left at 
room temperature for 1 hour and stored at 4°C until required. A schematic representation of 
C. difficile spore preparation is provided in Figure 2.1.  
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Figure 2-2 Preparation and harvest of C. difficile spores
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2.2  ANTIMICROBIAL SUSCEPTIBILITY TESTING AND MINIMUM INHIBITORY 
CONCENTRATION (MIC) DETERMINATION  
2.2.1 Antimicrobial agents  
Susceptibility of CD002 to a diverse panel of antimicrobial agents was performed using the 
agar dilution method in accordance with the Clinical and Laboratory Standards Institute 
guidelines for Antimicrobial Susceptibility Testing of Anaerobic Bacteria (Wilcox, Fawley, 
Freeman, & Brayson, 2000). The following antimicrobial agents were used in this study are 
listed in Table 2-3. 
Table 2-3 List of Antimicrobial agents used in this study 
Antimicrobial agent Product code Manufacturer 
Metronidazole M3761-25G Sigma, UK 
Vancomycin V2002-1G Sigma, UK 
Erythromycin E6376-25G Sigma, UK 
Ampicillin A9393-5G Sigma, UK 
Nitrofurantoin N7878-10G Sigma, UK 
Tetracycline T3383-25G Sigma, UK 
Penicillin G 13752-5G Sigma, UK 
Chloramphenicol C0378-25G Sigma, UK 
Clarithromycin C9742-250MG Sigma, UK 
Trimethoprim T7883-5G Sigma, UK 
Moxifloxacin 06669204 Bayer plc, Newbury, UK 
Clindamycin PNU21251F Pfizer, Tadworth, UK 
Ciprofloxacin 11939800 Bayer plc, Newbury, UK 
Linezolid PF00184033 Pfizer, Tadworth, UK 
Meropenem S1381 Selleckchem 
Fidaxomicin S4227 Selleckchem 
Rifampicin BP2679-5 Fluka 
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2.2.2 Preparation of Antimicrobial Agar Incorporation Plates  
Antimicrobial stock solutions were prepared in their respective solvents as shown in Table 2-
4. Antimicrobial stock solutions other than those prepared in DMSO (D8418-50ml, Sigma), 
DMF (D4551-100ml, Sigma) and ethanol (E/0600DF/21, Fisher Scientific) were sterilised by 
filtration through 0.22µm syringe filters (SLGP033RS, Millipore, Carrigtwohill, Ireland). 
Accordingly, serial two-fold dilutions of the antimicrobial stock solution were prepared in 
respective diluents to give a final concentration range of 0.03-128mg/L when 2mL was added 
to 18mL of molten Wilkins-Chalgrens Agar (WCA) (CM0619 Oxoid). Each antibiotic 
incorporated agar was mixed thoroughly and distributed into a sterile petri dish. Following 
solidification, antibiotic incorporated agars were left at room temperature for 24h or dried in 
sterile micro safety class II cabinet to removes excess moisture prior to inoculation.   
2.2.3 Preparation of Bacterial Inocula   
C. difficile strains were cultured anaerobically in pre-reduced 5ml Schaedler’s anaerobe broth 
(CM0497, Oxoid) using a sterile swab and incubated overnight at 37oC. Subsequently, 400µl 
of overnight C. difficile cultures (~1x107 CFU/ml) were transferred to the appropriate well of 
a sterile inoculating block. Using a multipoint inoculator (UriDot, Mast Group, UK), 1μl (104 
CFU) of the bacterial culture from an inoculating block was applied onto the surface of pre-
dried WCA plates containing doubling dilution of antibiotics and control plates containing no 
antibiotic and the respective solvent control plate. Pins of the multipoint inoculator were 
sterilised by flaming in 100 % absolute ethanol (1.02428, EMD Millipore) between each set of 
antibiotic incorporated agar plates. Control plates containing no antibiotic were inoculated at 
the start and end of the procedure. All plates and growth controls were incubated 
anaerobically for 48h at 37°C. Aerobic controls were incubated for 24h at 37°C. The plates 
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were recovered from the anaerobic cabinet after 48h incubation and MIC values were 
recorded. The MIC was determined as the lowest antimicrobial concentration where an 
absence or marked reduction of growth (multiple tiny colonies, haze or fine film of growth or 
one or two colonies) compared with the growth control was observed.  
 
Table 2-4 Antimicrobial agents, solvents and diluents used in this study (adapted from 
Andrews (2001) 
Antimicrobials Solvent  Diluent  
Metronidazole Water Water 
Vancomycin Water Water 
Ampicillin Saturated NaHCO3 (2056338, Fluka 
Biochemika, Location) 
Water  
Chloramphenicol Ethanol Water  
Ciprofloxacin Water Water  
Clarithromycin DMSO Water  
Clindamycin  Water Water  
Erythromycin Ethanol Water  
 Linezolid  Water  Water  
Moxifloxacin Water  Water  
Nitrofurantoin DMF DMF 
Penicillin G Water Water 
Tetracycline Water Water  
Trimethoprim Water (1ml + 10µl glacial acetic acid 
(10365020, Fisher Scientific) 
Water 
Meropenem Water Water 
Fidaxomicin DMSO 10% DMSO 
Rifampicin DMSO Water  
 
2.3 MAMMALIAN CELL CULTURE EXPERIMENTS  
2.3.1 Vero Cell Cytotoxicity assay 
2.3.1.1 Preparation of C. difficile cytotoxin extracts  
C. difficile cytotoxin extracts were produced by culturing strains in 5ml of Brain Heart Infusion 
broth supplemented with 5% yeast extract (LP0021, Oxoid) and 1% L-cysteine hydrochloride 
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(C7477, Sigma) (BHIS) broth and incubating anaerobically for 72 hours at 37oC. After 
incubation was complete, liquid cultures were retrieved from the anaerobic cabinet, 1ml of 
each sample was aliquoted into sterile microcentrifuge tubes and centrifuged at 13,000 rpm 
for 5mins using a Progen Genfuge 24D Digital Microcentrifuge (Progen Mexborough, UK). The 
supernatant was gently removed and sterilised by filtration through 0.22µm syringe filters 
(SLGP033RS, Millipore, Carrigtwohill, Ireland) into fresh sterile tubes, while the pellet was 
discarded. C. difficile culture supernatants were stored at 4°C until the cytotoxicity assay was 
performed.  
2.3.1.2 Vero cell preparation 
Vero cells (African green monkey kidney cells, PHE Culture collection, ECACC 84113001) were 
retrieved from liquid nitrogen storage vials and thawed in a 5% CO2 incubator at 37°C. Thawed 
Vero cells were cultured in 25cm3 flasks containing 7ml Dulbecco Modified Eagle’s medium 
(DMEM) (D6546, Sigma). DMEM (500ml) was supplemented with 50mL new-born calf serum 
(N4637, Sigma), 5mL antibiotic/antimycotic solution (A5955, penicillin 100U/mL, 100mg/L 
streptomycin, 0.25mg/L amphotericin, Sigma) and 5mL L-glutamine (G7513, Sigma). Vero cells 
were incubated in a 5% CO2 incubator at 37° C until a confluent monolayer was achieved upon 
examination under an inverted microscope (Olympus CKX41).  Vero cells were passaged 
before cytotoxicity assays were performed. 
2.3.1.3 Passaging of Vero cells  
Passaging of Vero cells was performed by discarding DMEM covering confluent Vero cell 
monolayers and washing of the monolayer with 0.5ml of Hanks Balanced Salt Solution, HBSS 
(H9394, Sigma), supplemented with 0.25g/L trypsin EDTA (T4174, Sigma) (HBSS trypsin EDTA) 
to remove dead cells. Following gentle agitation, excess HBSS trypsin EDTA was discarded and 
3ml of HBSS trypsin EDTA solution was added. Vero cell monolayers were incubated in 5% 
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CO2 for 10 minutes until the monolayer was dissociated (Trypsinised).  Trypsinised Vero cells 
were diluted either 1:10 into fresh DMEM or 1:20 dilution and aliquoted into flat-bottomed 
sterile 96-well microtitre plates (DK-4000, ThermoFisher) depending on when the cells were 
required for cytotoxin assays.  Microtitre plates containing diluted Vero cells were incubated 
in 5% CO2 at 37°C until a confluent monolayer was reached. 
2.3.1.4 Cytotoxicity assays 
Twenty microliters of C. difficile culture supernatants were serially 10-fold diluted in 180µl of 
sterile PBS (to 10-5).  Subsequently, 20 µl of diluted C. difficile supernatant was added in 
duplicate to Vero cell monolayers (as shown in the flow chart in Figure 2-3). Additionally, 20µl 
of undiluted C. difficile culture supernatant was added into all wells in rows A and B, while 20 
µl C. sordelli antitoxin (PL6508, Pro-lab, Diagnostics, South Wirral Cheshire, UK) was added 
into all wells in row B only.  C. sordelli antitoxin was added to neutralise C. difficile cytotoxin 
to confirm the specificity of the cytotoxic effect. Microtitre trays were incubated in 5% CO2 at 
37° C and examined under the inverted microscope at 24 and 48 hours. A positive reaction 
was considered when ≥80% of Vero cell rounding was present in the wells of the microtiter 
tray (as shown in figure 2-).  The total cytotoxin titre was expressed as log10 relative units (RU), 
where 1 RU represented ~80% cell rounding by the undiluted sample, 2 RU represents ~80% 
cell rounding by the 10-1 dilution of the sample (Underwood et al. 2009). 
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Figure 2-3 Flow chart of the Vero cell cytotoxicity assay 
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                              a) 
 
 
                            b) 
 
 
Figure 2-4 Vero cells a) Negative control: Vero cell monolayer (200x magnification). b) 
Cytopathic effect of C. difficile cytotoxin on Vero cell (200x magnification).
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2.3.2 Caco-2 cell culture preparations  
Caco-2 cells (Human adenocarcinoma, cells, PHE Culture collection, ECACC 86010202) were 
retrieved from liquid nitrogen storage vials and thawed in a 5% CO2 incubator at 37°C. Thawed 
Caco-2 cells were transferred into 15ml falcon tubes and centrifuged at 15000g for 10 
minutes. Subsequently, the supernatant was carefully removed and the cell pellet was re-
suspended in 7ml of Eagle’s Minimum Essential Medium (P04-08050, Pan Biotech) 
supplemented with 100mL fetal bovine serum (P30-1302, Pan Biotech), 5mL 
antibiotic/antimycotic solution (A5955, penicillin 100U/mL, 100mg/L streptomycin, 0.25mg/L 
amphotericin, Sigma),  5mL L-glutamine (G7513, Sigma),  5mL Non-essential amino acids (P08-
32100, Pan Biotech)  and 5mL sodium pyruvate (11360070, ThermoFisher). The suspension 
was transferred to a 25cm3 Nunc flask (163371, Fisher Scientific) and incubated in a 5% CO2 
incubator at 37 ⁰C until 70-80% of cell confluence was achieved (Figure 2-5). Cell culture 
media were changed media was changed every 2-3 days.  
2.3.2.1 Passaging of Caco-2 cells 
Passaging of Caco-2 cells was performed after 70-80% confluence was achieved (Figure 2-5). 
To achieve this, the culture medium covering confluent monolayers was discarded, and 
monolayers were washed with 5ml of Dulbecco phosphate-buffered saline, in order to 
maintain pH and osmotic balance of the cells. Subsequently, 2ml of 1% trypsin was added to 
cell monolayers incubated in 5% CO2 for 4-6 minutes until the monolayer was dissociated 
(Trypsinised). Trypsinised cells were viewed under an inverted microscope (CKX41, Olympus), 
and 5ml of cell culture medium was added to the flask, to neutralise the effects of trypsin. 
Subsequently, the suspension was transferred into a 15ml falcon tube and centrifuged at 
15,000g for 10 minutes (IEC CL30R, Thermo-Scientific). Subsequently, the supernatant was 
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discarded, and cells were resuspended in 3ml of culture medium. Trypsinised Caco-2 were 
diluted 1:5 and transferred into T-75 flask. For seeding of cells in 24 well plates, cell counting 
was performed (as described in 2.3.2.2) before cells were seeded at a density of 2 x105 per 
well. 24 well plates and flask were incubated in 5% CO2 at 37°C until a confluent monolayer. 
Cell culture media was changed every 24-72 hours until 70-80% confluence was attained. 
 
 
Figure 2-5 Caco-2 cells. a) Caco-2 cells at 50-60% confluency at 40x magnification. b) Caco-2 cells at 
50-60% confluency 100x magnification. 
 
2.3.2.2 Counting of Caco- 2 cells with Trypan blue  
To confirm the presence of viable cells in a cell suspension (post trypsinisation and 
centrifugation) cells were stained with Trypan blue to enable visualisation of the cell 
morphology. Fifty microliters of 4% (v/v) Trypan blue solution (T8154, Sigma) was added to 
50µl of an evenly mixed cell suspension and allowed to incubate at room temperature for 1-
2 minutes. Subsequently, 10µl of the Trypan blue mixture was carefully transferred to one 
chamber of a haemocytometer and viewed under a phase-contrast microscope (Olympus 
CKX41) 100X magnification. Viable cells were counted (unstained cells) in four 1x1 mm 
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squares of one chamber and the average number of cells was determined. To calculate the 
cell concentration per ml, the following equation was used: 
 
      Cell concentration (cells/ml) = Average number of cells x dilution factor x 104   
 
2.4 GROWTH RATE DETERMINATION   
2.4.1 Growth rate measurement 
To determine the growth rates of CD002, all strains were grown overnight in pre-reduced 
BHIS broth and incubated anaerobically 37⁰C. In order to ensure a standardised starting OD600 
for all strains, a starter culture was prepared by diluting overnight C. difficile cultures to OD600 
of 0.1 in sterile pre-reduced BHIS using the equation below: 
([Volume of New broth (ml) x desired OD600]/ (Overnight OD600)) = Volume of overnight 
broth to add to new broth (ml) 
 
The desired volume of the overnight broth obtained from the calculations (for each individual 
strain) was added to fresh pre-reduced BHIS broth and incubated anaerobically at 37⁰C for 
growth. To ensure that absorbance readings fell within the linear range of the 
spectrophotometer, samples with absorbance values above 0.700 were diluted in sterile BHIS 
and absorbance readings were retaken. This value was then multiplied by the dilution factor 
to determine the actual OD600 value of the sample. 
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2.4.2 Determination of the Maximum Specific Growth rate (µmax) 
The maximum specific growth rate for all strains (h-1) was calculated from the exponential 
phase (4-6h) of C. difficile growth by determining the gradient of the ln (biomass) versus time 
plot. 
2.5 VIABLE COUNTING OF C. DIFFICILE SPORES AND VEGETATIVE CELLS  
To measure the total viable counts present in C. difficile cultures, 100µl of each sample was 
aliquoted into a 96 well microtitre tray. Subsequently, 20µl of each sample were diluted 
tenfold in 180µl sterile PBS (P4417, Sigma) in a dilution series to 10-6 (as shown in Figure 2-6). 
Twenty microliters of four appropriate dilutions were inoculated to quarter plates of  Brazier’s 
CCEY agar (Cefoxitin/Cycloserine Egg Yolk, Lab M, Lancashire, UK)  supplemented with 2% 
lysed defibrinated horse blood (SR0050C, Thermo-scientific) and incubated anaerobically at 
37⁰C. Between 20-200 colony-forming units were counted and converted into CFU/mL in 
order to determine the total viable counts.  
To measure the colony-forming units (CFU) formed from spores, 100µl of 50% ethanol, was 
added to 100µl of C. difficile cultures that had been aliquoted into a 96 well microtitre tray 
and allowed to incubate at room temperature for 1h. Subsequently, viable counting was 
performed as described above.
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Figure 2-6 Schematic representation of total viable counting of C. difficile 
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2.6 PHENOTYPE MICROARRAY EXPERIMENT 
2.6.1 Deoxygenation of PM panels prior to inoculation 
Prior to phenotypic microarray experiments, all PM panels were converted to an anaerobic 
state by deoxygenation. To achieve this, PM panel packaging bags were cut open at one end 
and placed in a W- Zip plastic pouch (2 PM panels per plastic pouch bag), along with two 
anaerobic oxygen sachets (AN0010, Oxoid), an anaerobic strip indicator, and original 
desiccant sachets. The bags were sealed and kept at room temperature for 1 day and 
subsequently stored at 4°C for an additional 2 days or longer before use. Deoxygenated PM 
panels were warmed up to room temperature on the laboratory bench.  
2.6.2 Inoculum preparation for the phenotype microarray experiment 
Using a sterile deoxygenated swab, the inoculum for the phenotype microarray (PM) 
experiment was prepared by removing colonies of C. difficile (48h hours old) from a Columbia 
blood agar plate (LAB001, Lab M, Lancashire, UK). The retrieved C. difficile cells were 
resuspended in a pre-reduced suspension liquid (AN IF-0a) (72268, Biolog, Hayward, USA) 
supplemented with sodium bicarbonate (S6014, Sigma), sodium thioglycolate (T0632, Sigma) 
and methylene green (05208636, MP Biomedicals) at final concentrations of 10mM, 0.4mM, 
and 1µM respectively. This bacterial suspension was adjusted in AN IF-0a to achieve a 40% 
transmittance cell suspension (which measured spectrophotometrically as 0.139± 0.002 at 
OD750 using a CE1011 1000 series spectrophotometer. This suspension was further diluted at 
a ratio of 1:16 in an anaerobic Biolog Mix B solution. The mix B solution consisted of AN IF-0a 
supplemented with 0.2% (w/v) yeast extract (LP0021, Oxoid) for PM1 and 2, and 0.05% (w/v) 
of yeast extract for PM3-8. To provide a carbon source in PM3-8, glucose (41095-5000, Fisher 
Scientific) at a final concentration of 5mM was added to the inoculating fluid. The bacterial 
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suspension was used for inoculation of all PM panels. As a preliminary check to determine the 
cell density of the inoculating fluid (T40 1:16) prior to inoculation of the PM panels, the 
inoculum was plated on Columbia blood agar. This inoculum yielded an average colony count 
of 4.54 x 107 CFU/mL. 
2.7 FERMENTATION EXPERIMENTS  
2.7.1  Sterilisation and Calibration of pH probes fermentation vessels  
Fermentation experiments were performed in a one-litre New Brunswick Bioflo 115 
bioreactor with a working volume of 700ml (Figure 2-7). Prior to setting up the fermenter, the 
bioreactor vessel and its working accessories were sealed and sterilised in an autoclave. The 
bioreactor pH probe was calibrated using a two-point calibration system, which determines 
the electrode parameters zero (pH 7) drift and slopes with two buffer solutions, pH 4 (BS04, 
ThermoFisher) and pH 7 (BS07, ThermoFisher). The calibrated probe was then sterilised 
before attachment to the culture vessel.   
2.7.2 Fermentation media  
Peptone yeast glucose (PYG) media was used for fermentation experiments in accordance to 
the published recipe by Hardy diagnostics except that the concentration of glucose was set at 
1g per litre and 0.005g per litre for resazurin (R7017, Sigma) was added as an anaerobic 
indicator. Ingredients used for the preparation of the media are listed in Table 2-5. The media 
was prepared at a deficit volume of ingredients that were added post autoclaving, to ensure 
that the final concentrations were maintained. Following autoclaving and cooling down to 
room temperature, 20g of glucose, 100ml of 0.1 % hemin solution and 0.1g of resazurin was 
added by filter sterilization using 0.22µm sterile syringe filters (SLGP033RS, Millipore, 
Carrigtwohill, Ireland) to a 20L fermentation medium.  
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Additionally, 700ml of the fermentation medium was prepared and sterilised (autoclaved) in 
situ in the bioreactor vessel.  Post sterilisation, media additives (glucose, hemin and 
resazurin), were aseptically added to the bioreactor vessel through the sample port, using a 
sterile needle (Z192414, Sigma) and sterile syringe. To avoid contamination, the sample port 
was first sprayed with 70 % ethanol and then allowed to dry before media additives were 
aseptically added.  
 
Table 2-5 Ingredients used to make up 1L of peptone yeast glucose (PYG) broth  
Ingredients Volume Product code and 
manufacturer  
Pancreatic digest of casein 20 g 70169, Sigma 
Yeast extract 10 g LP0021, Oxoid  
L-Cysteine 0.5 g C7477, Sigma 
Glucose * 1g 410955000, Fisher Scientific 
Sodium Bicarbonate (NaHCO3) 0.4 g S56297, Fisher Scientific 
Sodium Chloride (NaCl) 0.08 g S3171, Fisher Scientific 
Monopotassium Phosphate (KH2PO4) 0.04 g P5379, Fisher Scientific 
Dipotassium Phosphate 0.04 g P3786, Fisher Scientific 
Calcium Chloride (CaCl2) 0.008 g C3881, Fisher Scientific 
Magnesium Sulphate (MgSO4) 0.008 g P1880, Fisher Scientific 
0.1% haemin Solution 5ml H9039, Sigma 
1% (v/v) Vitamin K1 0.1ml   V3501, Sigma 
Resazurin 0.005g R7017, Sigma 
 
2.7.3 Fermenter set up and sterility test 
Post sterilisation of the culture vessels and the working accessories, the fermenter was set up 
by aseptically connecting the necessary components to the culture vessel (as shown in figure 
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2-7). The pure nitrogen supply for the bioreactor was fed into the bioreactor vessel via a 
sterile membrane filter and sparged through the culture medium. Temperature and agitation 
were maintained at 37⁰C and 200 rpm respectively and the dissolved oxygen was set at zero. 
For pH control, a mixture of sterile 1M NaOH and 1M HCL was used. The fermenter was run 
under these conditions for 24h prior to inoculation in order to validate the sterility of the 
bioreactor. As an additional step, 1ml of the culture medium was aseptically retrieved from 
the culture vessel, and Gram staining was performed prior to inoculation to screen for any 
bacterial contamination.   
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Figure 2-7 Photograph of the single-stage fermenter set up for continuous culture competition studies
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2.8 MOLECULAR METHODS 
2.8.1 Bacterial DNA Extraction  
For all PCR amplifications, bacterial DNA was extracted by the boiling method. Three to five 
colonies of C. difficile were suspended into 100μl of sterile nuclease-free PCR grade water 
(SH30538.02, GE Healthcare). This suspension was boiled at 100°C for 10 mins on a Dry Block 
Thermostat (11456367, BTD, Grant, UK), and centrifuged at a low speed (3,000g) for 1min to 
remove cell debris. The DNA- containing supernatant was used for PCR amplification.  
2.8.2 Primers 
Table 2-6 is a list of primers used for amplification of antimicrobial resistance genes and 
investigation of the presence of the binary toxin genes in all isolates.  
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Table 2-6  Primers used in this study  
Gene Primer Sequence 5’-3’ DNA 
sequence 
length in 
(bp) 
References 
 
ermB 
ermB-F GAA AAG GTA CTC AAC CAA ATA 639 Solomon et al., 2011 
ermB-R AGT AAC GGT ACT TAA ATT GTT TAC 
 
gyrA 
gyrA- F AAT GAG TGT TAT AGC TGG ACG 390 Spigaglia et al., 2009 
gyrA-R TCT TTT AAC GAC TCA TCA AAG TT 
 
gyrB 
gyrB-F AGT TGA TGA ACT GGG GTC TT 390 Spigaglia et al., 2009 
gyrB-R TCA AAA TCT TCT CCA ATA CCA 
 
ermA 
erm (A)-F TCT AAA AAG CAT GTA AAA GAA 645 Patterson et al., 2007 
erm (A)-R CTT CGA TAG TTT ATT AAT ATT AGT 
 
ermC 
erm(C)-F TCA AAA CAT AAT ATA GAT AAA 642 Patterson et al., 2007 
erm(C)-R GCT AAT ATT GTT TAA ATC GTC AAT 
 
ermF 
erm(F)-F CGG GTC AGC ACT TTA CTA TTG 466 Patterson et al., 2007 
erm(F)-R GGA CCT ACC TCA TAG ACA AG 
 
ermQ 
erm(Q)-F AAG TTA TTG GGT TAC AGC TA 771 Patterson et al., 2007 
erm(Q)-R CAC CTC CTA ATT TAA ATC TAC TA 
 
rpoB 
CDrpoB2-F ATG GAA GCT ATA ACG CCT CAA 200 Curry et al., 2009 
CDrpoB2-R ACA GCA CCA TTT ACA GTT CTA 
cdtA 
cdtApos TGA ACC TGG AAA AGG TGA TG 
375 
Stubbs et al., 2000 
cdtArev AGG ATT ATT TAC TGG ACC ATT TG  
cdtB 
cdtBpos CTT AAT GCA AGT AAA TAC TGA G 
510 
Stubbs et al., 2000 
cdtBrev AAC GGA TCT CTT GCT TCA GTC  
 
2.8.3 PCR Amplifications 
PCR amplifications were performed in a reaction volume of 50μl, consisting of 3μl template 
DNA from CD002 strains, 1μl of each primer (0.5 μM in final concentration), 25μl of amplitaq 
gold master mix (439881, Thermo-Fisher) and 20μl of sterile PCR grade water (SH30538.02, 
GE Healthcare). The detailed volumes and concentrations for the PCR reactions are shown in 
Table 2-7.  
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Table 2-7 PCR reaction  
Reagent Final 
concentration 
50 μl 
25 μM forward primer 0.5 μM 1μl 
25 μM reverse primer 0.5 μM 1μl 
Amplitaq mix - 25 μl 
Template DNA - 3 μl 
Sterile PCR grade Water - 20 μl 
 
2.8.4 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to detect PCR amplification. Agarose gel (1.4%) was 
prepared by adding 1.4g of agarose powder (A9539, Sigma) into 70ml of TBE (Tris-Borate 
EDTA) buffer (T4415, Sigma). This mixture was heated in a microwave until dissolved and 
cooled. Subsequently, 7μl of SYBR safe DNA gel stain (S33102, Thermo Fisher) was added to 
the cooled solution and mixed gently. This mixture was poured into a casting tray, with an 
appropriate comb for loading samples. After 10-15 minutes, the tray was placed in an 
electrophoresis tank, TBE Buffer was added, and the comb was removed. Consequently, a 
10μl aliquot of each PCR product mixed with 2μl of loading buffer (G2526, Sigma) was loaded 
into the gel along with DNA Ladder. The gels were run at 100 V for 60-90 min. Gels were 
visualised under UV light using the InGenius Gel documentation system (Syngene, UK) and 
images were captured using GeneSnap software (Syngene, UK).  
2.8.5 Purification and analysis of DNA quantity and purity  
The resulting PCR products were purified using Wizard SV gel and PCR clean-up system 
(A9281, Promega, USA), according to the manufacturer's protocol. Nucleic acid quantification 
and purity analyses were carried out using a Qubit 4 fluorometer (Q33226, Invitrogen) and a 
NanoDrop 1000 spectrophotometer (ND-1000, Thermofisher) respectively. Both processes 
were carried out according to the manufacturer’s protocol. The 260/280nm absorbance ratio 
 91 
 
of 1.8-2.0 was used to assess the purity of DNA, and samples outside this range were not 
regarded as pure as they indicate the presence of protein, phenol or other contaminants. 
2.8.6 Sequencing  
PCR products were sequenced using the same amplification primers for target genes (as 
shown in Table 2-6). Sequencing of PCR products was done by Eurofins Genomics Germany 
(Eurofins GATC, Ebersberg, Germany), and Source BioScience (Cambridge, UK). Sequence data 
were visualized on SnapGene viewer and Pairwise alignments of DNA sequences were carried 
out using the BLAST server of the National Centre for Biotechnology Information (NCBI): 
http://blast.ncbi.nlm.nih.gov/Blast.cgi and Clustal Omega sequence alignment software: 
http://www.ebi.ac.uk/Tools/msa/clustalo/. Sequences that differed from the CD630 
reference genome were translated with EMBOSS Transeq to identify amino acid substitutions 
within the gene: http://www.ncbi.nlm.nih.gov/gorf/gorf.html 
2.8.7 Proteomic Analysis 
2.8.7.1 Growth conditions and whole-cell protein extraction  
Protein extraction was carried out according to methods previously described by Chilton et 
al. (2014). All strains were grown anaerobically on Columbia blood agar (CBA) at 37⁰C for 64h 
to obtain optimum reproducible protein profiles. Subsequently, CBA plates were recovered 
from the anaerobic cabinet, and all growth was harvested using a sterile swab. Cells were re-
suspended in 1ml of lysis buffer (50mM phosphate buffer, containing 0.5mM 
phenylmethanesulphonylfluoride (PSMF (10837091001, Sigma), protein inhibitor) and kept 
on ice in order to reduce proteolysis. FastPrep 0.1 mm silica spheres lysing beads (116911100, 
MP Biomedicals) were added to the cell suspension, and homogenisation was performed on 
the FastPrep-24 system (116004500D, MP Biomedicals).  Samples were shaken for 2 runs of 
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60 seconds at 4m/s and incubated on ice, before centrifugation for 30 minutes at 21,000g 
(4°C), to remove cell debris. Subsequently, the supernatant was removed and transferred to 
the sterile 0.5ml microcentrifuge tube. Protein concentrations of the lysates were determined 
using the Qubit protein assay kit (Q33211, Invitrogen) according to the manufacturer’s 
protocol. Protein extracts were stored at -20°C until use.  
2.8.7.2 1D gel electrophoresis  
Single dimension gel electrophoresis was carried out using the NuPAGE gel system (A25977, 
ThermoFisher). Five microliters of reduced 2x SDS sample buffer was added to 10µg of protein 
sample and made up to 16µl with distilled water. Each sample was loaded onto a sample well 
of a NuPAGE 10% Bis-Tris protein gels (NP0301, ThermoFisher) alongside 10µl of SeeBlue 
Plus2 pre-stained Protein standard (LC5925, Invitrogen).  Gels were run in NuPAGE MES SDS 
running buffer for 35 minutes at 200V (120mA, 25 W). Gels were stained in Coomassie dye 
overnight and destained using a destaining solution. Gels were visualised under UV light using 
the InGenius Gel documentation system (Syngene, UK) and images were captured using 
GeneSnap software (Syngene, UK). 
2.8.7.3 In-gel tryptic digestion  
Trypsin digestion was carried out using the In-gel tryptic digestion kit (89871, Thermofisher, 
UK) according to the manufacturer’s protocol.  Briefly, using a sterile scalpel, bands from 1D 
gels were excised and transferred into sterile 0.5ml micro-centrifuge tubes containing 200µL 
of destaining solution (25mM ammonium bicarbonate, in 50%(v/v) acetonitrile) added. 
Samples were incubated in a shaking incubator (SHKE8000, ThermoFisher) for 30 mins at 
37°C. The destaining step was then repeated, to ensure full decolourisation in the gel slices. 
The reduction step was performed in 30µl of reducing buffer (50mM TCEP (Tris [2-
carboxyethyl] phosphine), for 10 mins at 60°C, and alkylation in 30µL alkylation buffer (50mM 
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iodoacetamide (IAA)) for 1 hour in the dark.  The gel slices were washed in 200 µL of destaining 
buffer for 15 mins at 37°C (in a shaking incubator), followed by in 50 µl of 100% acetonitrile 
for 15mins at room temperature, and then air-dried for 10 mins. Trypsin digestion was carried 
out in 10 µL of activated trypsin solution (10ng/µl of pierce Trypsin protease in  9 µL of 25mM 
ammonium bicarbonate solution) for 15 mins at room temperature, followed by overnight 
incubation at 37°C in 25 µL digestion (25mM ammonium bicarbonate solution). The peptide 
extracts were transferred into a clean tube, further peptide extraction was performed by 
adding 10 µL of 1% (v/v) trifluoroacetic acid (TFA) (1082620025, EMD Millipore) to gel pieces 
and incubated for 5mins. The extraction mixture was added to the peptide extracts.  Peptides 
extracts were dried down in a speed vacuum and stored in -20°C until use. 
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3 ANTIMICROBIAL SUSCEPTIBILITIES AND RESISTANCE 
MECHANISMS OF CD002 ISOLATES 
3.1 BACKGROUND  
Clostridium difficile (C. difficile) is a Gram-positive pathogenic bacterium which is a leading 
cause of antibiotic-associated diarrhoea (AAD)(Planche & Karunaharan, 2017). Since the 
identification of this pathogen, it emerged globally, causing several epidemics with significant 
morbidity and mortality(McGlone et al., 2012). Currently, C. difficile infection (CDI), accounts 
for approximately 453,000 cases in the United States, 172,000 in Europe and 18,005 in 
England(Borren et al., 2017; Lessa et al., 2015). Recent estimates in Asia, reveal similar rates 
of CDI reported in Europe and North America (Borren et al., 2017). 
Prior or ongoing antimicrobial therapy is known to be an important risk factor for the 
development of CDI. Antibiotics disrupt the normal intestinal microbiota leading to the loss 
of colonisation resistance, thus creating an environment for C. difficile to grow, proliferate 
and cause a toxin-mediated disease(Peng et al., 2017; Pérez-Cobas et al., 2015). The first 
established link between the use of antibiotics and the development of CDI was reported in 
the 1970s, when cases of pseudomembranous colitis (PMC) were linked to the use of 
clindamycin(Bartlett et al., 1978; George et al., 1978; Tedesco et al., 1974). Since then several 
antibiotics, commonly used for the treatment of bacterial infections in the clinical settings 
have been implicated in the development of CDI (Baines & Wilcox, 2015). Clindamycin, a third-
generation cephalosporin, fluoroquinolones and aminopenicillins are reported of greater 
propensity to induce CDI(Loo et al., 2005; Owens et al., 2008; Pepin et al., 2005). 
Majority of C. difficile strains are susceptible to metronidazole and vancomycin, which are the 
first-line therapies for CDI, however, resistance to other antimicrobial agents in recent years 
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is a matter of great concern. Antimicrobial resistance enables C. difficile to thrive in the 
presence of increased levels of an antibiotic in the gut environment(Baines & Wilcox, 2015). 
Consequently, strains of C. difficile, that are resistant to multiple agents may have a selective 
advantage in the colon, possibly enhancing the risk of primary or recurrent CDI. Antimicrobial 
resistance does not only drive epidemiological change but also the emergence of new strain 
types. This was noted during the global emergence of hypervirulent C. difficile strain 
027/B1/NAP1, due to the use of fluoroquinolones(He et al., 2013). These strains exhibited 
mutations in DNA gyrase genes which were absent in reportedly historic strains of the same 
type. Currently, there is no universal resistance pattern that has been reported in C. difficile. 
However reports from different antimicrobial susceptibility studies (between 2012-2015) 
indicated that clinical isolates of C. difficile were commonly resistant to clindamycin, 
cephalosporins, erythromycin and fluoroquinolones (55%,51% and 47% respectively) 
according to the Clinical Laboratory Standards Institute (CLSI) and EUCAST interpretative 
breakpoints(Freeman et al., 2018; Freeman et al., 2015; Goudarzi et al., 2013; Oka et al., 2012; 
Pirš et al., 2013; Senoh et al., 2015; Spigaglia, 2016; Tenover et al., 2012). 
Many investigations have been made on the determinants of C. difficile antimicrobial 
resistance. Several resistance mechanisms have been identified, including the acquisition of 
genetic elements, alterations of antibiotic targets and the contribution of biofilm formation 
on persistence and tolerance(Chilton et al., 2016; Ðapa et al., 2013; James et al., 2018; Vuotto 
et al., 2016). Approximately 11 % of the C. difficile genome, harbours an abundance of mobile 
genetic elements (MGEs), and some of these have been implicated in C. difficile antimicrobial 
resistance (Mullany et al., 2015). An example of this is seen in C. difficile resistance to 
Macrolide-Lincosamide-Streptogramin B (MLSB) antibiotics, which is mediated by at least four 
kinds of transposons, including Tn5398, Tn5398-like derivatives, Tn6194 and Tn6215 
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(Spigaglia, 2016).  Tn5398 have been shown to facilitate the transfer of the ermB gene which 
encodes a 23S rRNA methylase and induces the resistance to the MLSB family antibiotics 
(Wasels et al., 2015). Transfer of Tn6215 between C. difficile strains via phage transduction 
has been demonstrated (Goh et al., 2013), and recent data suggest that both Tn6215 and 
Tn5398 can be transferred to a recipient C. difficile strain through a transformation 
mechanism (Wasels et al., 2015). The transfer of Tn6194 from strains of C. difficile to 
Enterococcus faecalis was also demonstrated in vitro  (Wasels et al., 2015).  
Alterations in the antibiotic target is another mechanism for mediating antimicrobial 
resistance in C. difficile. Many amino acid substitutions have been identified in target genes 
of different antibiotics in C. difficile. An example of this is seen in C. difficile resistance to 
fluoroquinolones, which is as a result of amino acid substitutions in the DNA gyrase genes 
(gyrA and/or gyrB). Mutations in the beta subunit of the rpoB gene, which encodes a bacterial 
RNA polymerase is known to mediate reduced susceptibility and resistance to rifamycins 
(Curry et al., 2009; O’Connor et al., 2008). Multiple factors may induce alterations in the 
antibiotic targets, however selective pressure from exposure to antibiotics in the 
environment is the most common mechanism. Recent reports by Vuotto and colleagues 
showed enhanced biofilm formation by C. difficile strains, due to selective pressure from 
exposure to antibiotics (Vuotto et al., 2016). It is suggested that biofilm formation may 
contribute to the acquisition of antimicrobial resistance in C. difficile, however, the 
mechanism is still poorly understood.  
Since the continued use of antibiotics drives epidemiological prevalence and the emergence 
of new strain types, it is imperative to test the susceptibility of emerging ribotypes of C. 
difficile to different antibiotics. As a result, the antibiotic susceptibility and resistant patterns 
of C. difficile ribotype 002, which emerged recently as the most prevalent ribotype in the UK 
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will be investigated in the present study. Numerous methods exist for antimicrobial 
susceptibility testing (AST); however, the agar dilution method is the recommended gold 
standard by the CLSI. Agar dilution methods employ the diffusion of the antibiotic into the 
agar, and susceptibility to C. difficile is determined by comparing the minimum inhibitory 
concentration (MIC) values to the MIC interpretative breakpoint values. 
3.1.1 Aims and objectives  
To characterise clinical isolates of C. difficile ribotype 002 from different time lineages and 
geographical locations, according to their sensitivity and resistance to different antibiotics. 
The aims will be achieved by the following objectives 
1. Determination of the minimum inhibitory concentrations to a diverse panel of 
antibiotics using the agar dilution method 
2. Determination of mechanisms of resistance using PCR and sequencing of resistance 
genes, clindamycin inducible resistance, and beta-lactamase assay 
3.2 MATERIALS AND METHODS 
3.2.1 Bacterial Strains 
The C. difficile isolates used for this study have been described in chapter 2.1.1. Control strains 
used included; E4 (PCR ribotype 010), which was previously characterised as being reduced 
susceptible to metronidazole(Brazier et al., 2001), p62 (PCR ribotype 001) as a clindamycin-
resistant control (Fawley et al., 2003), Bacteroides fragilis (B. fragilis) ATCC 25285 as a 
metronidazole-susceptible control, and Staphylococcus aureus (S. aureus) ATCC 29213 was 
included as an indicator for aerobic contamination. Escherichia coli (E. coli) NCTC 9001 was 
used as a nitrofurantoin-susceptible control.   
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3.2.2 Antimicrobials Susceptibility testing and Minimum Inhibitory 
Concentration (MIC) Determination 
Antimicrobial susceptibility testing was carried out according to methods described in 2.2. 
The MIC was determined as the lowest antimicrobial concentration where an absence or 
marked reduction of growth (multiple tiny colonies, haze or fine film of growth or one or two 
colonies) compared with the growth control was observed. The MIC values for individual 
strains were categorised as susceptible, intermediate and resistant based on the 
CLSI/EUCAST/BSAC MIC interpretative breakpoint values (Table 3-1). However, there were no 
approved breakpoints for the following antimicrobials: nitrofurantoin, clarithromycin, and 
trimethoprim against C. difficile; therefore, MIC breakpoint values for these antibiotics 
antimicrobials against S. aureus were used. 
3.2.3 Clindamycin inducible resistance 
Resistance to clindamycin was investigated by the clindamycin Inducible resistance (‘D test’) 
test. This test has been previously used to identify strains of Staphylococcus species that are 
inducible resistant to clindamycin(Prabhu et al., 2011). The aim of the test is to induce the 
expression of erm-mediated resistance through the exposure of isolates to both clindamycin 
and erythromycin, adjacent to one another on an agar plate. This test was performed on C. 
difficile isolates with MICs ≥8 mg/L, which according to CLSI guidelines were resistant to 
clindamycin. One hundred microliters of C. difficile overnight culture in Schaedler’s anaerobe 
broth was inoculated onto pre-dried Wilkins Chalgren agar (WCA). Using a sterile swab, the 
bacterial suspension was evenly spread out on the WCA agar plates. Subsequently, a 30µg 
disc of erythromycin (CT0021B, Oxoid) was placed at 15mm from a 10µg clindamycin 
(CT0015B, Oxoid) using an Oxoid disc dispenser and incubated anaerobically for 48h at 37°C. 
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Following incubation, plates were retrieved from the anaerobic cabinet and examined for 
flattening of inhibition zone (D-shaped) around the clindamycin disc in the area between two 
discs (Figure 3.1). This phenomenon is an indication of inducible clindamycin resistance.  
 
 
         A -Positive ‘D’- test              B- Negative ‘D’- test 
 
 
Figure 3-1 Schematic diagram showing clindamycin inducible resistance: A) is a representation of a 
positive D- test (D+ Phenotype). B) Is representation of a negative D- test phenotype E- Erythromycin, 
C-Clindamycin. 
 
3.2.4 Beta-Lactamase Activity Assay  
Beta-lactamase activity was assayed based on the hydrolysis of nitrocefin, a chromogenic 
cephalosporin that results in the generation of a coloured product. All isolates were 
investigated for β-Lactamase activity, using the broth method. Four drops of rehydrated 
nitrocefin (SR0112, ThermoFisher) solution was added to 1mL of C. difficile culture grown in 
Wilkins Chalgren broth. β- Lactamase activity was monitored by a visible colour change from 
yellow to red within 30 minutes of incubation. 
Zone of inhibition 
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3.2.5 Molecular analysis of mechanisms of resistance  
Molecular analysis of the mechanisms of resistance to erythromycin, clindamycin, rifampicin, 
ciprofloxacin and moxifloxacin were investigated using a PCR assay. PCR products were 
purified using Wizard SV gel and PCR clean-up system (A9281, Promega, USA), and sequencing 
was done by Eurofins Genomics Germany (Eurofins GATC, Ebersberg, Germany), and Source 
BioScience (Cambridge, UK). Pairwise alignments of DNA sequences were carried out using 
the BLAST server and Clustal W Omega as described in 2.6.6. 
 
Ciprofloxacin and moxifloxacin resistant isolates (MIC ≥8mg/L) were investigated for the 
mutations in the DNA gyrase genes (gyrA & gyrB). The quinolone resistance determining 
region (QRDR) of both gyrA and gyrB genes was amplified using two different pairs of primers, 
listed in Table 2-6. PCR amplification consisted of 30 cycles of denaturation at 94°C for 30 s, 
annealing at 54°C (gyrB)/ 58°C (gyrA) for 30 s, and extension at 72°C for 30s(Spigaglia et al., 
2011). Using agarose gel electrophoresis, described in 2.8.4, the resulting PCR products were 
assessed for the presence of a 390bp internal fragment of the gyrB and gyrA (Figure 3-5) by 
using standard molecular weight markers; Hyper ladder1-kb (BIO-33053, Bioline, London UK). 
 
Erythromycin and clindamycin-resistant isolates (MIC ≥ 8mg/L) were investigated for the 
presence of the erm (B) gene by using the primers pair ermBf and ermBr listed in Table 2-6, 
(Sutcliffe et al., 1996). Strain p62 (PCR ribotype 001), previously described as resistant to 
clindamycin (Fawley et al., 2003), was included as a positive control for erm (B) gene. 
According to published methods by Solomon et al, PCR amplification consisted of 35 cycles of 
denaturation at 94°C for 30s, annealing at 52°C for 60s, and elongation at 72°C for 60s. The 
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last elongation step was performed at 72°C for 5 minutes(Solomon et al., 2011). Using agarose 
gel electrophoresis as described in 2.8.4, the resulting PCR product were assessed for the 
presence of a 639bp internal fragment of the erm(B) (Figure 3-5) by using standard molecular 
weight markers; 1kb DNA ladder (D3937, Sigma). 
 
To detect the presence of other classes of erm (A, C, F and Q) in ermB negative isolates, 
primers described by Patterson et al (2007) as listed in Table 2-5 were used. PCR 
amplifications consisted of 35 cycles of denaturation at 94°C for 30 s, annealing at 48°C 
(ermA), 43°C (ermC), and 52°C (ermQ) for 1 min, and elongation at 72°C for 2 mins. For ermF, 
PCR amplification consisted of 35 cycles of denaturation at 94°C for 30 s, annealing at 50°C 
for 30 s, and elongation at 72°C for 2 min. Using agarose gel electrophoresis as described in 
2.8.4, the resulting PCR products were assessed for the presence of 645bp, 642bp, 466bp, 
and 771bp internal fragments of erm (A, C, F and Q respectively) (Figure 3-5) by using standard 
molecular weight markers; 1kb DNA ladder (D3937, Sigma). 
 
Rifampicin resistant isolates with an MIC ≥16mg/L were investigated for mutations in rpo (B) 
gene using previously published primers CDrpoB2F and CDrpoB2R (Curry et al., 2009) as listed 
in Table 2-6. PCR amplifications consisted of 35 cycles of denaturation at 95°C for 1 min, 
annealing at 49.9°C for 1 min, and elongation at 72°C for 1min. Using agarose gel 
electrophoresis as described in 2.8.4, the resulting PCR product were assessed for the 
presence of 200bp, internal fragments of rpo (B) (Figure 3-5) by using standard molecular 
weight markers; 100bp DNA ladder (D3687, Sigma). 
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3.2.6 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 6 software (GraphPad Software, La 
Jolla, CA). In order to determine the appropriate statistical test to use, data were assessed for 
normality of distribution using both D’Agostino-Pearson and Shapiro-Wilk normality test. 
Statistically significant differences were tested using Kruskal-Wallis tests and differences were 
considered significant at a P-value of <0.05. An additional post hoc testing using Dunn’s 
multiple comparison tests was used to determine the significant differences that existed 
between groups. 
3.3 RESULTS 
3.3.1 Antimicrobial susceptibility in all isolates and differences between 
groups 
The susceptibility of all isolates was determined according to the CLSI/BSAC/EUCAST MIC 
recommended breakpoint values (as shown in Table 3-1). All isolates were fully susceptible to 
metronidazole, vancomycin, fidaxomicin, chloramphenicol, meropenem, linezolid and 
tetracycline (Table 3-1). Nitrofurantoin susceptibility was observed in 98.3% (n=59) of 
isolates; 96.7% (n=58) were susceptible to both erythromycin and moxifloxacin; 93.3% (n=56) 
were susceptible to clarithromycin; 91.6 % (n=55) were susceptible to rifampicin, and 6.7% 
(n=4) were susceptible to penicillin while 5% (n=3) and 3.3 % (n=1) were susceptible to 
ampicillin and clindamycin respectively. The MIC50 was the same value as MIC90 for all 
antimicrobial agents in all lineages, except for metronidazole, vancomycin, clindamycin, and 
nitrofurantoin. 
As shown in figure 3-3, the older strains (UK 2007-8) had higher geometric mean MIC values 
for metronidazole (GM MIC= 0.4 mg/L, p<0.05), erythromycin (GM MIC= 2.6 mg/L,  p>0.05), 
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clarithromycin (GM MIC=1.5 mg/L, p<0.05 ), moxifloxacin (GM MIC= 2.3 mg/L, p>0.05), and 
ciprofloxacin (GM MIC = 18.4 mg/L, p>0.05). The geometric mean MICs for meropenem (2.7 
mg/L) and nitrofurantoin (6 mg/L) were higher in UK 2011-13 isolates, however, this was not 
statistically significant (p>0.05). Non-UK 2012-14 isolates had higher geometric mean MIC 
values for vancomycin (GM MIC =1.1 mg/L, p<0.05), and clindamycin (GM MIC= 9.6 mg/L, 
p>0.05).Conversely, the recent isolates (UK 2011-13 & Non- UK 2012-14) had higher 
geometric mean MICs for chloramphenicol (GM MIC= 3.8 mg/L, p>0.05).No statistical 
significant differences (p>0.05) existed between lineages for geometric mean MICs to 
penicillin, ampicillin, rifampicin, linezolid, fidaxomicin and tetracycline. 
3.3.2 Antimicrobial resistance of CD002 
Fluoroquinolone resistance was common in this study, as shown in Figure 3-2, all isolates 
were resistant to ciprofloxacin at an MIC of ≥8mg/L, only one UK isolate belonging to UK 2007-
08 lineage was resistant to moxifloxacin (MIC >128mg/L). Amplicons produced following 
amplification of the quinolone resistance determining region (QRDR) of gyrA and gyrB (Figure 
3-4a) were sequenced to detect sequence polymorphisms. A point mutation ACT- ATT in gyrA, 
resulting in the amino acid substitution Thr-82-Ile, was identified in two strains, one strain 
was of the recent non-UK lineage (Non- UK 2012-2014) while the second belonged to the 
older UK lineage (UK 2007-8). A novel nucleotide substitution Arg-98-Thr, Asp-103-His was 
identified in a non-UK isolate (Non- UK 2012-2014).  No other nucleotide substitutions were 
identified. No nucleotide substitutions were identified in the gyrB gene. 
 
Resistance to rifampicin (MIC of ≥32mg/L) was noted in one non-UK strain. Five isolates (1 
each in both UK lineages and 3 in the Non-UK lineage) were reduced susceptible to rifampicin 
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at an MIC ≥0.004-16 mg/L. Resistant and reduced susceptible isolates were investigated for 
mutations in the rpoB gene (Figure 3-5c). Sequence analysis revealed a point mutation AGA- 
AAA in rpoB, resulting in the amino acid substitution Arg-505-Lys. This substitution was 
identified in one strain (MIC ≥ 16mg/L) of a non-UK lineage (2012-14). Additionally, a novel 
amino acid substitution Leu-509-Phe (CTT- TTT) was identified in a reduced susceptible strain 
(MIC ≥ 0.016mg/L), this strain belonged to the UK 2007-8 lineage.  
 
Clindamycin resistance was present in 27% (n=16) of isolates, with many resistant isolates 
being of the non-UK lineage (n=8). Only two isolates (3.3%) belonging to two different UK 
lineages (UK 2007-8 & UK 2011-13) were resistant to erythromycin. The mechanisms of 
resistance to MLSB antibiotics were further investigated by clindamycin inducible resistance 
test and PCR amplification to assess the presence of the erm (B) gene. The clindamycin 
inducible resistance test was negative for all isolates tested as shown in Figure 3-4. The erm 
(B) gene was not detected in any of the clindamycin resistant or erythromycin-resistant 
strains (Figure 3-5b). These strains were further investigated for the presence of other erm 
genes (A, C, F and Q), but none of these genes were present in any of the resistant isolates 
(Data not shown). 
 
Intermediate resistance to ampicillin, penicillin, and clindamycin was observed in 93.3% 
(n=56), 93.3% (n=56), and 73.3%(n=44) of isolates respectively. To investigate the presence 
of beta-lactamase activity conferring resistance to penicillin, a beta-lactamase assay was 
performed. No isolates were positive for the Nitrocefin assay. All isolates were resistant to 
trimethoprim at an MIC breakpoint ≥128. Two isolates (3.3%), belonging to two different UK 
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lineages (UK 2007-8 & UK 2011-13) demonstrated resistance to clarithromycin, and while one 
isolate (1.7%) belonging to the UK 2007-8 lineage was resistant to nitrofurantoin.   
 
Multidrug resistance (MDR), defined as resistance to more than two antimicrobial classes was 
observed in one UK isolate (UK 2007-8). This isolate was resistant to four antimicrobial classes 
(Fluoroquinolones, nitrofurans, macrolide-lincosamide-streptogramin B, and beta-lactams).
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Table. 3-1 Antimicrobial susceptibilities (Geometric mean MIC, mg/L) of 60 clinical CD002 isolates to antimicrobial agents using agar 
incorporation MIC testing. PEN, penicillin G, AMP ampicillin, LZD, linezolid, MOX, moxifloxacin CHL, chloramphenicol, CLA, clarithromycin, ERY, 
erythromycin; VAN, vancomycin; MET, metronidazole; NIT, nitrofurantoin; CLI, clindamycin; TET, tetracycline; CIP, ciprofloxacin, MER, 
Meropenem, FDX, Fidaxomicin, RIF, Rifampicin and TMP, Trimethoprim  
Antimicrobial 
Agent 
Lineage N GM MIC 
(mg/L) e 
MIC range 
(mg/L) 
MIC 50 
(mg/L) 
MIC 90 
(mg/L) 
MIC Interpretative Breakpoints S, n (%)  I, n (%)  R, n (%)  
S I R 
 
METa 
UK 2007-8 14 0.4 0.25-2 0.25 0.5 ≤ 2 - >2 14 (100) 0 (0) 0 (0) 
UK 2011-13 22 0.3 0.25-0.5 0.25 0.5 22 (100) 0 (0) 0 (0) 
Non-UK 2012-14 24 0.3 0.25-0.5 0.25 0.25 24 (100) 0 (0) 0 (0) 
 
VANb 
UK 2007-8 14 0.8 0.5-2 1 1 ≤ 2 - >2  14 (100) 0 (0) 0 (0) 
UK 2011-13 22 0.9 0.5-2 1 1 22 (100) 0 (0) 0 (0) 
Non-UK 2012-14 24 1.1 0.5-2 1 2 24 (100) 0 (0) 0 (0) 
 
FDXc  
UK 2007-8 14 0.1 0.02-0.125 0.06 0.125  
<1 
 
>1  
 
- 
14 (100) 0 (0) 0 (0) 
UK 2011-13 22 0.1 0.02-0.125 0.06 0.125 22 (100) 0 (0) 0 (0) 
Non-UK 2012-14 24 0.1 0.02-0.125 0.06 0.125 24 (100) 0 (0) 0 (0) 
 
RIFa 
UK 2007-8 14 0.002 0.002-0.016 0.002 0.002  
≤0.002 
 
0.004-16 
 
≥16 
13(95.45) 1 (4.5) 0(0) 
UK 2011-13 22 0.002 0.002-0.004 0.002 0.002 21(95.45) 1 (4.5) 0(0) 
Non-UK 2012-14 24 0.003 0.002-32 0.002 0.004 21(87.5) 2(8.3) 1(4.1) 
 
ERYa  
UK 2007-8 14 2.6 2-128 2 2  
≤2 
 
4 
 
≥8 
13(92.9) 0 (0) 1 (7.1) 
UK 2011-13 22 2.3 2-128 2 2 21(95.5) 0 (0) 1(4.5) 
Non-UK 2012-14 24 1.9 1-2 2 2 24 (100) 0 (0) 0 (0) 
 
CLIa  
UK 2007-8 14 5.3 4-8 4 8  
≤2 
 
4 
 
≥8 
0 (0) 11(78.6) 3(21.4) 
UK 2011-13 22 7.1 2-8 4 8 1(4.5) 16(72.7) 5(22.7) 
Non-UK 2012-14 24 9.6 4-8 4 8 0(0) 17(70.8) 8 (29.1) 
  
CIPa 
  
UK 2007-8 14 18.4 16-128 16 16  
≤4 
 
- 
 
≥8 
0 (0) 0 (0) 14(100) 
UK 2011-13 22 16.5 8-32 16 32 0 (0) 0 (0) 22(100) 
Non-UK 2012-14 24 16 8-32 16 16 0 (0) 0 (0) 24(100) 
  
MOXa 
  
UK 2007-8 14 2.3 2-32 2 2  
≤2 
 
4 
 
≥8 
13(92.86) 0(0) 1 (7.14) 
UK 2011-13 22 1.8 1-2 2 2 22(100) 0(0) 0(0) 
Non-UK 2012-14 24 1.9 1-4 2 2 23(95.83) 1 (4.5) 0(0) 
 
PENa 
  
UK 2007-8 14 1 ≤1 1 1  
≤0.5 
 
1 
 
≥2 
0 (0) 14 (100) 0 (0) 
UK 2011-13 22 0.9 0.5-1 1 1 4(18.2) 18 (81.1) 0 (0) 
Non-UK 2012-14 24 1 ≤1 1 1 0(0) 24 (100) 0 (0) 
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Antimicrobial 
Agent 
Lineage N GM MIC 
(mg/L) e 
MIC range 
(mg/L) 
MIC 50 
(mg/L) 
MIC 90 
(mg/L) 
MIC Interpretative Breakpoints S, n (%)  I, n (%)  R, n (%)  
S I R 
  
AMPa 
  
UK 2007-8 14 1 0.5-2 1 1  
≤0.5 
 
1 
 
≥2 
1 (7.1) 12 (85.7) 1(7.1) 
UK 2011-13 22 1 0.5-1 1 1 1 (4.5) 21(95.5) 0 (0) 
Non-UK 2012-14 24 1 0.5-1 1 1 1 (4.5) 23 (95.5) 0 (0) 
  
MERa 
  
UK 2007-8 14 2.4 2-4 2 4  
≤4 
 
8 
 
≥16 
14 (100) 0 (0) 0 (0) 
UK 2011-13 22 2.7 2-4 2 4 22 (100) 0 (0) 0 (0) 
Non-UK 2012-14 24 2.5 2-4 2 4 24 (100) 0 (0) 0 (0) 
 
TETa 
 
UK 2007-8 14 0.2 0.125-0.25 0.25 0.25  
≤4 
 
8 
 
≥16 
14 (100) 0 (0) 0 (0) 
UK 2011-13 22 0.2 0.125-0.25 0.25 0.25 22 (100) 0 (0) 0 (0) 
Non-UK 2012-14 24 0.2 0.125-0.5 0.25 0.25 24 (100) 0 (0) 0 (0) 
  
CHLa 
  
UK 2007-8 14 3.5 2-4 4 4  
≤8 
 
16 
 
≥32  
14 (100) 0 (0) 0 (0) 
UK 2011-13 22 3.8 2-4 4 4 22 (100) 0 (0) 0 (0) 
Non-UK 2012-14 24 3.8 2-4 4 4 24 (100) 0 (0) 0 (0) 
  
LZDb 
  
UK 2007-8 14 2 ≤2 2 2  
≤4 
 
- 
 
>4  
14 (100) 0 (0) 0 (0) 
UK 2011-13 22 1.9 1-2 2 2 22 (100) 0 (0) 0 (0) 
Non-UK 2012-14 24 2.0 ≤2 2 2 24 (100) 0 (0) 0 (0) 
 
 CLAd  
UK 2007-8 14 1.5 1-128 1 2  
≤1 
 
2 
 
>2 
11(78.6) 2(14.3) 1(7.1) 
UK 2011-13 22 1.2 1-128 1 1 21(94.5) 0(0) 1(4.5) 
Non-UK 2012-14 24 1.1 1-2 1 1 24(100) 0(0) 0(0) 
  
NITd 
  
UK 2007-8 14 5.3 4-32 4 8  
≤8  
 
16  
 
≥32   
13 (92.9) 0 (0) 1 (7.1) 
UK 2011-13 22 6.0 4-8 8 8 22 (100) 0 (0) 0 (0) 
Non-UK 2012-14 24 4.8 4-8 4 8 24 (100) 0 (0) 0 (0) 
  
TMPd 
  
UK 2007-8 14 128 >128 - -  
≤1 
 
- 
 
>1 
0 (0) 0 (0) 60 (100) 
UK 2011-13 22 128 >128 - - 0 (0) 0 (0) 60 (100) 
Non-UK 2012-14 24 128 >128 - - 0 (0) 0 (0) 60 (100) 
a MIC breakpoint applied were those recommended by the Clinical and Laboratory Standards Institute (CLSI) b Vancomycin and linezolid MIC breakpoint applied was 
recommended by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (www.eucast.org) c Fidaxomicin  MICs were compared to the EUCAST 
epidemiological cut-off value (1 mg/L) and defined as sensitive or reduced susceptibility. dMIC breakpoints applied were those recommended for S. aureus by the British 
society for antimicrobial chemotherapy (BSAC) (http://bsac.org).   eGeo mean - The central number in a geometric progression (e.g. 9 in 3, 9, 27), also calculable as the nth 
root of a product of n number.
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Figure 3-2 Antimicrobial resistance (% of isolates above the susceptible MIC breakpoint) of clinical 
CD002 (N=60) to a range of antimicrobial agents using agar incorporation MIC testing. 
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Figure 3-3  Antimicrobial agents geometric mean (GM) MICs (mg/L) for CD002 using agar incorporation MIC testing. PEN, penicillin 
G; AMP ampicillin; LZD, linezolid; MXF, moxifloxacin; CHL, chloramphenicol; CLA, clarithromycin; ERY, erythromycin; VAN, 
vancomycin; MET, metronidazole; NIT, nitrofurantoin; CLI, clindamycin; TET, tetracycline; CIP, ciprofloxacin, FDX, fidaxomicin, MER, 
Meropenem, Rifampicin, RIF. GM MICs (mg/L) for MET, ERY, MOX, CIP, and CLA were higher in UK 2007-8, MER and NIT were higher 
in UK 2011-13, VAN, and CLI was higher in Non-UK 2012-14 isolates, while CHL was higher in both UK 2011-13 and Non-UK 2012-14 
isolates. The asterisk (*) indicates where a statistical difference was observed. 
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Figure 3-4 Disk diffusion testing for inducible clindamycin resistance of CD002 isolates. Erythromycin disk was placed 15mm apart from 
Clindamycin disk. A) C. difficile P62 strain, clindamycin resistant, negative D- test; B) CD002 strain 157, Erythromycin susceptible and clindamycin 
resistant, negative for D- test; C) CD002 strain 160, erythromycin and clindamycin resistant, negative D- test.  
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Figure 3-5 PCR analysis of antimicrobial resistance genes in CD002. Genomic DNA was extracted from CD002 isolates, and PCR was conducted to identify different target genes. PCR 
products were analysed by 1.4 % (w/v) agarose gel electrophoresis and visualized using UV light in a gel doc system. A) A PCR image for investigation of DNA gyrase subunit A and B genes, 
Lane1 represents 1kb DNA ladder, while lane 2-7 are amplified products for gyrB, lane 9-17 are amplified products for gyrA, lane 18 is a negative control. B) A PCR image for investigation 
or erm(B) gene; lane 1 is 1kb DNA ladder, while lane 2-16 are amplified products of the erm(B) gene, lane 18 is a negative control, while lane 19 is a positive control(P62) for the presence 
of DNA. C) A PCR image for investigation of rpoB gene in reduced susceptible and resistant CD002 isolates; Lane 1 and 10 1kb DNA ladder, lane 2-8 are amplified products of rpoB, Lane 9 
is a negative control. The investigated gene; gyrA, gyrB, and rpoB were present in all isolates. All strains were negative for the erm (B) gene and only positive for the P62 control at 639bp. 
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3.4 DISCUSSION 
Antimicrobial agents are known to play an important role in the induction and development 
of CDI. Some antimicrobial agents serve as treatments for CDI, while others are non-
treatment agents, and both categories have the propensity to induce CDI. For the non-
treatment agents, there is the potential that C. difficile strains, resistant to these agents might 
be able to cause CDI at an earlier stage in dosing when gut levels are still above the MIC of 
the indigenous microflora. On the other hand, C. difficile isolates sensitive to either treatment 
or non-treatment agents, are also able to induce CDI, following cessation of the antimicrobial 
therapy. CD002 emerged recently as the most prevalent ribotype in the UK, and evidence 
shows that it is the most frequently isolated ribotype in the community-associated CDI(CA-
CDI) cases (Fawley et al., 2016). There is a possibility that antimicrobial agents been 
prescribed in the community for unrelated conditions such as throat infections, might be 
facilitating the prevalence of this ribotype in the community, consequently, leading to the 
import of CD002 into the hospital settings. As a result, antimicrobial susceptibility profiles to 
different agents, particularly agents typically prescribed in the community settings is 
necessary. In the present study, C. difficile PCR ribotype 002 isolates from different time 
lineages in the UK were tested for their antimicrobial susceptibility to seventeen antimicrobial 
agents. Using the MIC breakpoint values recommended by CLSI, EUCAST or BSAC as 
appropriate.  
C. difficile resistance to first-line CDI therapies; metronidazole and vancomycin, is rarely 
reported (Freeman et al., 2015, 2018; Peláez et al., 2002). However, treatment failures 
associated with the use of metronidazole and vancomycin have been reported but not linked 
to resistance to these agents (Johnson et al., 2000; Musher et al., 2005; Pepin et al., 2005; 
 113 
 
Vardakas et al., 2012). It is hypothesised that the poor efficacy of metronidazole may be 
associated with the colon concentration (0-9.3mg/L in faeces) which is insufficient to treat 
cases of CDI caused by strains with higher MICs(Baines et al., 2008; Bolton & Culshaw, 1986; 
Moura et al., 2013). Additionally, the development of heteroresistance which is reported in 
several studies may also be a contributing factor in the poor treatment efficacy of 
metronidazole (Martínez-Meléndez et al., 2018; Peláez et al., 2008). 
The emergence of reduced susceptibility to metronidazole (i.e. MIC ≥ 4mg/L) was previously 
reported in C. difficile in ribotype 001 and subsequently in other ribotypes such as 027, and 
106 (Baines et al., 2008; Freeman et al., 2015,2018). Concurrently, decreased susceptibility to 
vancomycin (MIC ≥4mg/L) has also been reported around Europe and the United States 
(Freeman et al., 2015) in a small proportion of isolates. The mechanism(s) of reduced 
susceptibility to metronidazole and vancomycin are yet to be elucidated. However, a report 
by Baines and colleagues hypothesised that reduced entry or enhanced efflux of the drug 
could contribute to the reduced susceptibility of C. difficile isolates to metronidazole(Baines 
et al., 2008). Recently, proteomic analysis of a resistant and reduced-susceptible phenotypes 
of PCR ribotype 027, revealed multiple proteins (such as putative 5-nitroimidazole reductase) 
involved in DNA repair and iron metabolism (Chong et al., 2014). The authors suggested that 
these proteins may contribute to the resistance and/or reduced susceptibility to 
metronidazole in C. difficile. The clinical impact of reduced susceptibility to vancomycin on 
treatment response remains undefined, as it is widely known, that high levels of vancomycin 
is reached in the colon (>2200mg/L) (Martínez-Meléndez et al., 2018; Young et al., 1985). 
In this study, neither resistance nor reduced susceptibility to vancomycin and metronidazole 
was observed among clinical isolates of CD002. CD002 isolates were inhibited by 
metronidazole at MIC50 0.25mg/L and MIC90 0.5mg/L, this finding correlates with reports by 
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Freeman et al. (2015). Published data show that metronidazole susceptibility in other C. 
difficile ribotypes varies between 0.125mg/L- 1mg/L respectively, contingent to geographical 
region(Rahimi, Jalali, & Weese, 2014). Ninety per cent of CD002 isolates were inhibited at a 
range of 0.5- 2mg/L to vancomycin. This suggests that the emergence of CD002 in the UK and 
across Europe is not because of the acquisition of antimicrobial resistance elements or 
acquired resistance due to mutational events following exposure to current CDI treatments. 
Fidaxomicin was approved in 2011 as a therapy for CDI (Crawford et al., 2012). Since then, it 
has been reported to have excellent activity against C. difficile isolates (Ackermann et al., 
2004; Finegold et al., 2004; Freeman et al., 2015, 2018; Goldstein et al., 2011; Louie et al., 
2011).In a recent US-based surveillance study, 925 C. difficile isolates were inhibited at a range 
of (≤0.004-1mg/L) with an MIC90 of 0.5mg/L (Snydman et al., 2015). A recent analysis of C. 
difficile isolates in Mexico revealed an MIC90 of 0.06 mg/L to fidaxomicin(Martínez-Meléndez 
et al., 2018). In a previous study, 1323 isolates of C. difficile were inhibited at an MIC range of 
≤0.001-1mg/L, with MIC90 of 0.5mg/L (Goldstein et al., 2012). In a three-year pan-European 
surveillance study, 2830 isolates were inhibited at a range (≤0.002-0.25mg/L), with an MIC90 
of 0.125mg/L (Freeman et al., 2018). In the present study, all CD002 isolates were inhibited 
at an MIC range of (≤0.002-0.125mg/L), with an MIC90 of 0.125mg/L in all lineages, this is 
consistent with reports by Freeman et al. (2015, 2018). 
Reduced susceptibility and resistance of C. difficile to fidaxomicin is very rare. One isolate with 
an MIC of 16 mg/L, recovered from a patient with recurrent CDI has previously been reported 
(Goldstein et al., 2011). Recently, Martinez-Melendez et al. (2018) reported four clinical 
isolates of PCR ribotype 027 with an MIC of 2mg/L, which were recovered from patients with 
recurrent CDI. Previously, Finegold et al. (2004), reported a single isolate with an MIC of 
2mg/L. In vitro analysis by Leeds et al. (2014), demonstrated the presence of mutations in 
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rpoB or CD22120 which may confer reduced susceptibility or resistance of fidaxomicin to C. 
difficile.  The MICs of CD002, presented in this study were much lower than the concentrations 
of fidaxomicin that are achieved the gut lumen and stool i.e. >1000 µg/g (Sears et al., 2012). 
Consistent with reports by Freeman et al. (2015, 2018), reduced fidaxomicin susceptibility 
was not observed CD002. In addition, the authors reported that fidaxomicin susceptibility is 
retained among C. difficile ribotypes circulating around Europe, following its introduction for 
use in the clinical setting.  Based on reports by Freeman et al (2015, 2018) and the present 
study, we suggest that the emergence of CD002 in the UK is not due to reduced fidaxomicin 
susceptibility. However, continued surveillance is required, since reduced susceptibility to 
fidaxomicin in other ribotypes has previously been reported in different geographical 
locations (Goldstein et al., 2011; Martínez-Meléndez et al., 2018). 
Rifamycins (rifaximin) have been used as a therapy for CDI (Oldfield et al., 2014). Recently, 
rifaximin was proposed as a chaser therapy for the treatment of recurrent CDI (Oldfield et al., 
2014). C. difficile resistance to rifampicin has been reported in many studies, and mutations 
within the gene encoding the β-subunit of the RNA polymerase (rpoB), is the known 
mechanism for resistance (Huang et al., 2013; Martínez-Meléndez et al., 2018). Different 
amino acid substitutions have been identified within rpoB, however, Arg505Lys, known to 
confer a high- level of rifampicin resistance (MIC ≥128mg/L), and a low fitness burden, is the 
most common (Curry et al., 2009; Dang et al., 2016; O’Connor et al., 2008; Spigaglia et al., 
2011). In the present study, reduced susceptibility and resistance to rifampicin was 
uncommon, 91.7%(n=55) of isolates were fully susceptible at concentrations 
(MIC≤0.002mg/L) below the reported faecal concentrations(8000 µg/g)(Jiang et al., 2000). 
Only one isolate of CD002, from Spain, was resistant, while five other isolates from different 
lineages and geographical locations were reduced susceptible to rifampicin. In the pan-
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European surveillance study, 13.33% of isolates of different ribotypes originating from Spain, 
were resistant to rifampicin, none of these isolates was ribotype 002 (Freeman et al., 2015). 
Additionally, previous studies have reported higher rifampicin resistance amongst C. difficile 
isolates from Italy and Hungary (Freeman et al., 2015, 2018; Miller et al., 2011). However, in 
the present study, CD002 isolates from Italy were fully susceptible to rifampicin.  
Molecular analysis of resistant and reduced susceptible CD002 isolates in the present study 
revealed previously reported amino acid substitution in rpoB Arg505Lys, in a Non- UK 2012-
14 Strain. Additionally, a novel amino acid substitution (Leu509Phe) was identified in a 
reduced susceptible isolate belonging to the UK 2007-8 lineage. Mutational changes at this 
amino acid position 509, is very rare in C. difficile other species (including E.coli, S. aureus), 
but has been previously seen in Mycobacterium tuberculosis (Tan et al., 2012). The amino acid 
substitutions reported in the present study are located within position 488- 583 of the rpoB 
gene and mutations in this region are known to either disrupt the direct interaction between 
rifamycins and RpoB, or modify the rifamycin- binding pocket and therefore reduce affinity of 
the target for the antimicrobial(Baines & Wilcox, 2015; Curry et al., 2009). Although resistance 
to rifamycins was rarely seen in the present study, (which suggests that rifamycins are unlikely 
facilitating the emergence of CD002 in the UK), we cannot negate the observation from the 
three year pan-European surveillance study, that reported rifamycin resistance as being 
common among multiple C. difficile  ribotypes (Particularly, 027, 001, 018, 356, 017, 176  and 
198) (Freeman et al., 2018). As a result, continued surveillance in CD002 and other C. difficile 
ribotypes is required to monitor the spread of resistance and its impact on emerging C. difficile 
ribotypes. 
Fluoroquinolone resistance in Europe is linked with hospital outbreaks caused by common 
prevalent ribotypes, notably PCR ribotype 027 (Freeman et al., 2015; Spigaglia et al., 2010). A 
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high level of resistance to second-generation (ciprofloxacin) and third-generation 
(moxifloxacin) fluoroquinolones was reported in studies of clinical isolates(Barbut et al., 2007) 
and was proven to be the main event responsible for the emergence of CD027 globally(He et 
al., 2013). Resistance to fluoroquinolones can be associated with mutations present in the 
quinolone resistance determining region (QRDR) of gyr genes (the gene products of which are 
involved in the replication of bacterial DNA), with the majority of the resistant C. difficile 
strains showing amino acid substitutions in the gyrA gene (Keessen et al., 2013;  Spigaglia et 
al., 2011).In the present study, all CD002 isolates were resistant to ciprofloxacin (MIC ≥ 
8mg/L). This is in concordance with earlier reports by Cheng et al, who reported resistance to 
ciprofloxacin at MICs > 32mg/L in CD002 isolates(Cheng et al., 2011). Similarly, all human 
isolates of C. difficile (including CD002) in a previous study, were highly resistant to 
ciprofloxacin, while no resistance to moxifloxacin resistance was recorded(Pirš et al., 2013). 
Barbut et al (2007) and Freeman et al (2015) observed moxifloxacin resistance in 37.4 % and 
39.9% of C. difficile isolates respectively. In the present study, only one isolate of CD002 (UK 
2007-8) was resistant to moxifloxacin with an MIC ≥ 32mg/L. Tenover et al found three 
moxifloxacin resistant (MIC >32mg/L) CD002 isolates in North America, however, their 
methods for antimicrobial susceptibility was different from methods applied in this 
study(Tenover et al., 2012). Previous studies found amino acid substitutions in DNA gyrase 
genes for strains highly resistant to fluoroquinolones (MIC ≥ 32mg/L)(Solomon et al., 2011; 
Spigaglia et al., 2011). In the present study molecular characterisation of specific resistance 
to fluoroquinolones revealed the common amino acid substitution in gyrA, Thr-82-lle, in two 
isolates of CD002 belonging to the UK 2007-8 lineage and Non-UK 2012-14 lineage 
respectively. Additionally, two novel amino acid substitutions, Arg-98-Thr, Asp-103-His in 
gyrA, were identified in a non-UK strain, that was only resistant to ciprofloxacin (MIC= 32 
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mg/L). Mutations within the gyrB subunit or both subunits are known to be associated with 
strains that attained a higher level of resistance to moxifloxacin (MIC ≤ 32 mg/L), however, 
this was not the case in the present study. The moxifloxacin resistant (MIC= 32mg/L) isolate 
only harboured mutations in the gyrA subunit, and no other fluoroquinolone-resistant 
isolates in the present study harboured mutations in gyrB. This result suggests that the driving 
force of fluoroquinolone resistance in the emergence of epidemic strains, particularly 
ribotype 027, is less likely to be a driving factor in the recent emergence of CD002 in the UK. 
C. difficile resistance to MLSB antimicrobial agents (clindamycin and erythromycin) has been 
reported in the literature and is commonly associated with the presence of the erm(B) gene 
which encodes an rRNA methylase carried on a conjugative transposon Tn5398 (Spigaglia, 
2016)In the present study, MIC values for the MLSB group of antibiotics, clindamycin and 
erythromycin ranged between (≤1-8mg/L and ≥0.5-128mg/L, respectively) for all CD002 
isolates. Clindamycin resistance was observed in 26.7% (n=16) of CD002 isolates, with 
majority of these isolates being of the non-UK lineage. The GM MICs to clindamycin did not 
differ significantly between lineages (range 3.87- 5.1mg/L), which is slightly lower compared 
to published results in Europe, where the GM MIC for clindamycin observed in CD002 isolates 
was 5.4- 6.8mg/L (Freeman et al., 2018). Additionally, reduced susceptibility to clindamycin 
was observed in 71% of isolates (MIC >4mg/L). This finding is similar to published results by 
Pirs et al, in which animal and human isolates of CD002 demonstrated reduced susceptibility 
to clindamycin at 85% and 9.1% respectively(Pirš et al., 2013). Erythromycin resistance was 
uncommon in this study, only two UK CD002 isolates belonging to different lineages (UK 2007-
8, UK 2011-14) were resistant to erythromycin at an MIC of 128mg/L. Cross-resistance to 
clindamycin and erythromycin was uncommon. Prior studies identified C. difficile erm-
negative strains, resistant to both erythromycin and clindamycin or only to erythromycin 
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(Pituch et al., 2006; Spigaglia et al., 2011). All CD002 strains in the present study were erm (B) 
negative including strains resistant to both erythromycin and clindamycin or only 
erythromycin. Erm-negative CD002 isolates in the present study were also negative for the 
predominant alternative erm genes found in anaerobes (erm A, C, F and Q). This is in 
agreement with published results by Spigaglia and colleagues, where, fifty-three C. difficile 
strains were erm (B) negative and also negative for these other common erm genes found in 
anaerobes(Spigaglia et al., 2011). Further investigations by Spigaglia and colleagues were 
unable to delineate the mechanism of resistance in erm (B) negative isolates(Spigaglia et al., 
2011). Dingle et al identified a novel Tn916-like transposon, similar to Tn6218, that 
participates in the transfer of cfr and ermAB genes, it is suggested that the cfr gene could play 
a role in C. difficile resistance to MLSb antibiotics in the absence of erm(Dingle et al., 2014). 
Based on these reports, it would have been plausible to suggest that the erm (B) negative 
isolates identified in the present study, could be positive for the cfr gene, however since these 
isolates were susceptible to linezolid, this might be unlikely. 
Historically, beta-lactam antibiotics (aminopenicillins and cephalosporins) have been heavily 
implicated in the development of CDI (Goudarzi et al., 2013).  The mechanism by which this 
occurs is not fully known, however, increased exposures of ampicillin is thought to stimulate 
the expression of adhesins that are fundamental to C. difficile pathogenesis (Dawson, 
Valiente, & Wren, 2009). Additionally, as broad-spectrum antimicrobials, they perturb the 
microbiota balance in the gut thereby creating an environment for C. difficile to flourish. 
Resistance to β-lactams is found to be associated with antibiotic- degrading agents, β- 
lactamases or mutational events resulting in the modification of penicillin-binding proteins 
(PBPs), which affect the drug affinity(Spigaglia, 2016).In a previous study, patients carrying 
CD002 were found to have received more β- lactam antibiotics in preceding 3 months, 
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suggesting that these group of antimicrobial agents may induce CDI mediated by CD002 
(Cheng et al., 2011). A prominent observation in the present study was the high percentage 
of intermediate resistance to beta-lactam antimicrobial agents (ampicillin and penicillin G) in 
CD002. A majority (93.3%, n=56) of isolates demonstrated intermediate resistance to 
ampicillin and penicillin G. The MIC50 and MIC90 values of penicillin and ampicillin in all 
lineages was 1mg/L. This suggests that both antimicrobial agents exhibit the same 
antimicrobial activity on CD002 isolates. Although investigations into β-lactamase activity in 
all isolates were negative, reduced susceptibility to beta-lactams (ampicillin & penicillin), 
maybe a factor influencing the emergence of this ribotype in the UK. As strains exhibiting 
reduced susceptibility might be able to grow earlier in the pharmacokinetics (PK) cycle, before 
the recovery of the indigenous microflora, therefore aiding colonisation and subsequent 
likelihood of developing an infection. However, further studies utilising other model systems 
and ribotypes is warranted to support this hypothesis. 
Trimethoprim, a folate pathway inhibitor primarily used in the treatment of urinary tract 
infections, had a no activity against all CD002 isolates used in this study. All isolates were 
resistant to trimethoprim with MIC50 and MIC90 values that were greater than 128 mg/L. 
Clostridium species and anaerobes are reportedly intrinsically resistant to trimethoprim 
(Mazuet et al., 2016; Then & Angehrn, 1979). Markedly high trimethoprim MICs among C. 
difficile isolates have been recorded in other studies. An earlier study reported resistance to 
trimethoprim at MIC ≥512mg/L by 30 genotypically distinct C. difficile ribotypes(Freeman & 
Wilcox, 2001). Knight and colleagues, reported MIC50 and MIC90 of 64 mg/L to C. difficile 
isolates that were recovered from animals and humans in Australia(Knight et al., 2016). 
Despite widespread resistance to trimethoprim in C. difficile, this antimicrobial is not linked 
as having a high propensity to induce CDI, most likely due to its poor anti-anaerobe 
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activity(Mazuet et al., 2016) and therefore inability to disrupt host colonisation resistance. As 
a result, the use of this agent particularly in the community is unlikely, driving the emergence 
of CD002. 
Many studies highlight the emergence of multi-drug resistance among C. difficile strains, 
particularly hypervirulent RT027 and RT001/072 (Freeman et al., 2011; Spigaglia et al., 2011). 
More recently, high levels of multi-drug resistance in Europe is associated with emergent 
ribotypes, notably 017, 018, 198 and 356 (Freeman et al., 2015, 2018). In addition, 
antimicrobial resistance surveillance studies in Hong Kong reported the emergence of 
multidrug-resistant C. difficile PCR ribotype 017 and 002 (Chow et al., 2017). Other studies 
showed that the percentage of C. difficile multidrug-resistant strains vary from one 
geographic location to another. Tenover et al, identified no multi-drug resistant strains in 
CD002 isolates within North America(Tenover et al., 2012). The present study showed only 
3.3% of isolates were multi-drug resistant as they demonstrated resistance to at least three 
different antimicrobial classes. The low percentage rates of multidrug resistance among 
CD002 isolates in the present study and Tenover et al‘s study suggests CD002 strains with 
multi-drug resistance may not be circulating around the UK and other countries across Europe 
and North America. However, since multi-drug resistant CD002 is rapidly emerging in Asia, 
continuous surveillance is necessary, in order to prevent potential CDI outbreaks that may be 
caused by strains of this ribotype. 
The data generated in the present study highlighted the antimicrobial susceptibility patterns 
and resistance associated with CD002 isolates circulating across Europe. In general, the 
results obtained indicated that CD002 from the different lineages have comparable 
antimicrobial susceptibility patterns observed within other PCR ribotypes that have been 
previously studied(Aspevall et al., 2006; Freeman et al., 2015, 2018; Keessen et al., 2013; Pirš 
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et al., 2013). Therefore, it is highly unlikely that antimicrobial resistance might be a driver for 
the emergence of CD002 in the UK and in Europe.  
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4 INVESTIGATION OF VIRULENCE FACTORS AND BIOFILM 
FORMATION OF CD002 ISOLATES FROM DIFFERENT TIME 
LINEAGES 
 
4.1 BACKGROUND 
The notoriety of Clostridium difficile as the leading cause of nosocomial antibiotic-associated 
diarrhoea worldwide has increased in recent years (Planche & Karunaharan, 2017). The 
consensus for this dramatic increase is attributed to the emergence of hypervirulent strains. 
C. difficile is an anaerobic, spore-forming Gram-positive bacterium that causes a wide 
spectrum of diseases, ranging from asymptomatic carriage, mild and self-limiting diarrhoea, 
to severe life-threatening pseudomembranous colitis, toxic megacolon, sepsis and 
death(Smits et al., 2016).   
Clostridium difficile infection (CDI), is acquired through ingestion of C. difficile spores that 
have been shed into the environment by symptomatic or asymptomatic carriers, or 
potentially from environmental or zoonotic sources (Brown & Wilson, 2018; Eyre et al., 
2013;Freeman et al., 2010; Rabold et al., 2018). These highly resistant spores survive the 
acidic nature of the stomach and proceed to the small intestine, where they germinate into 
vegetative cells following stimulation by the host-derived germinants, most notably primary 
bile acids(Britton & Young, 2014). Primary bile acids (cholate and chenodeoxycholate) are 
derived from the liver, in the colon, they induce C. difficile germination through a Ger- type 
germinant receptor known as CspC (Buffie et al., 2015;  Francis et al., 2013; Paredes-Sabja et 
al., 2014). As a protective mechanism of colonisation resistance in the colon, certain members 
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of the gut microbiota (particularly Clostridium scindens) encode 7α-dehydroxylation enzymes 
in a bile acid-inducible (bai) CD (known as baiCD) gene cluster(Solbach et al., 2018; Theriot, 
Bowman, & Young, 2016). These 7α-dehydroxylating enzymes are responsible for 
metabolising primary bile acids to secondary bile acids (deoxycholate and lithocholate), that 
inhibit C. difficile growth (Crobach et al., 2018). Hence, a disruption of the gut microbiota 
(principally due to antimicrobial therapy) abolishes 7α-dehydroxylating activity and reduces 
resistance to Clostridium difficile colonisation. This has been demonstrated in several studies 
(Buffie et al., 2015; Solbach et al., 2018; Theriot et al., 2016). 
Following germination of C. difficile spores, a proteolytic cascade leads to the degradation of 
the spore peptidoglycan, release of calcium dipicolinic acid and rehydration of the 
spore(Paredes-Sabja et al., 2014). This ultimately results in the outgrowth of vegetative cells 
that colonise the host, following proliferation and adherence to host intestinal epithelial cells. 
Several cell surface proteins (such as Cwp66, Fbp68, and the C. difficile flagella) have been 
shown to aid adherence and colonisation in CDI (Baban et al., 2013; Barketi-Klai et al., 2011; 
Mora-Uribe et al., 2016). Subsequently, the main virulence factors, toxin A and/or toxin B, are 
released, for the full manifestation of disease. Toxins become internalised by the host cells 
and are subsequently transferred to the cytoplasm. Following activation, the toxin inactivates 
host GTPases, leading to the disruption of the actin cytoskeleton and an impairment of the 
tight junctions. This results in fluid accumulation and extensive mucosal damage to the large 
intestine (Smits et al., 2016). 
In addition to these large clostridial cytotoxins, several other virulence factors are implicated 
in CDI pathogenesis. An example is the C. difficile binary toxin, which is an additional toxin 
produced by some strains of C. difficile such as ribotypes 078 & 027. The exact role of binary 
toxin in CDI pathogenesis remains unclear, however, there is evidence to show that the binary 
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toxin facilitates the adherence of C. difficile cells to host epithelial surfaces (Gerding et al., 
2014; Schwan et al., 2009). Additionally, Stewart and colleagues identified the binary toxin as 
a predictor for recurrent CDI(Stewart et al., 2013). Furthermore, in-vitro studies have 
demonstrated the ability of C. difficile to form biofilms on surfaces, however, their role in 
disease pathogenesis remains poorly understood (Crowther et al., 2014a; Dapa & 
Unnikrishnan, 2013; Dawson et al., 2012; Hammond et al., 2014; James et al., 2018; Semenyuk 
et al., 2014). It is hypothesised that biofilms within the gut may play a role in recurrent CDI, 
by serving as a potential reservoir for C. difficile (vegetative cells and spores) to re-colonise 
the host after treatment has been administered(Baines et al., 2005; Crowther et al., 2014b; 
Dapa & Unnikrishnan, 2013). Indeed, this was demonstrated in an in vitro gut model 
comparing multi-species intestinal biofilms (Crowther et al., 2014). Approximately eighteen 
days after cessation of antimicrobial therapy, recurrent CDI occurred, following an initial 
episode of simulated CDI that had been successfully treated with vancomycin(Crowther et al., 
2014a).  
The acquisition and expression of virulence factors by pathogenic bacteria often promote 
their survival. This phenomenon has been demonstrated in hypervirulent C. difficile ribotype 
027. Prior studies suggest that the global emergence of hypervirulent C. difficile ribotype 027, 
is attributed to the strain’s acquisition of several virulence phenotypes, such as a higher 
sporulation ability and increased toxin production(Merrigan et al., 2010; Vohra & Poxton, 
2011). Additionally, some colonisation factors such as biofilm formation, spore formation 
during biofilm development and a high degree of adherence to intestinal epithelial cells have 
been identified in hypervirulent C. difficile ribotype 027 strains, particularly epidemic strain 
R20291(Dapa & Unnikrishnan, 2013; Dawson et al., 2012; Joshi et al., 2012; Mora-Uribe et al., 
2016; Semenyuk et al., 2014). Although controversial, it is suggested that these factors may 
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have granted hypervirulent C. difficile ribotype 027 strains, a competitive advantage over 
other ribotypes, which enabled their persistence in the human colon and contributed to their 
epidemiological prevalence alongside the development of antimicrobial resistance to 
fluoroquinolones. Based on this knowledge, understanding how recent emerging strains may 
differ from previously circulating strains of the same C. difficile ribotype is essential.  
Although speculative, it is possible that emerging strains of CD002 in the UK may have 
acquired strain-specific characteristics that may facilitate their survival and drive increased 
prevalence in clinical CDI. To investigate the emergence of CD002 it is important to evaluate 
key virulence determinants of CD002 strains of different epidemiological lineages, in other to 
ascertain if any specific traits exist that may help explain the recent emergence of this 
ribotype.   
In this study, the classical virulence phenotypes such as toxin production and sporulation 
were analysed. As well as phenotypes recently conceived to be involved in host persistence 
of C. difficile such as biofilm formation, sporulation during the development of biofilms and 
spore adherence to epithelial cells. 
4.1.1 Aims and objectives  
To study and quantify virulence characteristics of C. difficile ribotype 002 from different time 
lineages and geographical locations. The aims were achieved by the following objectives; 
1. Evaluation of the total sporulation capacities of CD002 isolates from different time 
and lineages using batch growth in BHIS and enumeration by ethanol shock and viable 
counting  
2. Evaluation of spore adherence properties to human gut epithelial cells at different 
stages of cell development using a Caco- 2 cells adherence assay 
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3. Evaluation of C. difficile toxins: cytotoxin production profiles using Vero cell 
cytotoxicity assay; and PCR for the C. difficile binary toxin gene  
4. Quantification of biofilm formation of CD002 isolates using the crystal violet assay and   
viable counting of spores and vegetative cells present within biofilms 
4.2 MATERIALS AND METHODS  
4.2.1 Bacterial strains  
C. difficile PCR ribotype 002 strains and controls used in this study have been described in 2.1. 
As indicated in Table 4-1, all 60 CD002 strains were investigated for cytotoxin production over 
time, binary toxins, total sporulation capacities, and biofilm studies. However, in the spore 
adherence assay, only two strains were selected per lineage (Table 4-2), making a total of 6 
CD002 strains being investigated for spore adherence. The criteria for selecting a strain for 
adherence assay was based on sporulation rates after 24h; i) one had to be below the average 
sporulation rate of that lineage, ii) and the second had to be above the average sporulation 
rate of that lineage.  
To compare results with hypervirulent strains, an 027 strain and 078 strain were included in 
cytotoxin studies. All strains were cultured according to methods described in 2.1.3- 2.1.6.  
Table 4-1 Number of strains used per assay 
Assay  CD002 strains used  
Toxin studies 60 
Total sporulation capacity 60 
Biofilm studies 60 
Spore adherence  6 
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Table 4-2 List of strains selected for spore adherence to epithelial cells 
Strain Spore formation 
at 24h 
Average spore 
formation per lineage 
at 24h  
Lineage 
159 1.25 x103 1.04 x104 UK 2011-13 
146 3.95 x104 
165 1.55 x 103 2.06 x 103 UK  2007-8 
174 4.52 x103 
140 1.90 x103 2.32 x104 Non- UK  2012-14 
141 6.83 x 104 
 
4.2.2 Growth rate (μ) measurement 
The growth rate for all CD002 strains was determined according to methods described in 2.4. 
4.2.3 Cytotoxin production profiles and investigations for the presence of binary 
toxin  
The cytotoxin production profiles of all CD002 strains was investigated according to methods 
described in 2.3.1.  Cytotoxin production over time was measured at time points: 0, 8, 12, 24, 
48 and 72h in Brain Heart Infusion (BHI) broth. Additionally, to see whether cysteine 
repressed toxin production, CD002 strains were grown in BHI (supplemented with 0.1% (w/v) 
L-cysteine HCl (C7477, Sigma) + 0.5% (w/v) yeast extract (LP0021, Oxoid) (BHIS), and cytotoxin 
production was investigated after 72h. To investigate the presence of binary toxin (cdtA and 
cdtB) in all isolates, primers described by Stubbs et al (2006) as listed in Table 2-6 were used 
in a PCR assay. PCR conditions were of 30 cycles of denaturation at 94°C for 45 s, annealing 
at 52°C for 1 min, and elongation at 72°C for 1 min 20s. Using agarose gel electrophoresis as 
described in 2.83- 2.8.4, the resulting PCR products were assessed for the presence of a 375bp 
internal fragment of the cdtA (Figure 3-5) and 510bp for cdtB (Data not shown) by using 
standard molecular weight markers; 100bp DNA ladder (D3687, Sigma). 
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4.2.4 Sporulation Studies   
4.2.4.1 Preparation of Sporulation medium and measurement of the sporulation rate    
Determination of the total sporulation capacities of all CD002 was achieved based on 
previously published methods by Burns et al (2011).  Overnight cultures of C. difficile grown 
in 5mL BHIS broth were diluted 1:10 into a fresh 24-hour pre-reduced 4.5 mL BHIS broth. 
These cultures were grown to an OD600 between 0.2-0.5 (early-log phase) to ensure the lack 
of spores (that will normally be present at stationary phase) upon inoculation into the 
sporulation medium. In triplicate, cultures grown to the desired OD600 (Between 0.2-0.5) were 
diluted 1:100 into fresh pre-reduced 4.95 mL BHIS broth (the sporulation medium). All 
cultures were then incubated anaerobically at 37°C for 120h.  
To measure the colony forming units (CFU) formed from spores present in C. difficile cultures, 
100µl of the sporulation medium was retrieved at time points: 0h, 24h, 48h, and 120h 
respectively. The total sporulation capacities were determined by enumerating the colony 
forming units at 0h, 24h, 48h and 120h according to methods described in 2.5.  
4.2.5 Spore adherence assay 
4.2.5.1 Spore preparation and purification 
As listed in table 4-2, six strains were selected for spore adherence assay.  The spores of these 
strains were prepared according to methods described by Joshi et al (2012). Strains were 
grown in 10mL of pre-reduced BHIS and incubated anaerobically for 10 days.  To recover 
sporulating cells, C. difficile cultures were centrifuged at 5000g (1004, Hettich, EBA 21, 
Canada) for 15 mins at room temperature, the supernatant was discarded. The retained pellet 
was resuspended in 10ml of cold sterile distilled water and centrifuged at 5000g. This washing 
cycle was repeated three times to release spores from mother cells. The free spores were 
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then resuspended in 1mL of 50% ethanol (E/0600DF/21, Fisher Scientific, Loughborough, UK) 
for 1h to kill all vegetative cells. Crude spore preparations were stored at 4°C until use.  
4.2.5.2 Hydrophobicity assay 
Microbial adhesion to hydrocarbon (MATH) has previously been described by Rosenberg et al 
(Rosenberg, Gutnick, & Rosenberg, 1980). To determine the hydrophobic characteristics of 
purified CD002 spores, the MATH test was performed according to methods described by 
Joshi et al (2012). Purified CD002 spores were resuspended in 9 ml of sterile distilled water 
(SDW) to achieve an OD600 between 0.5-0.6. Subsequently, in duplicates 4ml of the spore 
suspension was transferred into a sterile universal, and 0.4ml of n-hexadecane (H6703, 
Sigma) was added. This mixture was vortexed at full speed for 1min and incubated at room 
temperature for 15 mins to allow separation of the different phases of the solution. The loss 
of turbidity of the aqueous solution was then measured to determine the optical density 
(OD600) after hexadecane exposure. Changes in hydrophobicity were calculated by the 
formula below: 
=100 - (Final OD600/Initial OD600) x100) 
4.2.5.3 Spore adherence to epithelial cells  
To investigate the adherence capacity of CD002 spores, purified spores were exposed to 
human gut epithelial cells (Caco-2 cells- Human adenocarcinoma, cells, PHE Culture collection, 
ECACC 86010202) at different stages of cell differentiation. Caco-2 cells were prepared 
according to methods described in 2.3.2. These cells were seeded into 12-well plates (150628, 
ThermoFisher) to a final density of 2 x 105 cells per well and incubated for 7 days and 15 days 
according to methods described by Joshi et al (2012). These time points were selected for 
testing because Caco-2 cells require 15 days of culture to become fully differentiated, and 
possess a microvillus brush border that is absent at day 7(Joshi et al., 2012). At seven- and 
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fifteen-days incubation, Caco-2 cells were washed three times with sterile PBS (P4417, Sigma) 
and monolayers were inoculated with CD002 spores at a ratio of 100:1 (2 x 107 spores/mL: 2 
x 105 of Caco-2 cells) 200 µl of culture medium (EMEM). Spore exposed to Caco-2 cells were 
incubated for 100 mins at 37°C under aerobic conditions in a 5% CO2 incubator (15660667, 
Fisherbrand, Fisher Scientific UK). After incubation, spore-exposed Caco-2 cells were carefully 
washed three times with sterile PBS to remove non-adherent C. difficile spores. Subsequently, 
spore-exposed Caco-2 cells were lysed with 100µl 0.06 % Triton X-100(T8787, Sigma) for 30 
min at 37°C. The spore-cell lysate was serially diluted in sterile PBS, and viable counting was 
performed as described in 2.5. To determine total C. difficile spores counts, a second 12-well-
microtitre plate of spore-exposed Caco-2 cells were not washed but directly lysed with 100µl 
0.06 % Triton X-100(T8787, Sigma) and viable counting was performed as described in 2.5. All 
assays were performed with two biological and three technical replicates. The percentage of 
spore adherence was calculated by using the following formula:  
 [Final CFU/ml/initial CFU/ml)] X 100 
4.2.6 Biofilm formation  
4.2.6.1 Generation of C. difficile Biofilms 
CD002 biofilms were generated based on previously published methods by Dawson et al. 
(2012) and Ethapa et al. (2013). For the generation of the biofilms, overnight C. difficile 
cultures in 5mL BHIS broth were diluted 1:10 into fresh pre-reduced 4.5mL BHIS broth.  In 
triplicate, 200 µl of diluted C. difficile culture was aliquoted into each well of 96-well microtiter 
trays (DK-4000, ThermoFisher). To prevent evaporation of liquid, microtiter trays were 
wrapped in Parafilm® (10018130, Bemis PM992, USA) and incubated anaerobically for three 
and six days respectively. This process was repeated in BHIS+ 0.1M of glucose (BHISG) broth. 
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4.2.6.2 Measurement of Biofilm biomass  
The estimation of biofilm biomass was performed using a crystal violet staining method 
(Ethapa et al.,2013). After the required incubation time (3 and 6 days respectively), the 
growth medium (BHIS, BHISG) was carefully removed from each well of the 96- well plates 
using a multichannel pipette (46300100, ThermoFisher) and discarded. The wells of the 96-
well plates were gently washed three times with sterile phosphate-buffered saline (PBS) 
(P4417, Sigma) using a multichannel pipette, and then allowed to dry for 10 mins. The biofilm 
was stained with 200µl of 1% (w/v) crystal violet (C6158, Sigma) diluted in 95% industrial 
methylated spirits (M14450/17, Fisher Scientific), and incubated for 30 minutes at room 
temperature. Subsequently, excess crystal violet was removed from the wells, and stained 
biofilms were washed five times gently with sterile PBS. The dye was extracted from the 
biofilms by adding 200µl of methanol (M/4000/17, Fisher Scientific) per well and allowed to 
incubate for 15 minutes at room temperature. The absorbance of the 96-well microtitre trays 
was read at 590nm using a microtitre tray spectrophotometer (Thermo Scientific Multiskan 
EX, Vantaa, Finland). All experiments were performed with three biological replicates, and 
each experiment incorporated three technical replicates.  
4.2.6.3 Viable counting of vegetative cells and spores in C. difficile biofilms 
The population of vegetative cells and spores in biofilms was determined from three- and six-
day-old biofilms, grown in 96 well microtitre plates (BHIS broth) in triplicate.  After three and 
six days of incubation, BHIS was carefully removed from each well. The wells were washed 
twice with sterile PBS, and 100µL of sterile PBS was added to the wells of the plate. Three- 
and six-day-old biofilms were disrupted under anaerobic conditions, by agitating at 1300 rpm 
for 10 minutes on a microtiter personal plate shaker (1959, Mikura- Orbis, W, Sussex,). 
Disrupted biofilms were serially-diluted in sterile 24-hour pre-reduced PBS, and the 
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vegetative cells were enumerated on Brazier’s agar (LAB160, Lab M, Lancashire, UK), using 
the viable counting method described in 2.5. Similarly, spores were enumerated by the 
alcohol shock method described in 2.5. One hundred microliters of 50% ethanol were added 
to 100µl of disrupted biofilms and, the mixture was incubated at room temperature for 1h to 
kill all vegetative cells present. Subsequently, spores present in three day and six-day-old 
biofilms were enumerated by the viable counting method. All experiments were performed 
with three biological replicates, and each experiment incorporated three technical replicates. 
4.2.7 Statistical analysis  
Statistical analysis was performed using the GraphPad Prism 6 Software (GraphPad Software, 
La Jolla, CA). Normality tests were performed on all data to determine the appropriate 
statistical test to use. Statistically significant differences were tested using ordinary one-way 
analysis of variance (ANOVA) or two-way analysis of variance at the 95% confidence interval. 
This was done in conjunction with Tukey’s post-hoc test. A p-value of <0.05 was considered 
statistically significant. 
4.3 RESULTS  
4.3.1 Batch culture growth curves and maximum specific growth rate  
To evaluate the virulence characteristics among different isolates, it is important to first 
understand the various growth patterns that exist between bacterial groups. The maximum 
specific growth rate (μmax) of C. difficile ribotype 002 isolates was determined by growth 
kinetic analysis. The maximum specific growth rate (h-1) for all strains (µmax) was calculated 
from within the exponential growth phase (4-6h) by determining the gradient of the ln 
(biomass) versus time (hours) plot. The values of µmax ranged from 0.23 to 1.50 h-1. Lineage 
comparisons showed that strains of European origin (Non-UK 2012-14) grew significantly 
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(mean µmax 0.92, ±SE-0.05, Range 0.23-1.42 h-1, P <0.001) faster than UK 2011-13(mean µmax 
0.76, ±SE-0.06, Range 0.23-1.5 h-1) and UK 2007-8 strains (Mean µmax 0.69, ±SE-0.03, Range 
0.5-0.95 h-1) (Figure 4-1).Conversely, the values of the maximum specific growth rate (µmax) of 
both UK 2007-8 and UK 2011- 13 CD002 strains did not differ significantly (P<0.3), the growth 
curve distributions between lineages were similar, and no growth differences between strains 
were observed in the timing of the lag and stationary phases of growth (Figure 4-1a). 
However, in the exponential phase of growth (between 4-6h), a marked increase in biomass 
(OD600= 0.6, 1.6, 2.0 at 4, 5, 6h respectively) was observed with the UK 2007-8 strains 
compared to UK 2011-13 strains (OD600= 0.4, 0.8, 1.4 at 4, 5, 6h respectively) and Non-UK 
Lineage (2012-14) (OD600= 0.3, 0.6, 1.4 at 4, 5, 6h respectively), but this was not statistically 
significant (p=0.624). At 8 hours of growth, there was no significant increase in the biomass 
across all lineages. 
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Figure 4-1  Batch growth curve (OD600) and maximum specific growth rate (µmax) of CD002 (h -1, mean ±SE) in brain heart infusion broth. The 
growth of CD002 from different lineages in BHIS was measured by OD600 over an 8-hour period.  (a) The mean biomass (OD600) at 2, 4, 6, and 8h 
per CD002 lineage studied. The patterns of growth were similar in all lineages. (b) The mean µmax per lineage of all CD002 studied. Strains of the 
Non-UK lineage had a higher µmax. Data represent the average of three independent experiments and error bars are standard error of the mean. 
The asterisk (*) indicate where a significant difference was observed.
a) b) 
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4.3.2 Cytotoxin production over time and investigation for the presence of CDT 
locus  
All strains were examined for cytotoxin production using Vero cells cytotoxicity assay at 
different time intervals. C. difficile BHI culture supernatants were retrieved at time points: 0, 
8, 12, 24, 48, and 72h of incubation. A sample was regarded as positive for cytotoxin, when a 
characteristic cytopathic effect against Vero cells (Figure 2-4) was observed, rounding ≥80% 
of cells within the field of view.  No detectable cytotoxin production was observed between 
0-8h, for all strains. After 24h of incubation, all strains produced cytotoxin (titre of ≥1RU). As 
shown in figure 4-2a the median cytotoxin titres in all lineages after 12h and 24h of incubation 
were 1RU. At 48h of incubation, the median cytotoxin titres in all lineages were 2RU. The 
recent isolates (UK 2011-13, and Non- UK 2011-14) cytotoxin titres ranged between 1 – 2RU 
at 48h, while UK 2007-8 isolates ranged between 1 – 3RU. Compared with the UK 2007-8 
lineage, the median titre for recent isolates (UK 2011-13, and Non- UK 2012-14) was higher 
(3RU). The cytotoxin titres at 72h for all isolates grown in BHIS cultures ranged between 2-
4RU. These values did not differ significantly from BHI cultures at 72 hours, suggesting that 
the L-cysteine hydrochloride in BHIS did not repress cytotoxin production. Additionally, all 
strains were investigated for the presence of binary toxins, through PCR amplification of cdtA 
and cdtB genes. As shown in figure 4-2b all strains were negative for cdtA gene. CD002 isolates 
were also negative for cdtB gene (data not shown). 
Furthermore, in comparison to hypervirulent strains (Data not showed), detectable toxins 
(1RU) was observed only in 078 after 12h of incubation. After 24h of incubation, the cytotoxin 
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titre of 078 was 3RU, while 027 was 2RU. Meanwhile, at both 48h and 72h, the cytotoxin titres 
in 078 were 4RU and 2RU in 027. 
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Figure 4-2 Cytotoxin production profile and assessment of binary toxin in CD002. All CD002 strains were 
investigated for cytotoxin production at time points: 0, 8, 12, 24, 48,72h using a Vero cell cytotoxin assay. The total 
cytotoxin titres were expressed as log10-relative units (RU), where 1 RU represented ≥80% cell rounding by an 
undiluted C. difficile culture supernatant (a) Median cytotoxin titres for all isolates, grouped into different lineages. 
Median titres at different time points were similar in all lineages (b) A PCR image showing the presence of C. difficile 
binary toxin A (cdtA) in all CD002 isolates; lane 1 is a 1kb DNA ladder, lane 2-17 are amplified products of cdtA, lane 
18 is a negative control and lane 19 is a positive control for cdtA (derived from a ribotype 027 strain). cdtA was 
absent in all CD002 isolates. 
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4.3.3 Sporulation Studies  
4.3.3.1 Sporulation over time  
In order to understand the rate at which CD002 strains formed spores in vitro, the 
development of spores that are resistant to alcohol was measured over a period of 5 days in 
batch culture. Sporulation capacities were determined through the ethanol shock treatment 
method and CFU were enumerated at time points: 0h, 24h, 48h, and 120h. Colony-forming 
units (CFU) yielded from ethanol shocked C. difficile cultures were assumed to have risen from 
spores within the culture. The total spore counts were calculated by calculating the mean 
CFU/mL of three independent experiments at each experimental time-period. All strains 
produced alcohol-resistant spores, and their numbers in cultures increased over the time-
course of the experiment (Figure 4-3).  
At the start of the experiment (0h), no spores were recovered in cultures of all lineages, thus 
the possibility of spores being carried over from previous passages was ruled out. After 24h 
of growth, recent Non-UK 2012-14, produced significantly (P<0.0001) more spores than 
recent UK 2011-13 strains (Figure 4-3). Additionally, recent strains (UK 2011-13, Non- UK 
2012-14) produced significantly (P<0.0001) more spores (Average CFU/mL: 1. 04 x 104, 2.32 
x104 respectively) than the UK CD002 from 2007-8 (Average CFU/mL: 2.06 X 103). After 48h 
(Figure 4-4) and 120h (Figure 4-5) of incubation, the spore formation did not differ 
significantly in any CD002 lineages (P= 0.093). 
4.3.3.2 Hydrophobicity of spores to hydrocarbons  
The ability of a spore to adhere to a surface is influenced by its hydrophobicity. To characterise 
the relative hydrophobicity of spores of CD002 strains, the MATH test with hexadecane as the 
organic solvent was used. The relative hydrophobicity (RH) of all CD002 isolates were 
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investigated (appendix 2). The most hydrophobic isolates belonged to strains of UK 2011-13 
lineage, with a mean RH value of 58%. Non- UK (2012-14) isolates, also had high RH values, 
with an average RH of 51 %. The RH values of isolates belonging to the UK 2007-8 lineage was 
33%, which is significantly (P= 0.0382) lower than spores of recent isolates (UK 2011-13, Non- 
UK 2012-14. As can be seen in figure 4.6a, strains selected for the adherence assay had similar 
hydrophobic characteristics. As shown in figure 4.6a, only one strain (174) belonging to the 
UK 2007-8 lineage, had a significantly lower (P=0.02) RH value.  
4.3.3.3 Adherence of CD002 spores from different times and lineages to 
intestinal epithelial cells (Caco-2) 
Given that the phenotypic difference in microvilli expression between undifferentiated and 
differentiated Caco-2 cells might affect the specificity of spore adherence, the abilities of 
CD002 spores to adhere to human gut epithelial cells at different stages of cell development 
(at 7 and 15 days respectively, figure 4-6b), was determined in vitro. Spores of six different 
CD002 strains of different lineages adhered to 7-day old Caco2 cells at a range of 21-57% 
(Figure 4-6b), this represents, the percentage of the initial spore count of the strain.  All spores 
exhibited similar adherence capacities, except strain 146 (of the UK CD002 2011-13 lineage), 
which was significantly (P= 0.024) lower than all other strains tested. Spores adhered more 
strongly to 15–day old Caco-2 cells, at a range of 50-86% (Figure 4-6b), and the differences 
between strains were not statistically significant. 
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Figure 4-3 Spore formation (CFU/mL) by CD002 in BHIS. The development of CFU after ethanol shock treatment for all CD002, enumerated after 
24h of incubation in BHIS. The data represents the average of three independent experiments, and the error bars, indicate the standard error of 
means. The dotted line represents the average CFU/ml for all isolates. Asterisk (***) indicate where a significant difference was observed. 
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Figure 4-4 Spore formation (CFU/mL) by CD002 in BHIS. The development of CFU after ethanol shock treatment for all CD002, 
enumerated after 48h of incubation in BHIS. The data represents the average of three independent experiments, and the error 
bars, indicate the standard error of means. The dotted line represents the average CFU/ml for all isolates.  
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Figure 4-5 Spore formation (CFU/mL) by CD002 in BHIS. The development of CFU after ethanol shock treatment for all CD002, enumerated after 120h of 
incubation in BHIS. The data represents the average of three independent experiments, and the error bars, indicate the standard error of means. The 
dotted line represents the average CFU/ml for all isolates.  
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Figure 4-6 Relative hydrophobicity of CD002 spores and adherence to human gut epithelial cell monolayers. A) The relative hydrophobicity of six different strains of 
CD002 (2 strains per lineage) was determined by the MATH test. B) The ability of CD002 spores to adhere to monolayers of Caco-2 human colorectal cell line that had 
been incubated for the 7 and 15 days was enumerated, the adherence capacities at different stages of cell differentiation were similar in all lineages. The data (a&b) 
represent the average of two independent assays, and the error bars, indicate the standard error of means. Asterisk (*) indicates where a significant difference was 
observed. 
* 
a) b) 
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4.3.4 Quantification of biofilm formation using a crystal violet assay  
The biofilm biomass in three- and six-day-old biofilms formed by C. difficile in BHIS and BHISG 
media, were quantified using the crystal violet assay following methanol extraction (OD595). 
To identify the differences in biofilm formation between the lineages, the mean biofilm 
formation at three and six days was calculated. Lineage-specific and media-specific 
differences were identified.  
As shown in figure 4-7, the recent strains (UK 2011-13 and Non-UK 2012-14) formed 
significantly higher amounts of biofilm biomass, at three days compared to UK 2007-8 strains 
(p<0.0001) in both BHIS and BHISG. Additionally, Non-UK 2011-14 strains produced 
significantly (p=0.0361) more biofilm biomass in BHISG compared to BHIS. There was no 
significant difference in the biofilm formation by UK CD002 (UK 2007-8 and UK 2011-13) 
strains in BHIS and BHISG at three days.  
At six days, the biofilm formation in all lineages was significantly reduced (Figure 4-7 p> 0.001) 
in BHIS media. Also, there was no significant difference in the biofilm formation between 
lineages in BHIS.  Conversely, a two-fold increase in BHISG biofilm formation (Figure 4-7, 
p>0.001) was observed in all lineages. However, when compared to three-day-old BHISG 
biofilms, this did not differ significantly (p=0.226). In similarity to three-day-old BHISG 
biofilms, recent CD002 strains (UK 2011-13 and Non-UK 2012-14) formed significantly greater 
quantities of biofilm biomass in BHISG compared to UK 2007-8 strains.
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Figure 4-7 Mean biofilm production (OD590, ±SE) in Microtiter plate assay with crystal violet staining Mean OD590 derived from methanol elution of crystal violet 
stain from 3 day old, and 6 day old CD002 biofilms from different times and lineages, grown in BHIS & BHISG in 96-well microtitre plates.  Statistical analysis was 
performed to determine the lineage or media specific differences in biofilm formation, with *** indicating were a significance difference was observed (p<0.005). 
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4.3.5 Enumeration of the C. difficile vegetative cells and spores within the biofilm 
The proportion of vegetative cells and spores within three and six-day-old CD002 biofilms (in 
BHIS) were quantified in triplicate, and the mean CFU count per lineage was determined. As 
shown in figure 4.8, CD002 biofilms show an abundance of vegetative cells and spores within 
three- and six-day-old biofilms. Similar to the observation from the crystal violet biofilm assay, 
recent UK CD002 (UK 2011-13) and non-UK 2012-14 CD002 formed significantly more 
pronounced biofilms by 3 days than UK CD002 from 2007-8 (P<0.009) as determined using 
viable counting techniques. Spore counts within biofilms were significantly greater (P<0.05) 
in recent UK CD002 from 2011-13 (1.3 x106 CFU/ml) than non-UK 2012-14 CD002 (8.2x105 
CFU/ml) and UK CD002 from 2007-8 (2.9x105 CFU/ml). Likewise, vegetative cell counts were 
significantly greater (P<0.001) in recent UK CD002 (UK 2011-13) and non-UK 2012-14 CD002 
(5.2 X106 CFU/ml and 4.2 x105 CFU/ml respectively). 
In comparison to the crystal violet assay, where a decline in BHIS biofilm biomass was 
observed at six days, the proportion of vegetative cells and spores within six-day-old CD002 
biofilms show an increase in biomass. More spores were present in six-day-old biofilms 
indicating that spore formation within biofilms had increased over time. As shown in figure 
4.6, the biofilm total viable counts of non-UK 2012-14 CD002 (1.14 x 107CFU/ml) were 
significantly greater (p<0.002) than UK CD002 from 2011-13 and 2007-8 (8.8x 106 and 2.7 
x106CFU/ml respectively). Also, recent UK CD002 (UK 2011-13) and non-UK 2012-14 CD002 
biofilms contained significantly more spores (p<0.002) (2.4x 106 and 2.7x106 CFU/ml) than UK 
CD002 from 2007-8 (2.3x105 CFU/ml).
 147 
 
U
K
 2
0
0
7
- 8
 
U
K
 2
0
1
1
- 1
3
N
o
n
-  
U
K
 2
0
1
2
- 1
4
U
K
 2
0
0
7
- 8
 
U
K
 2
0
1
1
- 1
3
N
o
n
-  
U
K
 2
0
1
2
- 1
4
 
0
4 .01 0 6
8 .01 0 6
1 .21 0 7
 C
F
U
/
m
L
V e g e ta t iv e  c e lls
S p o r e s
* *
* *
3  d a y s 6  d a y s
*
*
Figure 4-8 Enumeration of vegetative cells and spores within CD002 three- and six-day old Biofilms.  Biofilms were grown for three and six days in 96 well microtiter 
plates. Residual BHIS was removed from the wells, and biofilms were disrupted by vortexing.  The biofilm suspensions were serially diluted to determine the proportion 
of vegetative cells and spores per mL, of three-day and six-day old mature biofilms per CD002 lineage. Asterisk (*) Indicates, where a significant difference was observed 
(P>0.0001). 
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4.4 DISCUSSION  
Since the identification of C. difficile as a pathogenic organism, several investigations have 
been performed to help explain its pathogenesis. The consensus is that C. difficile 
pathogenesis is a multifactorial process, dependent on virulence factors produced by an 
infecting strain (Lessa et al.,2012; Rupnik et al., 2009). Accordingly, it is important to 
characterise the virulence factors of emerging strains of C. difficile.  In this chapter, some 
virulence characteristics and potential host colonisation factors of emerging strains of CD002 
were investigated in vitro.   
Spores are the main morphotype of CDI transmission, and C. difficile strains found to have an 
increased sporulation capacity have been suggested to be more prolific in environmental 
dissemination and recurrent infections (Akerlund et al., 2008; Cheng et al., 2011; Merrigan et 
al., 2010). However, Burns and colleagues have since refuted these claims, as they 
demonstrated considerable variability in the rate at which different isolates of the same 
ribotype produced spores(Burns et al., 2011). They also found sporulation rates of the 
epidemic and non-epidemic isolates to be broadly similar, suggesting that increased 
sporulation ability may not largely influence increased severity and disease occurrence. In the 
present study, the total sporulation capacity of 60 CD002 isolates was assessed, and the data 
generated indicated that recent strains (UK 2011-13 & Non-UK 2012-14) sporulates more 
rapidly after 24h (P= 0.005, fig 4-3a) than UK strains isolated in 2007-8. No previous study has 
investigated the sporulation rates in different lineages of CD002. However, the increased 
sporulation frequency associated with this ribotype was previously reported by Cheng et al. 
(2011). Accordingly, we can suggest that the greater sporulation capacity demonstrated by 
recent CD002 isolates, may increase their persistence in the intestinal lumen (or mucosal-
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associated biofilm) following cessation of antimicrobial therapy, subsequently allowing re-
establishment of the vegetative C. difficile population when the conditions in the gut are 
favourable. Additionally, the persistence of CD002 spores in the intestinal lumen (due to 
greater sporulation capacity) may indicate a greater propensity for transmission, as spores 
are normally shed into the environment, approximately 1-4 weeks after CDI treatment(Sethi 
et al., 2010). Spores shed into the environment are difficult to eradicate because of their 
resistance to heat, chemicals and radiation. Thus, elevated contamination of the environment 
potentially has contributed to the increased prevalence of this ribotype.  
Adherence of gastrointestinal pathogens to the host intestinal cells is a crucial aspect of 
colonisation (Crobach et al., 2018). Initially, C. difficile spores were regarded as a means of 
disease transmission, however, several studies suggested that spores play a major role in host 
colonisation. There is evidence to show that C. difficile spores adhere to intestinal epithelial 
cells surfaces at relatively high levels (Crowther et al., 2014a; Hong et al., 2017; Joshi et al., 
2012; Mora-Uribe et al., 2016; Paredes-Sabja & Sarker, 2012; Phetcharaburanin et al., 2014). 
Several spore surface properties have been identified as being involved in mediating 
adherence of C. difficile. An earlier in vitro study on spores of C. difficile 630, revealed that the 
exosporium layer was required for adherence and interactions was receptor-mediated( 
Paredes-Sabja & Sarker, 2012). Phetcharaburanin and colleagues (2014) provided evidence 
that the BclA1 spore glycoprotein affects the susceptibility to host colonisation and initial 
stages of infection. Recently an in vivo and ex vivo study showed that CotE (spore coat protein) 
facilitated host colonisation by enabling the binding of C. difficile spores to mucous (Hong et 
al., 2017). 
While spore surface properties involved in mediating adherence were not investigated in the 
present study, the adherence of CD002 spores to human adenocarcinoma cells (Caco-2) in 
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vitro was evaluated. Joshi et al (2012), suggested that spores of a CD002 strain were 
hydrophilic and thus less efficient in binding to intestinal epithelial cells. Another study 
showed a correlation between spore hydrophobicity and adherence to undifferentiated Caco-
2 cells, suggesting that less hydrophobic spores are less adherent to cell surfaces(Paredes-
Sabja & Sarker, 2012). In the present study, spores of CD002 isolates from different lineages 
were found to be predominantly hydrophilic and exhibited higher levels (21-57%) of 
adherence to seven-day-old Caco-2 cells than was previously reported by Joshi et al (2012). 
Additionally, Joshi et al (2012), revealed the lack of an exosporium layer in less hydrophobic 
isolates, including spores of CD002 by transmission electron microscopy (TEM). An earlier 
study revealed that sonication of the exosporium layer in C. difficile 630 spores, resulted in 
reduced hydrophobicity and adherence to Caco-2 cells(Paredes-Sabja & Sarker, 2012), 
suggesting that the exosporium layer plays a key role in mediating spore adherence to cells. 
Controversially, Mora-Uribe and colleagues reported higher adherence to Caco- 2 cells (both 
undifferentiated and differentiated) and mucin, by spores of a cdeC mutant R20291 strain, in 
comparison to wild type spores(Mora-Uribe et al., 2016). cdeC is a cysteine-rich protein that 
is required for the morphogenesis of the spore coat and exosporium layer of R20291(Barra-
Carrasco et al., 2013). Mora-Uribe and colleagues, observed an increased adherence to mucin 
following the sonication (to remove remnants of the exosporium layer) of cdeC mutants 
R20291 spores, while adherence to the intestinal epithelial cells (Caco-2 & HT-29) did not 
improve(Mora-Uribe et al., 2016). As a result, the authors suggested that the spore coat might 
hold a higher affinity to mucin, thus spores with a defective exosporium layer will likely 
colonise a susceptible host, while spores with an intact exosporium are prone to shedding. In 
an even more recent study, cdeC mutants R20291 spores exhibited an increased infection and 
persistence during recurrent CDI in a mouse model(Calderón-Romero et al., 2018). 
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Additionally, cdeC R20291 mutant spores demonstrated an increased fitness over wild type 
spores in a competitive infection mouse model(Calderón-Romero et al., 2018). Based on 
these reports, it is possible that the hydrophilic nature of the CD002 strains demonstrated in 
the present study may be due to the lack of an exosporium, as suggested by Joshi et al (2012), 
possibly influencing colonisation ability within the host. Conversely, since recent studies 
(Hong et al., 2017; Mora-Uribe et al., 2016)indicated that the spore coat is important for 
persistence and colonisation, it is tempting to speculate that spores of CD002 are able to 
persist and colonise a susceptible host through binding to mucin (via means of the spore coat). 
However, further work investigating the CD002 spore coat, exosporium layer, and their 
potential in vivo implication remains to be determined before any firm conclusions can be 
made.   
It has previously been demonstrated that C. difficile spore interacts specifically with proteins 
and putative receptors on the surface of apical microvilli of Caco-2 cells(Cerquetti et al., 2002; 
Mora-Uribe et al., 2016; Phetcharaburanin et al., 2014). Fully differentiated Caco-2 cells are 
known to express apical microvilli and brush border proteins (Joshi et al., 2012). Consistent 
with reports by Joshi et al (2012), CD002 spores in the present study, were found to adhere 
more strongly to fully differentiated Caco-2 cells than undifferentiated Caco-2 cells. This 
suggests that the spore surface harbours proteins that may have encouraged their adherence 
to cells, despite being less hydrophobic. However, further investigations into the CD002 spore 
surface proteins are required to clarify their role in adherence to intestinal epithelial cells.  
The severity of CDI symptoms is expected to increase with higher toxin levels(Cohen et al., 
2018). Recent studies report the emergence of ribotype 002 as a virulent strain associated 
with severe CDI and high mortality rates (Chow et al., 2017; Dauby et al., 2017; Wong et al., 
2016). However, whether severe CDI due to CD002 correlates with higher toxin levels is 
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unknown. Many studies have described a correlation between sporulation and toxin 
production as alternate mechanisms for survival by C. difficile, though this has long been 
debated (Akerlund et al., 2008; Blanco et al., 2018; Carlson et al., 2013; Di Bella et al., 2016; 
Koenigsknecht et al., 2015; Underwood et al., 2009).Recently, Blanco and colleagues (2018), 
demonstrated a positive correlation between in vivo toxin and spore levels in 200 C. difficile 
positive stool samples. Koenigsknecht et al. (2015) observed that spores and toxins were 
produced simultaneously 24h after infection in a murine model, suggesting a positive 
correlation between faecal toxin and spore levels. Warny and colleagues reported that 
hypervirulent PCR ribotypes produce quantitatively more toxin, therefore, cause more severe 
disease(Warny et al., 2005). Conversely, in vitro  CDI gut model study revealed that C. difficile 
PCR ribotype 027 releases toxins earlier in the growth cycle, but peak cytotoxin titres (a 
maximum of 5RU) did not exceed those of other ribotypes that had been reported in CDI gut 
model studies(Baines et al., 2008). Taken together, it is suggested that strains with increased 
spore formation might germinate rapidly, and release toxins earlier in the growth cycle, 
thereby causing infections more readily. In the present study, no link can be established 
between the sporulation and toxin production, but we can comment on the total toxin 
production overtime. Detectable toxin titres were present by 12h, which agrees with earlier 
studies by Vohra and Poxton (2011). Although speculative, the ability of CD002 strains to 
produce toxins earlier in the growth cycle could mean that they are more efficient in eliciting 
symptoms, and thus have a greater phenotypic advantage over other ribotypes in vivo. 
Additionally, the increased sporulation observed with recent isolates of CD002 had no 
significant influence on the total cytotoxin titres between lineages. Perhaps, this was not 
observed because cytotoxin titres between lineages were not measured at the same intervals 
as the spore- formation was quantified. The cytotoxin titres ranged between 2- 3RU for all 
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lineages, this contrasts with the previous study by Keighley et al. (2015), which reported 1RU 
as the cytotoxin titres for all CD002.   
The growth rate between lineages was investigated to determine any differences in the 
growth patterns among all strains. As demonstrated in figure 4-1a, the recent isolates of Non- 
UK 2012-14 origin had significantly increased µmax values when compared to the UK isolates 
(UK 2007-8 & UK 2011-13). Previous studies had demonstrated similar growth pattern among 
strains of C. difficile (Burns et al., 2011; Vohra & Poxton, 2011). A more recent study 
demonstrated elevated CD002 μmax (0.84 h-1) compared to hypervirulent ribotypes 027 (0.67 
h-1) and 078(0.36 h-1) (Keighley et al., 2015). However, fewer strains (n=11) of each ribotype 
were examined in comparison to the present study. Consistent with reports by Keighley and 
colleagues (2015), the μmax values of CD002 in the present study ranged between 0.69 - 0.92 
h-1. These values are higher than μmax of hypervirulent 027 and 078 (0.67 h-1, and 0.36 h-1 
respectively) reported by Keighley et al (2015). Based on this observation, we can assume that 
recent isolates of CD002 have a faster μmax, which means that they form vegetative cells 
faster, produce toxin earlier, sporulates earlier, and therefore better at causing disease and 
being transmitted or surviving therapy. However, it is noteworthy that the experimental assay 
used to quantify growth rates in this study may not be fully reflective of what happens in vivo.  
Recurrence is a major challenge encountered in the management of CDI, as 35% of patients 
reportedly undergo recurrence after the first episode(Marsh et al., 2012). Additionally,  
approximately 25- 85 % of recurrent CDI cases have been associated with the initial infecting 
strain (Barbut et al., 2000; Oka et al., 2012),  raising questions as to what factors may 
contribute to this process. Several studies addressed these questions, yet the factors 
contributing to a relapse of infection remains unknown. There are speculations that biofilms 
formation by C. difficile may be one of the mechanisms, and this has been demonstrated in 
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many in vitro  and murine studies(Crowther et al., 2014a; Dapa & Unnikrishnan, 2013; Dawson 
et al., 2012; Hammond et al., 2014; James et al., 2018; Plaza-Garrido et al., 2015; Semenyuk 
et al., 2014; Soavelomandroso et al., 2017). Similar to earlier C. difficile in vitro biofilm studies, 
the ability of CD002 to form biofilms in vitro was demonstrated in the present study (Dapa & 
Unnikrishnan, 2013; Dawson et al., 2012; Plaza-Garrido et al., 2015; Semenyuk et al., 2014). 
Consistent with previous studies, an abundance of spores was observed in CD002 biofilms, 
especially after six days of growth (Dapa & Unnikrishnan, 2013; Dawson et al., 2012; Plaza-
Garrido et al., 2015).  A major observation in this study is that more recent isolates of CD002, 
(UK 2011-13 & Non-UK 2012-14) produced more biofilms in vitro compared to older isolates 
(UK 2007-8). The biofilm biomass also correlated with the spore abundance observed in 
different lineages. Although colonisation of these strains has not been examined in vivo, given 
the observations in vitro, it is plausible that higher biofilm formation by the recent isolates 
may indicate better colonisation in vivo. In this regard, more recent isolates may stimulate 
recurrent infection after initial therapy is administered, which may have contributed to the 
recent prevalence of these strains. However, until further evaluation using other model 
systems is performed, and evidence supporting the association of these strains in recurrent 
CDI cases, we can only leave room for conjecture as pure culture C. difficile biofilms are not 
reflective of multispecies biofilms that are present in the gut. 
Carbohydrates have been reported to modulate the development of biofilms in different 
pathogens. In Burkholderia pseudomallei, the presence of low concentrations of glucose 
(2mM) enhanced biofilm formation(Ramli et al., 2012). Biofilm formation by Streptococcus 
gordonii was influenced by carbohydrates(Gilmore et al., 2003). Dapa et al demonstrated that 
addition of glucose, increased the levels of biofilm formation in C. difficile strain 630, 
suggesting that glucose is an important factor in the growth and formation of biofilm in C. 
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difficile(Ðapa et al., 2013). Contrastingly, the addition of glucose had no effect on the levels 
of biofilm formed in strain R20291. A recent study provided evidence to show that glucose 
represses sporulation during the development of C. difficile biofilms (Plaza-Garrido et al., 
2015). The mechanism of glucose-repression of sporulation during biofilm formation is 
unknown, however, the authors suggested that it may be mediated by CcpA (The glucose and 
carbon regulator)(Plaza-Garrido et al., 2015). In the present study, the presence of spores in 
BHISG mediated CD002 biofilms were not investigated. Consistent with earlier studies (Dapa 
& Unnikrishnan, 2013), enhanced biofilm formation was observed when all CD002 isolates 
were tested in BHISG, supporting the aforementioned statement that carbohydrates facilitate 
the formation of biofilms. In addition, these pure culture biofilms give an indication of biofilm 
formation in vivo, however, they are likely to be complex multi-species biofilms in 
vivo(Crowther et al., 2014a), therefore study of CD002 is warranted in more complex models 
to see if the biofilm formation results translate. 
In conclusion, the virulence and colonisation phenotypes of CD002 strains have been 
demonstrated in this study. The observed phenotypic differences (Increased sporulation 
capacity, increased biofilm formation, as well as the abundance of spores during biofilm 
development) between UK 2007-8 and recent (UK 2011-13 and Non- UK 2011-14) strains may 
explain the recent emergence of this ribotype. However, other factors such as spore 
germination frequency reported to vary among different strains of C. difficile (Carlson et al., 
2015; Crobach et al., 2018), and the response of CD002 biofilms to current therapies need to 
be explored.  
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5 THE NUTRIENT UTILISATION PROFILES OF CD002 STRAINS AND 
COMPETITION IN VITRO 
 
5.1 BACKGROUND 
The human gut is inhabited by a diverse population of microorganisms with an estimate of 
over 100 trillion cells. It is populated mostly by bacteria, but also viruses, fungi and protozoa 
(Thursby & Juge, 2017). These community of microorganisms, termed the gut microbiota form 
a mutually beneficial relationship with the host and provide a range of physiological functions 
such as colonisation resistance, metabolic functions and maintenance of gut integrity 
(Cameron & Sperandio, 2015). An alteration of the gut microbiota referred to as dysbiosis 
significantly compromises the host response to pathogenic organisms. A clear illustration of 
this phenomenon has been demonstrated by Gram-positive spore-forming bacterium, C. 
difficile, which flourishes in the presence of an altered microbiota.  
A wide variety of nutrients derived endogenously or exogenously are present in the gut, 
however, the availability of these nutrients to the diverse population of microbes is often 
limited (Thursby & Juge, 2017). Therefore, ‘survival of the fittest’ is the norm for these 
microbes, leading to fierce competition for finite resources (Pacheco & Sperandio, 2015). Due 
to these challenging living conditions, many microbes evolved different competitive strategies 
that are either active or exploitative to ensure their survival the gut. In 1983 Rolf Freter 
hypothesised, that the ability of a pathogen to thrive during intestinal colonisation depends 
on its ability to efficiently utilise nutrient sources and a suitable niche for colonisation (Freter 
et al., 1983). Supporting this, Pacheco and colleagues demonstrated how Enterohemorrhagic 
Escherichia coli upregulates its virulence genes following the detection of fucose released 
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through the enzymatic break down of mucins by Bacteroides thetaiotaomicron (Pacheco et 
al., 2012). Maltby and colleagues demonstrated how commensal Escherichia coli strains (HS 
and Nissile 1917) were able to prevent E. coli O157 colonisation(Maltby et al., 2013). This was 
achieved through the commensal strains’ ability to utilise the five sugars that were used by 
the pathogenic organism. However, if the mouse was colonised by only one of the commensal 
strains, the pathogen could exploit the other sugar sources that have not been consumed by 
the commensal, this is known as exploitative competition.  
Similarly, commensal E. coli strain Nissile 1917 was able to outcompete Salmonella enterica 
serovar Typhimurium (S. Typhimurium) due to its superior iron uptake capacity (Deriu et al., 
2013). Furthermore, an in vivo study on germ-free mice, showed how metabolic competition 
over monosaccharides by the commensal organism Bacteroides thetaiotaomicron, provided 
colonisation resistance against Citrobacter rodentium (C. rodentium) (Kamada et al., 2012) 
This was largely possible because Bacteroides species can utilise a diverse profile of 
monosaccharides and polysaccharides, serving as carbon sources, therefore B. 
thetaiotaomicron was able to outcompete C. rodentium, an organism with a similar metabolic 
profile. In addition, the study of the C. difficile 630 genomes by Sebiaha and colleagues 
revealed a vast array of substrates that are utilised by C. difficile for its growth and survival 
within the challenging gut environment (Sebiaha et al., 2006). This suggests that C. difficile is 
a uniquely adaptable organism that can exploit several nutrient niches within the host gut.  
Antagonism by the production of inhibitory compounds such as bacteriocins or short-chain 
fatty acids is another mechanism by different bacterial species limit the growth of their 
competitors (Britton & Young, 2012; Stecher et al., 2013) This type of competition is referred 
to as interference or active competition. A recent study demonstrated the ability of 
Clostridium scindens (C. scindens) to inhibit the growth and pathogenesis of C. difficile through 
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its capacity to generate secondary bile acids that are required for the inhibition of C. difficile 
spore germination (Buffie et al., 2015). Similarly, a recent study by Passmore and colleagues 
shows that para-cresol production by C. difficile affects the biodiversity of the gut microbiota, 
and thus contributes to the survival and pathogenesis of C. difficile (Passmore et al., 2018).   
 
Using in vitro and in vivo studies, Robinson and colleagues, demonstrated, how epidemic C. 
difficile (ribotype 027), was able to outcompete endemic strains (ribotype 001, 002, 014 and 
053) in the presence of the complex microbiota(Robinson et al., 2014). Scaria and colleagues, 
reported an expanded nutrient utilisation profile associated with epidemic C. difficile strain 
(ribotype 027), suggesting that this may have also contributed to the virulence of these 
strains(Scaria et al., 2014). More recently, reports suggest that epidemic lineages of C. difficile 
ribotype 027 and 078 acquired independent mechanisms to metabolise trehalose, a food 
additive, which have helped select for their emergence and contributed to their 
hypervirulence (Collins et al., 2018). Based on this prior knowledge on the epidemic C. difficile 
strain (ribotype 027) nutrient utilisation, the importance of studying the metabolic profiles as 
well as the competitive fitness of recent emerging strains or ribotype cannot be 
overemphasized. Understanding the full metabolic profile of a pathogen or strain can give 
insights into the conditions under which, they are likely to proliferate. Consequently, 
surveillance measures may be introduced to help curb the eventual spread of that pathogen 
or strain. Since Clostridium difficile ribotype 002 has emerged recently as the most prevalent 
ribotype in the UK, it is important to investigate the nutrient utilisation profile as well as the 
competitive fitness of this ribotype, to see if these factors may help explain its prevalence. 
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5.1.1 Aims and Objectives 
To identify the nutrient utilisation profiles of selected strains of CD002 from different time 
and lineages and to investigate their competitive fitness in vitro. The aims will be achieved by 
the following objectives, 
1. Nutrient utilization profile using Biolog Phenotype Microarray plates (PM1- 8) 
2. Investigation of the competitive fitness of strains in a single-stage continuous flow 
chemostat  
5.2 MATERIALS AND METHODS  
5.2.1 Bacterial strains  
Due to the nature of experiments in this chapter, only five CD002 strains of different time 
lineages were selected. These strains were selected from the different lineages based on their 
maximum specific growth rate values (µmax) in BHIS (reported in chapter 4) and antibiotic 
resistance profiles (reported in chapter 3) in order to allow selective culture. The 
characteristics of the strains used are given in Table 5-1. C. difficile strain (630, ribotype 012), 
isolated in Zurich Switzerland in 1982, was provided by Dr Shan Goh at the University of 
Hertfordshire and was used as a control in the phenotype microarray experiments.  
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Table 5-1 Characteristics of CD002 strains used for phenotype microarray comparisons and 
competition studies in vitro  
Strain 
Number 
Isolation 
Year 
Isolation location Lineage Antimicrobial  
Resistance * 
µmax 
71 2012 Maidstone, UK UK 2011-13 Sensitive 1.04 
137 2014 Spain Non-UK 
2012-14 
Rifampicin 0.87 
157 2012 Taunton, UK UK-2011-13 Erythromycin 1.13 
160 2008 Salisbury, UK UK 2007-8 Moxifloxacin 0.50 
164 2008 Dublin, Ireland Non-UK  
2007-8 
Sensitive 0.56 
*Strain resistance to an antimicrobial agent was used to prepare selective agars used in the 
competition study  
 
5.2.2 Phenotypic microarray experiment 
The metabolic profiles of five CD002 (Listed in Table 5-1) strains were measured using the 
Biolog Phenotype Microarrays (PM). PM experiments were carried out according to the 
manufacturer’s protocol as described in 2.6.1- 2.6.2.  Briefly, strains were grown overnight in 
5mL brain heart infusion (BHI) broth (CM1135, Oxoid). Subsequently, 300µL of C. difficile 
culture was plated onto pre-reduced Columbia blood agar plates (LAB001, Lab M, Lancashire, 
UK), and incubated anaerobically overnight at 37°C. Consequently, C. difficile cells were 
retrieved from the cultured agar plates using a sterile deoxygenated swab and inoculated into 
a pre-reduced IF-0a (72268, Hayward, USA), to achieve a 40% transmittance cell suspension 
(which measured spectrophotometrically as 0.139± 0.002 OD at 750nm using a CE1011 1000 
series spectrophotometer). This suspension was further diluted (1:16) in anaerobic Biolog Mix 
B solution. One hundred microliters of the final cell suspension were transferred to each well 
of the respective deoxygenated PM panels and incubated anaerobically at 37°C for 48 h. 
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Bacterial growth was then determined by reading the absorbance at 750 nm using a Multiskan 
FC Microplate photometer (51119000, ThermoFisher). Due to the financial constraints, 
biological replicates were not included in this experiment, instead, CD630 was used as a 
control and results were compared to published data by Scaria et al (2014), to validate the 
results of the test strains. However, PM analysis of CD630 was performed in duplicate.  
5.2.3 Competition Studies  
5.2.3.1 Preliminary batch culture growth experiments to investigate glucose limitation 
Prior published research indicated that C. difficile growth is limited by the absence of glucose 
in peptone yeast extract (PY) broth(Dupuy & Sonenshein, 1998; Karlsson et al., 1999; Karlsson 
et al., 2000). As a result, peptone yeast extract glucose (PYG) broth was used for the glucose 
competition study. All strains were grown according to conditions described in 2.14- 2.16. C. 
difficile strains were inoculated in pre-reduced peptone yeast extract glucose (PYG) (as 
described in Table 2-5) broth and allowed to grow overnight. Overnight C. difficile cultures 
were diluted 1:10 in pre-reduced PYG medium and grown for 24h to determine the growth 
rates (µ and µmax) and inform on the dilution rate (D=F/V) that was to be used in the 
competition studies. All strains were cultured in duplicate, and samples were retrieved every 
2 hours to determine the growth rate of the strains. At the stationary phase of bacterial 
growth, 1g of sterile glucose (41095-5000, Fisher Scientific) was introduced into the sample 
medium, the growth rate was then monitored every two hours from this point. After 6 hours, 
an increase in C. difficile growth was observed. This preliminary work was undertaken to 
mimic growth conditions in the fermenter and to determine the suitable nutrient medium 
and glucose concentration for the competition of strains. 
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5.2.3.2  Experimental design for competition experiments  
The same medium used in batch culture was used in continuous culture experiments. 
Continuous cultivation was performed in a one-litre New Brunswick Bioflo 115 bioreactor with 
a working volume of 700ml.  This process was performed in accordance with methods 
described in 2.7.1- 2.7.4. To perform competition for glucose in continuous culture, individual 
C. difficile strains were grown separately in PYG broth overnight.  Overnight cultures of C. 
difficile grown in PYG broth were diluted 1:10 into a fresh 24h pre-reduced PYG broth. These 
cultures were grown to an OD600 between 0.2-0.4, to ensure biomass of 103 was achieved by 
both competing strains, as it was necessary for both strains to have the same starting biomass 
in the fermenter. The chosen biomass of 103 achieved at OD600 between 0.2-0.4 was 
determined prior to the experimental set up through viable counting (Data not shown). 
Subsequently, 10mL of each competing strain (listed in Table 5-2) was aseptically transferred 
to a sterile universal for inoculation into the bioreactor.  
To inoculate the bioreactor, 20mL of media was aseptically removed from the bioreactor and 
replaced with 20mL of the mixed C. difficile culture (Made up of 10mL of one strain and 10mL 
of the competing strain). The bioreactor stirrer impeller was set at 400 rpm to allow sufficient 
time for adaption of both strains within the fermenter. Subsequently, samples were collected 
at 0h to determine the initial biomass at the start of the experiment. The overall biomass of 
the mixed culture was monitored every two hours over a period of 12 h, by retrieving samples 
from the culture vessel and measuring the absorbance at OD600. The Watson Marlow 
peristaltic pumps were turned on to start the continuous flow of media to the culture vessel 
at a dilution rate of 0.39h-1. This dilution rate was chosen because it was below the maximum 
specific growth rate of the competing strains.   
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Two millilitres of the sample was retrieved from the culture vessel daily. One hundred 
microliters of the retrieved sample were serially diluted (according to methods described in 
2.5) and plated on to on Brazier’s agar with the appropriate selective antibiotic (Table 5-2) 
and without the antibiotic, to enumerate CFU/ml of the different strains. The antibiotics used 
were selective for one strain (per pair), therefore enumeration of the second strain (without 
a selective antibiotic) in the competing pair, was determined by subtracting the number of 
colonies on antibiotic selective plates from the number of colonies on non-selective plates 
(Total viable count plate). Prior to fermentation studies, pre-experimental validation was 
performed on the selective agars to ensure that it yielded selectivity required for the 
experiment (data not shown). 
 
Table 5-2 The competing pair and selective media used for viable counting of strains during 
glucose competition studies  
Competing 
pair 
Selective agar CD Strain MIC to selective 
antimicrobial(mg
/L) 
Drug concentration 
in agar  (mg/L) 
164+ 137 Rifampicin Braziers 
Agar 
164 0.002 1 
137  32 
160+ 71 Moxifloxacin 
Braziers Agar 
160 32 10 
71 2 
137+157 Erythromycin 
Braziers Agar 
137 1 10 
157 64 
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5.3 RESULTS 
5.3.1 Phenotype Microarray experiments 
5.3.1.1 CD002 Carbon source utilisation  
The Biolog PM metabolic panels for carbon source metabolism (PMs 1 and 2) consisted of 190 
assays.  To validate the carbon source utilisation by CD002 strains listed in Table 5-1, the 
carbon utilisation profile of CD630 (630B) in this study was first compared with data (630A) 
obtained from a PM analysis study by Scaria et al (2014). Although there was a variation in 
the number of carbon sources utilised by strain CD630B (54 carbon sources) as opposed to 
CD630A (57 carbon sources) from Scaria et al’s (2014) study (Figure 5-1 and Figure 5-2), the 
difference was not statistically significant (P=0.132).  In PM 1 (Figure 5-1), strain 630B utilised 
some carbon sources that were not utilised by strain 630 in the study of Scaria et al (2014). 
This included: D- threonine, pyruvic acid, D-Galactonic acid-g-Lactone, D- serine, L- Arabinose, 
l-Lyxose. Conversely, strain 630B demonstrated a much lower affinity (≥1.3-1.1) to some 
compounds which were of a higher affinity (≥1.4) to 630A in Scaria et al’s (2014) study. This 
included; α-Hydroxy Glutaric Acid -γ- Lactone, Uridine, α-D-Lactose, α-Hydroxy Butyric Acid, 
Sucrose. In PM 2, 630B was negative (≤ 1) for L- Arabitol, L- Tartaric acid, butyric acid and L-
lysine, with a low affinity (≥1.3-1.1) to β-Hydroxy Butyric Acid, Turanose, L-Alaninamide, and 
L-Phenylalanine. A high affinity to these compounds was demonstrated by CD630A in the 
Scaria et al (2014) study. Additionally, CD630B demonstrated a very strong affinity (≥ 2) to 
five compounds that were negative in Scaria et al (2014) study, this included: Dihydroxy 
Acetone, D-Arabinose, 2, 3-Butanedione, Sorbic Acid and 2-Deoxy-D-Ribose. 
Out of the 190 carbon sources tested, simple sugars were utilised by most CD002 strains. 
Complex carbohydrates such as pectin and arbutin were also utilised by all CD002 strains. A 
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very strong affinity (≥2) for D- ribose, 2-Deoxy-D-Ribose, Dihydroxyacetone, L-Lyxose, D-
Xylose, L- arabinose, and D- arabinose was demonstrated by all strains. Among all the CD002 
strains studied, UK 2011-13 Strain (71) had the broadest carbon utilisation profile; this strain 
was positive for 65 carbon sources. Strain 137 (Non- UK 2012-14) was positive for 56 carbon 
sources, while strain 157 (UK 2011-13) was positive for 55 carbon sources.  The older strain, 
164 (Non- UK 2008) was positive for 52 carbon sources, while UK 2007-8 strain (160), had the 
narrowest carbon utilisation profile; this strain was positive for only 43 carbon sources.   
In comparison to the hypervirulent outbreak, associated strains R20291 (PCR ribotype 027) 
and 078 studied by Scaria et al (2014), the range of utilised carbon sources by CD002 strains 
in this study was narrower. Interestingly, UK 2011-13 strain (71) which had the broadest 
carbon utilisation profile among the CD002 strains studied, had a comparable carbon 
utilisation profile (in terms of the number of sources) with 078 (Scaria et al., 2014). Strain 078 
and 027 (strain R20291) utilised 69 and 84 carbon sources respectively (Scaria et al., 2014) 
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Figure 5-1 Carbon utilisation phenotype microarray (PM1) of CD002 strains from different time lineages. The 
list includes all positive carbon source phenotypes (red) and negative phenotypes (blue), represented by the 
scale bar given at the top of the figure. The title given at the top of the column represents the strain as follows: 
630A= CD630 data from Scaria et al (2014); 630B= CD 630(In the present study); CD078= CD 23m63 (Scaria et 
al., 2014); NAP1= CD R20291 (Scaria et al, 2014); C. difficile ribotype 002 strains: 1= 157; 2= 71; 3= 137; 4= 164; 
5= 160.  
≥1.4 <1.4 
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Figure 5-2 Carbon utilisation phenotype microarray (PM2) of CD002 strains from different time lineages. The 
list includes all positive carbon source phenotypes (red) and negative phenotypes (blue), represented by the 
scale bar given at the top of the figure. The title given at the top of the column represents the strain as follows: 
630A= CD630 data from Scaria et al (2014); 630B= CD 630(In the present study); CD078= CD 23m63 (Scaria et 
al., 2014); NAP1= CD R20291 (Scaria et al, 2014); C. difficile ribotype 002 strains: 1= 157; 2= 71; 3= 137; 4= 164; 
5= 160.
≥1.4 <1.4 
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5.3.1.2 CD002 Nitrogen and Peptide utilisation profile  
The Biolog PM metabolic panels for nitrogen source metabolism (PM 3) consisted of 95 
assays. As shown in figure 5-3, CD630B had a comparable nitrogen metabolic profile as 
CD630A (Scaria et al., 2014).  Although CD630B was negative for inosine, glucuronamide and 
Met-Ala, which were positive in CD630A (Scaria et al., 2014), the difference was not 
statistically significant (P= 0.0535).  Out of the five CD002 strains tested, strain 157 (UK 2011-
13) had the broadest nitrogen utilisation profile. This strain was positive for 25 nitrogen 
sources.  Strain 137 (Non- UK 2012-14) was positive for 22 nitrogen sources, while strain 160 
(UK 2007-8) was positive for 18 nitrogen sources. Strain 164 (Non- UK 2007-8) and strain 71 
(UK 2011-13) were positive for only 13 and 11 nitrogen sources respectively. In comparison 
to data obtained from Scaria et al. (2014), CD002 strains utilised a broader array of nitrogen 
sources. Strain 078 and 027 (strain R20291) both utilised only 11 nitrogen sources.   
The peptide nitrogen sources consisted of 285 assays (PMs 6-8), the utilisation of these 
peptides as demonstrated by strain CD630B in the present study (Figure 5-4- 5-6), was much 
narrower compared with PM analysis data on CD 630A in the study of Scaria et al. (2014). The 
differences between CD630A and CD630B in PM 6 and 7 (Figure 5-4 and figure 5-5) was not 
significantly different (p= 0.0545), however, there was a significant difference in PM 8 (P= 
0.0001) (Figure 5-6). In total, data obtained from Scaria et al (2014), showed that CD630A 
utilised 43 peptide sources (Scaria et al., 2014), however in the present study, CD630B utilised 
only 30 peptide sources.  Of all CD002 strains tested, strain 137 (Non- UK 2012-14), had the 
broadest peptide utilisation profile, this strain was positive for 57 peptide sources.  Strain 71 
(UK 2011-13), strain 164 (Non- UK 2007-8) and strain 157 (UK 2011-13) utilised 35, 30 and 22 
peptide sources respectively. Strain 160 (UK 2007-8) had the least peptide utilisation profile, 
this strain utilised only 6 peptide sources. In comparison to a hypervirulent outbreak-
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associated strain R20291 (PCR ribotype 027) and 078 reported by Scaria et al (2014), strain 
137 (Non- UK 2012-14), had a comparable peptide utilisation profile to ribotype 078, while 
ribotype 027 was positive for 110 peptide sources. 
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Figure 5-3 Nutritional Phenotype of CD002 strains from different time lineages determined using Biolog 
phenotype microarray panel 3. The affinity of nutrient utilisation is represented by the scale bar given at the 
top of the figure (red for positive and blue for negative). The title given at the top of the column represents the 
strain as follows: 630A= CD 630 data from Scaria et al (2014); 630B= CD 630(In the present study); CD078= CD 
23m63 (Scaria et al., 2014); NAP1= CD R20291 (Scaria et al, 2014); C. difficile ribotype 002 strains: 1= 157; 2= 71; 
3= 137; 4= 164; 5= 160. Each row represents a nitrogen source tested.
≥1.4 <1.4 
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Figure 5-4  Nutritional Phenotype of CD002 strains from different time lineages determined using Biolog 
phenotype microarray panel 6. The affinity of nutrient utilisation is represented by the scale bar given at the 
top of the figure. The title given at the top of the column represents the strain as follows: 630A= CD 630 data 
from Scaria et al (2014); 630B= CD 630(In the present study); CD078= CD 23m63 (Scaria et al., 2014); NAP1= CD 
R20291 (Scaria et al, 2014); C. difficile ribotype 002 strains: 1= 157; 2= 71; 3= 137; 4= 164; 5= 160. Each row 
represents a peptide source tested.  
≥1.4 <1.4 
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Figure 5-5 Nutritional Phenotype of CD002 strains from different time lineages determined using Biolog 
phenotype microarray panel 7. The affinity of nutrient utilisation is represented by the scale bar given at the 
top of the figure. The title given at the top of the column represents the strain as follows: 630A= CD 630 data 
from Scaria et al (2014); 630B= CD 630(In the present study); CD078= CD 23m63 (Scaria et al., 2014); NAP1= CD 
R20291 (Scaria et al, 2014); C. difficile ribotype 002 strains: 1= 157; 2= 71; 3= 137; 4= 164; 5= 160. Each row 
represents a peptide source tested. 
≥1.4 <1.4 
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Figure 5-6  Nutritional Phenotype of CD002 strains from different time lineages determined using Biolog 
phenotype microarray panel 8. The affinity of nutrient utilisation is represented by the scale bar given at the 
top of the figure. The title given at the top of the column represents the strain as follows: 630A= CD 630 data 
from Scaria et al (2014); 630B= CD 630(In the present study); CD078= CD 23m63 (Scaria et al., 2014); NAP1= CD 
R20291 (Scaria et al, 2014); C. difficile ribotype 002 strains: 1= CD 157; 2= CD 71; 3= CD 137; 4= CD 164; 5= CD 
160. Each row represents a peptide source tested.
≥1.4 <1.4 
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5.3.1.3 CD002 utilisation of phosphorus and sulfur  
The Biolog PM metabolic panels for phosphorus and sulfur (PM4) metabolism consisted of 95 
assays. As shown in figure 5-7, strain 630B had a similar utilisation pathway as 630A (Scaria 
et al. 2014), the differences were not statistically significant (P= 0.065). As well as 630A, 630B 
was positive for 16 phosphorus and sulfur sources. The only notable difference is that 630B 
utilised pyrophosphate, a source that was not utilised by 630A in the prior published study 
(Scaria et al., 2014). Out of all the CD002 strains tested, strain 157 (UK 2011-13), had the 
broadest phosphorus and sulfur utilisation profile. This strain utilised 26 sources, while strain 
137 (Non- UK 2012-14) and 71 (UK 2011-13), utilised 18 and 17 sources respectively.  The 
older isolates, strain 160 (UK 2007-8) and strain 164 (Non- UK 2007-8), had the least 
phosphorus and sulfur utilisation profile. Both strains utilised only two phosphorus and sulfur 
sources. In comparison to a hypervirulent outbreak-associated strain R20291 (PCR ribotype 
027) and 078 reported by Scaria et al (2014), recent CD002 (71, 137 and 157) strains 
demonstrated a comparable phosphorus and sulfur utilisation to strain R2029, while 078 
utilised only six sources. 
A notable observation is that recent UK (UK 2011- 13) strains, 71 and 157 demonstrated a 
greater ability to utilise taurocholate and taurine. Similar to the hypervirulent outbreak-
associated strain R20291 (PCR ribotype 027) as reported in Scaria et al (2014) study, strain 
137(Non- UK 2012-14) demonstrated the ability to utilise tetrathionate and taurine.  
5.3.1.4 CD002 Utilisation of Nutritional supplements    
The Biolog PM metabolic panel for nutritional supplements (PM 5), consisted of 95 assays. As 
shown in figure 5-8, Strain CD630B, utilised similar nutritional supplements as CD630 
previously reported (Scaria et al., 2014). The differences between the nutrient utilisation by 
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strain 630 in this study and Scaria et al (2014) were not significantly different (p= 0.2512).  Out 
of all the CD002 strains studied, strain 137 (Non- UK 2012-14), had the highest nutrient 
supplement utilisation profile. This strain was positive for 35 nutritional supplements which 
are higher than hypervirulent outbreak-associated strain R20291 (PCR ribotype 027) and 078 
reported by Scaria et al (2014). Strain 164 (Non- UK 2007-8), utilised 19 nutritional 
supplements, while UK 2011-13 strains (157 and 71), utilised 8 and 6 nutritional supplements 
respectively.  The UK isolate 160 (UK 2007-8) had the narrowest metabolism of the nutritional 
supplements, this strain only utilised one of the nutritional sources.  
5.3.1.5  Overall nutrient utilisation profile 
It is a well-known fact that genomic variation exists among C. difficile strains, and this was 
also demonstrated in the phenotypic metabolic profiles of CD002 strains in the present study. 
Despite strains being of the same ribotype, they exhibited varied metabolic profiles to all the 
760 nutrient sources (PM1-8). Among all the CD002 strains studied, the Non- UK (2011-14) 
CD002 strain (137) of Spanish origin appeared to have the broadest nutrient utilisation 
capability 
. As shown in table 5-3, this strain was found to utilise 183 nutrient sources. Recent UK CD002 
(Strains 157 and 71) isolates also had a more expanded nutrient utilisation profile compared 
to older UK CD002 (160).  Both recent UK CD002 (157 and 71) strains utilised 130 nutrient 
sources, while the older strain (160) utilised only 61. Non- UK strain (164), belonging to the 
older lineage (Non- UK 2007-8), appeared to have a more expanded nutrient utilisation profile 
compared with Old UK CD002 (160). This strain was found to utilise 113 nutrient sources.  
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Table 5-3 Nutrient utilisation profile of five CD002 strains and controls  
Nutrient 630A* 630B** CD078 NAP1 157 71 137 164 160 
UK 2011-13 Non-UK 
2012-13 
Non-UK 
2007-8 
UK 2007-8 
Carbon (PM1 &PM2) 56 53 69 84 55 65 56 52 43 
Nitrogen (PM 3) 36 23 11 11 25 11 22 13 17 
Phosphorus & Sulphur (PM 4) 16 17 6 32 26 18 20 2 4 
Nutrient supplements (PM 5) 16 11 12 12 6 5 34 19 1 
Peptide (PM6, PM7 & PM 8) 47 27 58 110 22 35 55 30 6 
Total 172 131 156 249 134 131 187 116 65 
*630A- Nutrient utilisation profile of C. difficile strain 630 reported by Scaria et al., 2014. 
**630B- Nutrient utilisation profile of C. difficile strain 630 reported in the present study.
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Figure 5-7  Nutritional Phenotype of CD002 strains from different time lineages determined using Biolog 
phenotype microarray panel 4. The affinity of nutrient utilisation is represented by the scale bar given at the 
top of the figure. The title given at the top of the column represents the strain as follows: 630A= CD 630 data 
from Scaria et al (2014); 630B= CD 630(In the present study); CD078= CD 23m63 (Scaria et al., 2014); NAP1= CD 
R20291 (Scaria et al, 2014); C. difficile ribotype 002 strains: 1= CD 157; 2= CD 71; 3= CD 137; 4= CD 164; 5= CD 
160. Each row represents a phosphorus and Sulphur source tested.  
≥1.4 <1.4 
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Figure 5-8  Nutritional Phenotype of CD002 strains from different time lineages determined using Biolog 
phenotype microarray panel 5. The affinity of nutrient utilisation is represented by the scale bar given at the 
top of the figure. The title given at the top of the column represents the strain as follows: 630A= CD 630 data 
from Scaria et al (2014); 630B= CD 630(In the present study); CD078= CD 23m63 (Scaria et al., 2014); NAP1= CD 
R20291 (Scaria et al, 2014); C. difficile ribotype 002 strains: 1= CD 157; 2= CD 71; 3= CD 137; 4= CD 164; 5= CD 
160. Each row represents a nutrient supplement tested. 
≥1.4 <1.4 
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5.3.2  Competition Studies  
5.3.2.1 Glucose limitation and Maximum specific growth rate (µmax) in PYG 
Having investigated the nutritional phenotypes of CD002 strains (Table 5-1) from different 
time lineages, it was important to investigate the competitive fitness of these strains to 
limiting nutrients in a bioreactor. Here, the limiting nutrient chosen was glucose, and prior to 
competition in the bioreactor, the batch growth rate in peptone yeast glucose media was 
determined.  As shown in figure 5-9, the growth curves obtained for all the strains were similar 
and the differences were not statistically significant (P= 0.7253).  An increase in bacterial 
biomass was observed six hours after 1g of glucose was added to the growth media in the 
stationary phase.  The maximum specific growth rate (µmax) for all strains was determined 
(Table 5-4), and the difference between strains was not statistically significant (P= 0.325). 
 
Table 5-4 Maximum specific growth rate of five CD002 strains in peptone yeast glucose 
broth (PYG) 
 
 
 
 
 
 
 
 
CD strain µmax in PYG Lineage 
71 0.75 UK 2011-13 
137 0.90 Non-UK 2012-14 
157 0.74 UK 2011-13 
160 0.87 UK  2007-8 
164 0.87 Non-UK 2007-8 
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Figure 5-9 The growth curves of five CD002 strains in peptone yeast glucose broth (PYG), 
measured by OD600 over 32h.  Data represent the average of three independent experiments 
and error bars are the standard error of mean.   
5.3.2.2 Competition growth studies  
After the limiting nutrient and maximum specific growth rate of the strains in PYG was 
determined, exponentially growing pure cultures of CD002 were inoculated into the 
bioreactor. Twelve hours after strain mixing and inoculation into the fermenter vessels, the 
continuous flow was started. As indicated in table 5-2 three CD002 competing pairs were 
investigated in this study.   
The first competing pair consisted of a recent non-UK 2011-14 strain; 137 and an older non-
UK 2007-8 strain; 164.  As shown in figure 5-10, after 12h of continuous culture growth, strain 
164 demonstrated a significantly (p= 0.0001) higher biomass compared to strain 137. 
However, at 48h of growth, a decline in the biomass for strain 164 and 137 was observed 
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(2.3x107 and 4.65 x107CFU/ml respectively). Both strains maintained their biomass levels for 
three consecutive days, although the levels of 137 remained significantly (p= 0.0001) higher 
than 164. Interestingly, at day six, a dramatic decline was observed in both strain populations, 
and these levels were maintained until the experiment was complete (at 12 days). However, 
strain 137 appeared to have a competitive advantage through maintaining a biomass 
population at one log10 unit higher than strain 164, this was insufficient to wash out 164 
completely. When the predicted biomass washout rate was calculated using the mass balance 
equation, this was similar for both strains. After five days of post continuous culture growth, 
the predicted biomass washout rate was below a limit of detection (data not shown).  
The second competing pair consisted of a recent UK CD002 strain (71) and an Older UK CD002 
strain (160).  As shown in figure 5-11, 12h post-initiation of continuous culture flow, the 
biomass concentrations of strains 160 and strain 71 in the bioreactor were 2.8 x108 and 4.04 
x 108 CFU/mL respectively. After 48h of growth, there was a slight decline in the biomass of 
strain 71, while strain 160 had declined significantly (P= 0.0001). Strain 71 appeared to have 
a competitive advantage over strain 160 to glucose, as this strain thrived at 107 CFU/ml until 
the end experiment, while the populations of strain 160 declined continuously over the 
course of the experiment. Additionally, after four days post continuous culture flow, the 
predicted biomass washout rate for both strains was below the limit of detection (data not 
shown). 
 A competition for glucose between recent UK CD002 strain (157) and a recent Non- UK CD002 
strain (137) was performed. As shown in figure 5-12, 12h post-initiation of continuous culture 
flow into the bioreactor, the biomass of both strains; 157 and 137 was 7.8 x 107 and 5.8 x107 
CFU/mL respectively. Following the 48h of growth, there was a significant (p= 0.0001) decline 
in the biomass of strain 137 to 3.9 x 105 in the bioreactor. Six days into the experiment, the 
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population of 137 had significantly (p= 0.0001) declined to 167 CFU/mL, while strain 157 
thrived. Recent UK CD002 appeared to have a competitive advantage over non-UK CD002. 
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Figure 5-10 Competition of a recent Non-UK CD002 Strain (137) Vs an Older Non- UK CD002 strain 
(164) for glucose in a bioreactor. Growth populations of each strain were measured over a period of 
12 days. A) The mean batch growth (OD600) of the competing pair(137+164) at 2, 4, 6, 8 and 12h post-
inoculation into the bioreactor.B) The mean biomass (CFU/ml) of each strain during continuous culture 
flow, enumerated daily through plating on selective Brazier’s agar (with 1mg/L of rifampicin), and 
Brazier’s agar without a selective antibiotic. Enumeration of the colony-forming units was done in 
triplicate, the asterisk(***) indicates where a significant difference was observed (P=0.0001). 
 
a) 
b) 
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Figure 5-11 Competition of a recent UK CD002 Strain (71) Vs an Older UK CD002 strain (160) for 
glucose in a bioreactor. Growth populations of each strain were measured over a period of 12 days. 
A) The mean batch growth (OD600) of the competing pair(71+160) at 2, 4, 6, 8 and 12h post-inoculation 
into the bioreactor.B) The mean biomass (CFU/ml) of each strain during continuous culture flow, 
enumerated daily through plating on selective Brazier’s agar(with 10 mg/L of moxifloxacin), and 
Brazier’s agar without a selective antibiotic. Enumeration of the colony-forming units was done in 
triplicate, the asterisk(***) indicates where a significant difference was observed (P=0.0001). 
a) 
b) 
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Figure 5-12  Competition of a recent Non- UK CD002 Strain (137) Vs a recent UK CD002 strain (157) 
for glucose in a bioreactor. Growth populations of each strain were measured over a period of 12 
days. A) The mean batch growth (OD600) of the competing pair (137+157) at 2, 4, 6, 8 and 12h post-
inoculation into the bioreactor.B) The mean biomass (CFU/ml) of each strain during continuous culture 
flow enumerated daily through plating on selective brazier’s agar(with 1mg/L of rifampicin and 
10mg/L of erythromycin). Enumeration of the colony-forming units was done in triplicates, the 
asterisk(***) indicates where a significant difference was observed (P=0.0001). 
a) 
b) 
 185 
 
5.4 DISCUSSION  
Nutrients and space are important for the survival of microorganisms. The nutrients required 
for microbial growth and metabolic functions include; carbon, nitrogen, potassium, 
magnesium phosphorus, sulphur, hydrogen, calcium, iron and vitamins (Bren et al., 2013; 
Ghoul & Mitri, 2016). In the human gut, these nutrients are derived from the host diet, 
mucosal secretions and nutrients released by commensal bacteria. Successful colonisation by 
pathogens requires scavenging of nutrients, sensing of chemicals, competing with the 
resident bacteria and regulating the expression of virulence genes (Pacheco et al., 2012). 
Knowledge of a pathogen’s full metabolic potential as well as competitive fitness is important 
in deciphering its virulence potential and factors driving the emergence of epidemic lineages. 
Due to the increased incidence of Clostridium difficile infection (CDI) in the early 2000s, which 
is attributed to the emergence of hypervirulent strains(He et al., 2013; Loo et al., 2005; L. C. 
McDonald et al., 2005), several studies have examined the metabolic potential and 
competitive fitness of these strains, as well as the reference C. difficile (strain 630). However, 
the metabolic potential and competitive fitness of recent emerging ribotypes (002, 005, and 
014) of C. difficile have not been reported. Here, the nutrient utilisation of different strains of 
C. difficile ribotype 002 was investigated using phenotypic microarray analysis, and the 
competitive fitness of these strains was investigated in a single-stage fermenter.  
Colonisation resistance by the host microbiota is important in preventing CDI and must be 
overcome in order for C. difficile to proliferate in the colon (Robinson et al., 2014). Data 
generated from several mouse model studies have demonstrated C. difficile ability to adapt 
its metabolism to exploit a variety of nutrient sources within the gut environment(Fletcher et 
al., 2018; Janoir et al., 2013; Jenior et al., 2017; Kansau et al., 2016). Despite the ability of C. 
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difficile to conform to a subset of metabolic pathways, carbohydrate and amino acid 
metabolism are regarded the most important in C. difficile colonisation and infection (Jenior 
et al., 2017). Janior and colleagues (2013) reported genes encoding the 
phosphoenolpyruvate-dependent phosphotransferase system (PTS), which are involved in 
the up-regulation and down-regulation of a variety of carbon sources during in vivo C. difficile 
colonisation. In vivo transcriptomic analysis of C. difficile revealed a heterogeneous 
expression in catabolic pathways for a variety of carbon sources (Jenior et al., 2017). 
Consistent with earlier findings, CD002 strains in the present study, utilised a variety of carbon 
sources. Interestingly, recent strains (Isolated 2012-2014) demonstrated an expanded carbon 
utilisation profile, which was comparable to a strain of the common ribotype, 078  (Scaria et 
al., 2014). In agreement with previous studies by Scaria and colleagues (2014), CD002 strains 
were able to readily utilise simple sugars such as maltose, α-D-glucose, D-fructose and D-
mannose.  
Genomic diversity exists between strains of C. difficile, supporting this, different strains of the 
same ribotype in PM analysis study by Scaria et al (2014) exhibited different nutrient 
utilisation profiles. An interesting observation in the present study was the ability of CD002 
strains to utilise five carbon sources (D-ribose, L-lyxose, L- arabinose, Dihydroxy Acetone, D-
Arabinose and 2- deoxy- D- ribose) which were not utilised by hypervirulent C. difficile strains 
(RT 078 and RT 027). These are simple sugars, some of which are derived from the host diet 
and end products of other commensal gut organisms. The significance of these carbon 
sources in C. difficile physiology and virulence is unknown, however, it is tempting to 
speculate that it may help select for the emergence and spread of these strains. In view of 
this hypothesis, a recent study by Collins and colleagues identified independent mechanisms 
which have been acquired by epidemic lineages of C. difficile ribotypes (027 & 078) to 
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metabolise dietary sugar trehalose(Collins et al., 2018). The authors, identified a single point 
mutation(L172I) in the trehalose repressor gene (treR) that was unique to C. difficile ribotype 
027 strains, and a cluster of four genes involved in trehalose metabolism, as well as a PTS 
premase which was unique to strains of ribotype 078 (Collins, et al., 2018). Subsequent 
studies on ribotype 017 strains, revealed a single point mutation (C171S) in treR, in a location 
(the predicted effector binding pocket of TreR) adjacent to where the L1721 amino acid 
substitution is found in 027 strains(Collins et al., 2018). Additionally, the authors suggested a 
link between the adoption of trehalose as an additive in the human diet in the 21st century,  
and the emergence of both ribotype 027 and ribotypes 078 outbreaks(Collins, et al., 2018a; 
Collins, et al., 2018b). The hypothesized that the introduction of trehalose to human diet may 
have contributed to driving the epidemiological prevalence of these strains. As a result, the 
speculation that the aforementioned carbon sources may drive epidemiological prevalence 
in CD002 may not be farfetched, however, further analysis utilising other model systems is 
required to support this hypothesis. Additionally, only one CD002 strain (157, UK 2011-13) 
utilised trehalose in the present study, suggesting that the introduction of trehalose in human 
diet may not be a factor driving the epidemiological prevalence of CD002. 
One of the limited resources in the mammalian lower gastrointestinal tract is nitrogen, and 
through Stickland reactions, C. difficile uses amino acid fermentation to provide energy and 
nitrogen in the lower gastrointestinal tract (Jenior et al., 2017). Stickland reactions involve the 
fermentation of two amino acids, in which one acts as an electron donor (leucine, isoleucine 
and alanine) and another acts as an electron acceptor (proline and glycine) (Kansau et al., 
2016). An earlier in vivo study revealed a Stickland pair, leucine and proline as preferential 
substrates utilised by C. difficile to generate ATP (Janoir et al., 2013). A recent in vivo study by 
Jenior and colleagues demonstrated how C. difficile preferentially metabolised nitrogen-
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containing carbon sources derived through fermentation of Stickland substrates (such as 
alanine, leucine and proline), and host-derived glycans(Jenior et al., 2017). Additionally, 
Moore and colleagues demonstrated how low protein diets were found to be protective 
against CDI in mice, suggesting that fermentation of proteins is an alternative energy source 
for C. difficile(Moore et al., 2015). Consistent with previous studies, recent CD002 strains 
(strain 157 & 137) in the present study, utilised a wider range of nitrogen sources in 
comparison to strains of epidemic C. difficile ribotypes, 027 and 078 that were reported in a 
study by Scaria et al (2014). Additionally, recent UK CD002 (157 and 71) utilised both L-leucine 
(PM3) and L-proline (PM5), which are preferential Stickland substrates. Although it might 
appear trivial, the ability of recent CD002 isolates to readily utilise preferential Stickland 
substrates could have a profound effect on the strain’s dissemination and colonisation. 
It has previously been reported that guanosine and methylamine are strong toxin inducers 
(Lei & Bochner, 2013). In the present study, strain 157 and 137 were positive for two toxin 
inducers (guanosine and methylamine). After 12h of growth, both strains (In chapter 4) had 
produced a cytotoxin titre of 1RU, while it took most CD002 strains 24h to achieve a titre of 
1RU. The ability of these strains to utilise toxin inducing nutrients may explain why they were 
able to produce toxins earlier in the growth cycle, also at 72h, the toxin titre of these strains 
was high (4RU). The phenomenon that high toxin producers may cause severe infections (Di 
Bella et al., 2016) may explain why strains of this ribotype have been implicated in severe CDI 
cases recently(Chow et al., 2017; Dauby et al., 2017; Wong et al., 2016). However, until clinical 
information linking these strains to severe forms of CDI in the UK and the rest of the EU is 
obtained, we can only speculate.  
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The expanded metabolic potential demonstrated by recent CD002 strain (137 of Spanish 
origin), in comparison to other CD002 strains investigated in the present study might help 
explain the emergence of this ribotype. Although speculative, it is reasonable to believe that 
a strain with a wide utilisation of nutrients coupled with an ability to use spore germinants 
such as taurocholic acid and alanine, will readily colonise a susceptible host, thereby leading 
to the increased prevalence of strains of that ribotype. However, it is noteworthy that an 
expanded metabolic potential demonstrated by one strain of a ribotype does not reflect the 
behaviour of other strains of that ribotype. Additionally, studies by Jenior and colleagues 
(2017) revealed that C. difficile is able to exploit various nutrient niches within the host, 
suggesting an ecological generalist rather than a specialist lifestyle(Gripp et al., 2011; Jenior 
et al., 2017).  This means that in the absence of predisposing factors, a strain with a wide 
metabolic potential will be unable to outcompete a specialist organism in the gut microbiota. 
Conversely, we can infer that, in the presence of an altered microbiota, a strain with a wide 
metabolic potential will have a competitive advantage over strains of other ribotypes with 
narrower substrate utilisation profiles.   
Beyond utilisation of nutrients, competition for nutrients is a key aspect of host colonisation. 
A study by Janior and colleagues highlighted the importance of glucose as a preferred 
substrate for C. difficile colonisation in the gut(Janoir et al., 2013). In the present study, 
competition for glucose by different strains was investigated in vitro. The data generated from 
the three competing pairs, suggests that recent strains of CD002 may have a competitive 
advantage in terms of glucose affinity over older strains of CD002. However, due to the 
predicted biomass washout rate for each strain observed in two (Recent Non-UK CD002 vs 
Old Non-UK CD002, Recent UK CD002 vs Old UK CD002) out of the three competing pairs, it 
appears that strains co-existed together and were being washed out a similar rate. 
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Interestingly, a recent UK CD002 was able to outcompete recent non-UK CD002 in the 
fermenter. Nevertheless, it is difficult to make assumptions as to whether these strains will 
behave similarly in the presence of a complex gut microbiota since competition in the present 
study incorporated the use of pure cultures of CD002. However, previous C. difficile 
competition studies by Robinson and colleagues observed the dominance of C. difficile 
ribotype 027 strains over non- 027 strains in vitro as well as in vivo(Robinson et al., 2014). C. 
difficile ribotype 027 strains appeared to outcompete non-027 strains, leading to a complete 
loss of non- 027 strains, while 027 strains remained dominant. This suggests that the 
observations made in the present study could potentially be replicated in vivo. 
This study had several limitations, the most important, was the inability to include biological 
replicates in the phenotypic microarray analysis. While steps were taken to ensure validity of 
results, through comparative analysis of C. difficile 630 with data obtained from Scaria et al 
(2014) study, and Gram staining of wells that yield very high biomass after 48h incubation, 
we cannot rule out the possibility that some of the results could have been false positives. 
Also, due to the cutoff point for positives, which was 40 % above the negative control (1.4), it 
is also possible that some other positive nutrient sources which yielded readings of <1.4 may 
have been excluded in the overall profile. In the competition study, the inability to compete 
for strains that had each attained a steady state in a fermenter before a competing strain was 
introduced may be an important limitation. Though steps were taken to ensure that the same 
biomass of each strain was inoculated into the fermenter, it is reasonable to believe that the 
experimental design was not conducive for both strains to thrive.  As a result, it was difficult 
to ascertain, if strains which maintained higher biomass, have a more competitive advantage.  
Another limitation was not determining the substrate utilisation constant of these strains to 
glucose, as this would have informed about the affinity of the strains to glucose.  
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The data generated here has provided insights into the nutrient utilisation profiles of CD002 
strains which may then translate to their in vivo colonisation potential. Whether these factors 
might contribute to the prevalence and virulence of these strains, is yet to be elucidated using 
other model systems. Nevertheless, we can conclude that recent CD002 have a more 
expanded nutrient utilisation profile than older CD002 strains. This suggests, that recent 
strains of CD002 may have acquired mechanisms to better utilise various nutrient sources and 
this may have contributed to the recent prevalence of this ribotype. 
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6 COMPARATIVE PROTEOMIC ANALYSIS OF CD002 ISOLATES FROM 
DIFFERENT TIME LINEAGES 
 
6.1 BACKGROUND 
Clostridium difficile (C. difficile) is a Gram-positive spore-forming anaerobic bacterium that 
has rapidly emerged as the leading cause of nosocomial diarrhoea around the world (Ternan 
et al., 2014). Symptoms range from mild, self-limiting diarrhoea to toxic megacolon, intestinal 
perforation or death(Chen et al., 2013). In recent years, the clinical and molecular 
epidemiology of this problematic pathogen has received considerable attention due to the 
emergence of hypervirulent strains types, which are responsible for higher incidence rates 
and a financial burden on the health care system (Lessa et al., 2015; Planche & Karunaharan, 
2017).  
Advances in next-generation sequencing technologies have proven useful in understanding 
the evolution, genetic relatedness, and physiology of several problematic pathogens including 
C. difficile. In 2006, Sebaihia and colleagues described the first complete genome sequence of 
C. difficile strain 630 (PCR ribotype 012), a multi-drug resistant strain, originally isolated from 
a patient with pseudomembranous colitis (PMC) in 1982 in Zurich, Switzerland. Since then, 
the genome sequence of this strain has been re-annotated by other researchers(Dannheim 
et al., 2017; Monot et al., 2011) and the fully sequenced genomes of other C. difficile strains 
have been described(He et al., 2010; Janoir et al., 2013; Pereira et al., 2016; Stabler et al., 
2009; Suzuki et al., 2017) and made publicly available on several databases (such as EMBL-EBI 
and GenBank). Analysis of the C. difficile 630 genomes by Sebaihia and colleagues, revealed 
its dynamic nature and a vast spectrum of genes involved in resistance to antimicrobial 
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agents, virulence, host interactions, and various metabolic activities that allow its survival 
within the challenging gut environment (Sebaihia et al., 2006). Subsequent comparative 
genomic analysis of different strains of C. difficile revealed the massive genomic diversity 
existing between strains, and this genomic variation extends to the core genome of this 
pathogen(He et al., 2010).  
Despite the success in delineating C. difficile physiology and pathogenesis using whole-
genome sequencing technologies, proteomics studies are crucial in better understanding the 
diversity and adaptive mechanisms of this widespread pathogen. Proteomic studies provide 
information complementary to the genome information, as the proteome of an organism, 
translates the genome sequence into cellular functions and structures. During pathogenesis, 
proteins catalyse crucial metabolic reactions as well as cellular processes (Maaß et al., 2018). 
Access to highly sensitive techniques such as mass spectrometry has made it possible for 
proteins to be rapidly analysed.  
Alterations in C. difficile  gene expression in response to environmental stimuli have been 
investigated in several proteomic studies (Boetzkes et al., 2012; Chen et al., 2013; Chong et 
al., 2014; Dresler et al., 2017; Jain et al., 2011; Jain et al., 2010; Maaß et al., 2018; Moura et 
al., 2013; Ternan et al., 2014). Mukherjee and colleagues analysed proteins released in vitro 
during high toxin production in C. difficile strains 630 and VPI10463.  Subsequently, Moura et 
al. (2013) analysed purified C. difficile large clostridial toxins (TcdA and TcdB) and identified 
several surface proteins present in the culture filtrates. Additional studies have characterised 
the insoluble sub-proteome of C. difficile reference strain 630 (Jain et al., 2010), the cell 
surface proteins (Wright et al., 2005), and the spore proteins (Lawley et al., 2009; Pizarro-
Guajardo et al., 2018).In addition, proteins involved in antimicrobial resistance, reduced 
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antimicrobial susceptibility, drug metabolism and stress responses have been reported(Chong 
et al., 2014; Jain et al., 2011; Maaß et al., 2018)  
Comparative proteomic analysis of the secretome of reference strain 630 and two 
hypervirulent PCR ribotype 027 strains (CD196 and CDR20291), revealed five proteins 
specifically secreted by hypervirulent strains(Boetzkes et al., 2012). Furthermore, differences 
in the level of expression of proteins, including adhesions, S-layer proteins, cell wall proteins 
and other potential virulence factors have been identified among different strains, confirming 
the variation between strains (Boetzkes et al., 2012; Chen et al., 2013; Chilton, et al., 2014). 
More recently, Dresler and colleagues (2017) analysed the proteins released in vitro in eight 
C. difficile PCR ribotypes (001, 005, 010, 012, 014, 027, 078, and 176), and also highlighted the 
unique expression of specific proteins identified in ribotypes 027 and 176, confirming their 
genetic relatedness. 
The data generated from the aforementioned proteomics studies emphasise the importance 
of proteomic characterisation of emerging strains and ribotypes. Since Clostridium difficile 
ribotype 002 has emerged as prevalent ribotype in the UK, detailed biological characterisation 
in conjunction with comparative proteomic analysis is crucial in explaining the emergence of 
this ribotype in the UK. Analysis of the whole-cell proteome of strains from different 
geographical locations and lineages could potentially give insights into adaptive changes that 
may have occurred over time.  
6.1.1 Aims and Objectives  
The aim of these studies was to characterise the whole cell proteome of three CD002 strains 
(1 per lineage) and identify changes at the proteomic level. This will be achieved through the 
following objectives: 
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1. Extraction and analysis of the whole-cell proteome using fast prep system and single 
dimension gel electrophoresis. 
2. Tryptic digestion of peptides and analysis using Liquid Chromatography-Tandem Mass 
spectrometry (LC-MS/MS).   
3. Analysis of spectra using bioinformatics tools such as MASCOT server and Scaffold.  
6.2 MATERIALS AND METHODS 
6.2.1 Bacterial strains and proteomic analysis 
To investigate the differences between CD002 isolates at the proteomic level, one strain was 
selected per lineage (Table 6-1). Whole-cell proteins were extracted according to methods 
described in 2.8.7.1., and one-dimensional gel electrophoresis was performed according to 
methods described in 2.8.7.2. The resultant gels (Figure 6-1) were excised into 12 bands for 
each isolate and in-gel trypsin digestion was carried out according to methods described in 
2.8.7.3 for identification by LC-MS/MS. 
 
Table -6-1 List of CD002 Strain per lineage, selected for proteomic analysis 
Strain No Lineage  Origin Year of Isolation 
71 UK 2011-13 Maidstone 2012 
137 Non-UK 2012-14 Spain 2014 
174 UK 2007-8 Leeds 2007 
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Figure 6-1-Coomassie-stained 1D gel used for LC-MS/MS analysis. Lanes 1 and 10 are the 
pre-stained see blue molecular markers. Lanes 2 and 3 are biological replicates of the strain 
71 extract, lanes 4 and 5 are biological replicates of the strain 137 extract, and lanes 6 and 7 
are biological replicates of the strain 174 extracts. Lane 8 is an extract of strain CD630, as a 
control. Each lane was cut into 12 bands, as shown in lane 4, for digestion and identification 
by LC-MS/MS 
 
6.2.2 LC-MS/MS analysis and Database search 
Experts within the mass spectrometry laboratory, UCL School of Pharmacy, London, UK, 
performed the LC-MS/MS analysis on the proteomes of three CD002 strains (with biological 
replicates). All LC-MS/MS data were processed using the MASCOT server (Version 2.6, Matrix 
Science, and London, UK) and searched against NCBI and SwissProt database for all species of 
bacteria. The peptide tolerance was set at ± 1.2 Da, the MS/MS tolerance was set at ± 0.6 Da 
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and the search was set to allow two missed cleavages, oxidation of methionine and 
carbamidomethylation of cysteine and a significance threshold of ≤0.05. Subsequently, 
MASCOT output files per biological replicate were imported to the Scaffold proteome 
software (Version 4, Oregon, USA) and re-analysed against the UniProt database with the 
following parameters: The protein threshold was set at 95%, the peptide threshold was set at 
95% and a minimum of at least two peptides per protein was allowed.  Although a minimum 
of two peptides was allowed per protein, identifications based on one peptide was considered 
valid if the scaffold probability score was ≥95% and if the same peptide had been detected in 
other samples. The MASCOT and Scaffold search parameters were stringent, so the 
probability of a wrong assignment was below 0.1%.  
6.3 RESULTS 
6.3.1 Total number of identified proteins and strain distribution  
A single-dimensional (1D) gel electrophoresis followed by LC-MS/MS analysis was used to 
identify strain-specific differences in the proteome of three CD002 strains from different time 
lineages and geographical locations (Table 6-1). A total of 250 different proteins were 
identified in the whole-cell proteome retrieved from strains grown for 64h on Columbia blood 
agar (LAB001, Lab M, Lancashire, UK) plates. Out of the identified proteins, 165 (66%) of these 
were shared between all strains (Figure 6.2a, Table 6.2). Some of the proteins identified were 
only detected in one of the three strains, with 15 (6%) proteins only detected in strain 71 (UK 
2011-13), 5(2%) proteins only in strain 137 (Non- UK 2011-14) and 10 (4 %) proteins only in 
strain 174(UK 2007-8).  
The fifteen proteins detected only in strain 71 included: 4-hydroxy-tetrahydrodipicolinate 
synthase, 50S ribosomal protein L11, anti-sigma F factor, Arginine--tRNA ligase, Biotin 
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synthase, Energy-coupling factor transporter ATP-binding protein EcfA2, flavodoxin family 
protein, lysyl-tRNA synthetase, Methionyl-tRNA formyltransferase, Oligoendopeptidase F , 
Peptide chain release factor 3, putative peptidase, putative purine permease, putative 
transcriptional regulator and XRE family transcriptional regulator. The five proteins detected 
only in strain 137 included; Holin-like pore-forming protein, bifunctional protein GlmU, DNA 
polymerase IV, N-acetylmuramic acid 6-phosphate etherase, and a putative phage protein. 
The ten proteins detected only in strain 174 include, DNA polymerase III subunit alpha, Fe-S 
cluster assembly scaffold protein, hypothetical protein BM529_15905, Lrp/AsnC family 
transcriptional regulator, Peptidylprolyl isomerase, putative septation protein, rubrerythrin 
(21kDa) small acid-soluble spore protein alpha, small, acid-soluble spore protein beta, Surface 
layer protein A (37kDa).  
Using the scaffold proteome software (Version 4), the identified proteins were annotated 
using gene ontology (GO terms) to determine their cellular localisation as well as biological 
processes. Majority of proteins identified were cytoplasmic (74%) proteins and ribosomal 
proteins (18.3%) (Figure 6.2b) with most proteins being involved in metabolic processes (60-
67%).  
6.3.2 Proteins associated with Toxins regulation and synthesis 
Using LC-MS/MS analysis, the major virulence factors for C. difficile, toxin A and B were 
detected in all three CD002 investigated strains. Additionally, the GTP-sensing transcriptional 
pleiotropic repressor CodY known to repress toxin gene expression was detected in all three 
isolates. The holin-like pore-forming protein, tcdE was detected in only strain 137 (Non-UK 
2011-12) (Figure 6-2c). 
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6.3.3 Spore associated proteins  
Spores are the vehicle for CDI transmission, using LC-MS/MS analysis, 10 spore proteins were 
identified.  Four of these proteins were identified in all investigated strain, and they included; 
Sporulation membrane protein SpoIIIJ, Sporulation sigma-E factor-processing peptidase, 
Stage IV sporulation protein A, Cell division/stage V sporulation protein. The spore coat 
protein, peroxiredoxin (CotE), was detected in only strain 71 and 137. Small acid-soluble spore 
protein alpha, small acid-soluble spore protein beta (sspB), a putative septation protein 
SpoVG, and a putative cold shock protein (CspA) was detected only in strain 174. While the 
anti-sigma F factor was detected only in strain 71. 
6.3.4 Proteins involved with the assembly of the C. difficile flagellum 
Flagella are essential for motility and are believed to contribute to C. difficile virulence. Using 
LC-MS analysis, eight different flagella proteins were identified and one of these was a 
putative flagella filament core protein. Flagella proteins, flagellin (fliC), flagellar hook protein 
(fliD), flagella M-ring protein (fliF) and flagellar export protein (fliJ) were detected in all three 
CD002 investigated strains. While flagellar assembly factor (fliW), flagellar basal-body rod 
protein (FlgC) and flagellar biosynthesis protein (FlhA) was detected in only strain 71 and 137. 
The putative flagella filament core protein was identified in only UK CD002 strains, strain 71 
and 174. 
6.3.5 Cell surface-associated proteins  
Cell surface proteins are known to play a role in C. difficile adherence. Using LC-MS/MS 
analysis, a total of 10 cell surface proteins were identified. Eight cell surface proteins were 
detected in all strains, these included cwp20, cwp22, cwp66, cell wall bind repeat 2 family 
protein, S-layer protein precursor, S-layer protein and putative cell wall binding protein 
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Cwp25. The ATPase activity, protein translocase subunit SecA, known to be necessary for the 
secretion of surface layer proteins (Fagan and Fairweather, 2011) was detected in all 
investigated strains. Only the cell wall binding protein cwp2 was detected in only two strains; 
strain 71 (UK 2011-13) and strain 137(Non-UK 2012-14).
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Figure 6-2 Overview of identified CD002 proteins a) A Venn diagram showing the distribution of proteins identified by LC-MS/MS analysis 
according to the strains in which they were identified. b) A pie chart from the scaffold proteome software, showing the cellular location of 
identified proteins in the three investigated CD002 strains. c) The percentage distribution of proteins according to the biological processes in 
which they are involved.
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6.3.6 Heat Shock and stress-related proteins  
Using LC-MS/MS analysis, chaperones and several stress-response related proteins were 
identified. In total, nine heat shock proteins were identified, and eight of these were detected 
in all investigated strains. They included; 33 kDa chaperonin, 60 kDa chaperonin (groL), ATP-
dependent Clp protease ATP-binding subunit ClpX, ATP-dependent Clp protease proteolytic 
subunit, Chaperone protein ClpB, Chaperone protein DnaJ, Chaperone protein DnaK (Hsp70), 
and Hsp90. The 10 kDa chaperonin (gros) protein was identified in only strain 137 and 174. 
Additionally, one stress-related rubrerythrin was identified in strain 174 only, while 
rubrerythrin family protein was detected only in strain 71 and 174.  
 
6.3.7 Proteins associated with leucine pathway metabolism  
Using LC-MS/MS analysis, seven proteins involved in leucine pathway metabolism were 
identified. Of the seven proteins identified, six of these were detected in all investigated 
strains. They included; (R)-2-hydroxyisocaproyl-CoA dehydratase alpha subunit (hadB), (R)-2-
hydroxyisocaproyl-CoA dehydratase beta subunit (hadC), electron transfer flavoprotein beta-
subunit (etfB), electron transfer flavoprotein subunit alpha (etfA), acyl-CoA dehydrogenase , 
short chain specific (acdA),  Isocaprenoyl-CoA:2-hydroxyisocaproate CoA-transferase (hadA). 
Leucine metabolism associated protein, 2-hydroxyisocaproyl-CoA dehydratase activator 
(hadI) was detected in only strain 137 and 174. 
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Table 6-2 List of all proteins identified in the proteome of three CD002 strains investigated by 1D gel electrophoresis followed by LC-MS/MS 
analysis. Proteins were identified using MASCOT search parameters and further validated as greater than 95% peptide probability, a minimum 
of 2 peptides and 95% protein probability using Scaffold proteome software. 
Protein IDs Gene Molecular 
Weight 
Accession 
Number 
No of Unique peptides 
71 137 174 
 No  Ribosomal proteins A B A B A B 
1 30S ribosomal protein S10  rpsJ 12 kDa RS10_PEPD6 2 3 0 0 4 3 
2 30S ribosomal protein S12  rpsL 15 kDa RS12_PEPD6 2 2 2 2 2 3 
3 30S ribosomal protein S13  rpsM 14 kDa RS13_PEPD6 5 4 0 0 3 4 
4 30S ribosomal protein S15  rpsO 10 kDa RS15_PEPD6 0 0 3 4 2 2 
5 30S ribosomal protein S19  rpsS 11 kDa RS19_PEPD6 2 4 2 4 2 3 
6 30S ribosomal protein S2  rpsB 26 kDa RS2_PEPD6 0 0 2 3 2 3 
7 30S ribosomal protein S3  rpsC 30 kDa RS3_PEPD6 2 8 4 2 3 5 
8 30S ribosomal protein S4  rpsD 24 kDa RS4_PEPD6 3 4 3 4 5 2 
9 30S ribosomal protein S5  rpsE 18 kDa RS5_PEPD6 3 2 4 2 2 5 
10 30S ribosomal protein S6  rpsF 11 kDa RS6_PEPD6 3 2 4 2 4 3 
11 30S ribosomal protein S7  rpsG 18 kDa RS7_PEPD6 5 4 2 2 3 3 
12 30S ribosomal protein S8  rpsH 15 kDa RS8_PEPD6 4 6 0 0 5 4 
13 30S ribosomal protein S9 rpsI 15 kDa RS9_PEPD6 3 3 2 2 3 3 
14 50S ribosomal protein L1  rplA 25 kDa RL1_PEPD6 4 2 5 2 4 4 
15 50S ribosomal protein L10 rplJ 19 kDa RL10_PEPD6 3 2 4 3 4 3 
16 50S ribosomal protein L11  rplK 15 kDa RL11_PEPD6 4 3 0 0 0 0 
17 50S ribosomal protein L13  rplM 16 kDa RL13_PEPD6 5 5 8 3 4 2 
18 50S ribosomal protein L15  rplO 16 kDa RL15_PEPD6 4 5 2 2 2 3 
19 50S ribosomal protein L18  rplR 14 kDa RL18_PEPD6 3 2 4 2 2 2 
20 50S ribosomal protein L19  rplS 13 kDa RL19_PEPD6 2 3 0 0 2 5 
21 50S ribosomal protein L2  rplB 30 kDa RL2_PEPD6 2 4 2 3 4 6 
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22 50S ribosomal protein L21  rplU 11 kDa RL21_PEPD6 4 3 5 3 0 2 
23 50S ribosomal protein L24 rplX 14 kDa RL24_PEPD6 2 5 0 6 2 7 
24 50S ribosomal protein L29 rpmC 8 kDa RL29_PEPD6 2 3 0 0 4 1 
25 50S ribosomal protein L3 rplC 22 kDa RL3_PEPD6 4 2 5 0 2 3 
26 50S ribosomal protein L30  rpmD 7 kDa RL30_PEPD6 2 0 4 2 2 5 
27 50S ribosomal protein L5  rplE 20 kDa RL5_PEPD6 2 2 0 8 2 2 
28 50S ribosomal protein L7/L12  rplL 13 kDa RL7_PEPD6 2 2 1 2 3 3 
29 50S ribosomal protein L9  rplI 17 kDa RL9_PEPD6 2 2 2 2 2 2 
30 Ribosomal protein S12 methylthiotransferase RimO  rimO 51 kDa Q18BJ2 2 2 2 2 0 0 
31 Ribosomal RNA small subunit methyltransferase G rsmG 24 kDa C9YSG6 4 2 3 0 2 2 
32 Ribosomal RNA small subunit methyltransferase A rsmA 32 kDa Q181C1 2 2 2 2 2 3 
33 Ribosome maturation factor RimM  rimM 20 kDa Q18BB6 4 3 4 2 0 0 
34 Ribosome-recycling factor  frr 21 kDa RRF_PEPD6 4 3 3 2 3 0 
Cell Surface-associated proteins 
35 Cell surface protein (putative penicillin binding protein) cwp20 111 kDa Q18BY9 4 5 3 0 6 2 
36 cell wall-binding protein cwp2 cwp2 67 kDa Q183M5 2 2 2 2 0 0 
37 cell wall binding protein cwp22 cwp22 72 kDa Q183E7 3 3 4 2 4 5 
38 cell wall binding protein cwp66 cwp66 68 kDa Q183M7 2 2 2 2 2 2 
39 Cell wall binding repeat 2 family protein cwp 39 kDa T4HAJ2_CLODI 2 2 3 5 4 5 
40 Surface layer protein A slpA 37 kDa BAE48149 0 0 0 0 2 2 
41 S-layer protein SlpA  slpA 77 kDa WP_059026871 18 20 15 11 11 13 
42 Protein translocase subunit SecA  secA1 102 kDa Q18CN0 4 2 0 3 2 4 
Proteins involved in sporulation 
43 Small acid-soluble spore protein alpha sspA 8 kDa Q183C2 0 0 0 0 2 4 
44 Small, acid-soluble spore protein beta  sspB 7 kDa Q17ZZ3 0 0 0 0 2 3 
45 Sporulation membrane protein SpoIIIJ CD630_36780 27 kDa Q181T0 2 2 2 2 2 2 
46 Sporulation sigma-E factor-processing peptidase spoIIGA 32 kDa Q182X8 2 2 2 2 2 2 
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47 Stage IV sporulation protein A spoIVA  56  kDa Q182W3 2 2 2 2 2 2 
48 anti-sigma F factor  spoIIAB 16 kDa Q189W4 4 2 0 0 0 0 
49 Cell division/stage V sporulation protein spoVE 41 kDa Q182Y5 2 3 0 2 4 3 
50 Peroxiredoxin (Spore coat protein) cotE 81 kDa  Q18BV5 5 2 2 3 0 0 
Toxins  and  transcriptional regulators 
51 Toxin A  toxA 308 kDa TOXA_CLODI 12 3 5 10 11 5 
52 Toxin B toxB 270 kDa TOXB_CLODI 2 4 2 5 4 2 
53 GTP-sensing transcriptional pleiotropic repressor CodY  Cody 29 kDa Q18BE1 2 5 2 7 2 3 
54 Holin-like pore-forming protein TcdE tcdE 19 kDa Q189K6 2 2 2 2 2 2 
Proteins involved in Leucine Metabolism 
55 (R)-2-hydroxyisocaproyl-CoA dehydratase alpha subunit  hadB 46 kDa HADB_CLODI 5 5 6 3 6 2 
56 (R)-2-hydroxyisocaproyl-CoA dehydratase beta subunit  hadC 42 kDa HADC_CLODI 5 2 5 4 5 3 
57 2-hydroxyisocaproyl-CoA dehydratase activator hadI 28 kDa HADI_CLODI 0 0 2 8 5 2 
58 electron transfer flavoprotein beta-subunit/FixA etfB 29 kDa Q188I4 2 5 0 3 2 6 
59 electron transfer flavoprotein subunit beta/FixA eftB 28 kDa WP_009888867.1 6 5 2 3 6 6 
60 electron transfer flavoprotein subunit alpha/ FixB etfA 37 kDa Q18AQ5 2 3 0 4 4 6 
61 electron transfer flavoprotein subunit alpha/FixB etfA 36 kDa WP_003428573.1 4 5 3 4 7 8 
62 acyl-CoA dehydrogenase , short chain specific acdA 41 kDa Q188I5 8 0 7 4 3 9 
63 Isocaprenoyl-CoA:2-hydroxyisocaproate CoA-transferase hadA 44 kDa Q188I3_PEPD6 5 9 3 11 7 12 
Proteins  involved in  Flagellar assembly of C. difficile  
64 Flagellar assembly factor fliW 15 kDa FLIW_PEPD6 2 2 2 2 0 0 
65 Flagellar basal-body rod protein FlgC flgC 15 kDa Q18CY6 9 8 4 6 0 0 
66 Flagellar biosynthesis protein FlhA  flhA 76 kDa Q18CZ8 8 4 3 4 0 0 
67 Flagellar Hook Protein (flagellar cap protein) fliD 56 kDa Q18CX9 2 2 2 3 3 3 
68 Flagellar M-ring protein fliF 56 kDa Q18CY4 4 0 2 3 2 2 
69 Flagellin fliC 31 kDa Q18CX7 5 9 4 11 5 9 
70 Flagellar export protein FliJ flij 17 kDa A0A386FPC4 4 2 3 2 3 4 
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Stress related proteins  
71 10 kDa chaperonin  groS 10 kDa CH10_CLODI  0 0 4 2 1 2 
72 33 kDa chaperonin hslO 33 kDa Q17ZW5 2 2 2 2 2 2 
73 60 kDa chaperonin  groL 58 kDa CH60_CLODI  13 8 9 6 9 6 
74 ATP-dependent Clp protease ATP-binding subunit ClpX  clpX 46 kDa Q180E8 7 2 5 3 4 2 
75 ATP-dependent Clp protease proteolytic subunit  clpP 21 kDa Q180F0 0 5 2 3 4 5 
76 Chaperone protein ClpB ClpB 98 kDa Q187Y8 5 3 0 4 2 2 
77 Chaperone protein DnaJ  dnaJ 42 kDa Q182E7 0 5 7 3 3 4 
78 Chaperone protein DnaK(Hsp70)(Heat Shock protein 70) dnaK 66 kDa DNAK_PEPD6 12 5 10 3 10 13 
79 Heat shock protein 90 htpG 75 kDa Q18D10 2 2 3 4 2 3 
80 rubrerythrin  rbr 21 kDa Q18A24_PEPD6 0 0 0 0 3 2 
81 rubrerythrin family protein  rbr 22 kDa WP_021397258 3 2 0 0 5 2 
Elongation factors 
82 Elongation factor G  fusA 76 kDa EFG_PEPD6 11 13 10 14 17 18 
83 Elongation factor P efp 21 kDa EFP_PEPD6 4 4 3 2 2 2 
84 Elongation factor Ts  Tsf 33 kDa EFTS_PEPD6 6 2 8 2 2 4 
85 Elongation factor Tu tuf1 44 kDa EFTU_PEPD6 8 8 10 8 10 7 
86 Translation elongation factor G tuf1 61 kDa EQK72467.1 7 11 0 0 4 5 
87 Transcription elongation factor GreA greA 18 kDa GREA_PEPD6 2 2 2 2 2 2 
88 Trigger factor Tig 48 kDa TIG_PEPD6 2 3 5 4 3 2 
Proteins Involved in Histidine  pathway metabolism       
89 ATP phosphoribosyltransferase  hisG 23 kDa Q18C67 4 4 3 2 2 2 
90 ATP phosphoribosyltransferase regulatory subunit  hisZ 37 kDa Q18C68 2 2 3 4 2 3 
91 Histidine--tRNA ligase  hisS 48 kDa Q183H5 7 2 5 3 4 2 
Probable and Putative proteins       
92 Probable butyrate kinase  buk2 39 kDa Q181W4 4 5 0 0 2 3 
93 Probable cytosol aminopeptidase pepA 53 kDa Q18BF9 2 2 3 4 2 2 
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94 Probable transaldolase tal 23 kDa TAL_PEPD6 2 3 2 2 0 2 
95 Probable transcriptional regulatory protein CD630_07950 26 kDa Y795_PEPD6 5 2 2 2 0 4 
96 putative alanine racemase  alr 43 kDa CBA64716.1  2 4 5 3 3 5 
97 Putative cell wall-binding protein cwp25 cwp25 34 kDa Q18A40 4 4 3 2 2 2 
98 Putative cold shock protein CspA 7 kDa Q18A83 2 2 2 3 3 3 
99 putative cyclase CD196_1850 24 kDa A0A0H3N331 0 2 3 2 0 0 
100 putative flagellar filament core protein   34 kDa EHJ39341   2 2 0 0 5 2 
101 Putative flavodoxin FloX 19 kDa C9YJJ1 2 3 2 4 0 0 
102 putative peptidase pepT 42 KDa C9YRZ0 2 5 0 0 0 0 
103 Putative phage protein CD630_09760 17 kDa Q183Y1 0 0 4 6 0 0 
104 Putative pre-16S rRNA nuclease CD630_12850 15 KDa Q18BF1 2 2 2 3 3 3 
105 Putative purine permease CD630_31800 47 KDa Q181U5 3 4 0 0 0 0 
106 Putative septation protein SpoVG  spoVG 10 kDa SP5G_PEPD6 0 0 0 0 2 3 
107 putative transcriptional regulator  puuR_2 21 kDa A0A031WFQ5 2 5 0 0 0 0 
108 putative translation elongation factor  tuf 73 kDa EFH08170.1 0 0 5 4 1 2 
Other proteins       
109 1-deoxy-D-xylulose 5-phosphate reductoisomerase dxr 43 kDa Q185R8 5 4 3 4 5 2 
110 1-deoxy-D-xylulose-5-phosphate synthase dxs 69 kDa Q18B68 6 5 2 3 6 6 
111 2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase dapD 30 kDa DAPD_PEPD6 0 2 4 3 6 2 
112 3-hydroxybutyryl-CoA dehydrogenase  hbd 31 kDa HBD_CLODI 9 12 6 8 10 8 
113 3-methyl-2-oxobutanoate hydroxymethyltransferase  panB 28 kDa PANB_PEPD6 5 7 4 3 0 0 
114 3-methyl-2-oxobutanoate dehydrogenase subunit VorB vorB 39 kDa WP_003432442.1 2 3 1 2 3 3 
115 3-oxoacyl-[acyl-carrier-protein] synthase 3 fabH 35 kDa Q18B40 12 6 3 5 1 7 
116 3-phosphoshikimate 1-carboxyvinyltransferase  aroA 49 kDa AROA_PEPD6 4 2 1 2 3 3 
117 4-Hydroxybutyrate CoA-transferase  abfT 48 kDa Q185L2 2 3 1 2 3 3 
118 4-hydroxybutyryl-CoA dehydratase abfD 54 kDa Q185L4 3 2 0 0 3 4 
119 4-hydroxy-tetrahydrodipicolinate synthase dapA 33 kDa Q181M9 5 4 0 0 0 0 
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120 5-methyltetrahydrofolate:corrinoid/iron-sulfur protein co-
methyltransferase, 
acsE 29 kDa A0A0N0NZV1 5 4 3 4 5 2 
121 ABC-type transport system, oligopeptide-family permease protein appB 35 kDa Q183A7 3 6 4 2 7 4 
122 Acetate kinase  ackA 43 kDa ACKA_PEPD6 2 4 1 2 1 2 
123 Acetyl-CoA acetyltransferase  thlA 41 kDa THLA_PEPD6 17 19 17 18 18 19 
124 Acetyl-coenzyme A carboxylase carboxyl transferase subunit alpha accA 35 kDa Q187P7 2 4 4 3 2 4 
125 Acetyl-coenzyme A carboxylase carboxyl transferase subunit beta  accD 32 kDa Q187P6 6 3 7 13 12 14 
126 Acetylglutamate kinase  argB 26 kDa ARGB_STRGC 4 3 6 0 5 7 
127 Adenylosuccinate synthetase  purA 48 kDa PURA_PEPD6 7 2 1 5 8 5 
128 Alanine-glyoxylate amino-transferase family protein QQG_0004 45 kDa T4IP56 2 3 0 0 4 2 
129 Alanine racemase  alr 43 kDa Q180W0 0 0 4 2 2 2 
130 Alanine--tRNA ligase alaS 98 kDa Q18BE7 1 2 3 4 2 1 
131 aldehyde alcohol dehydrogenase family protein adhE 96 kDa Q18D77 13 8 9 6 9 6 
132 Amino acid-binding ACT domain-containing protein CDIF1296T 14 kDa A0A125V679 5 3 2 1 2 4 
133 Aminomethyltransferase (Glycine cleavage system T protein) gcvT 92 kDa Q186L1 7 1 2 4 2 3 
134 aminotransferase  aspB 45 kDa Q18BK6 2 2 2 3 2 4 
135 Arginine--tRNA ligase  argS 65 kDa SYR_PEPD6 5 4 0 0 0 0 
136 Argininosuccinate lyase  argH 50 kDa ARLY_PEPD6 2 2 2 3 2 4 
137 aspartate aminotransferase  OJT83395.1  45 kDa OJT83395.1  5 1 4 6 3 4 
138 Aspartate carbamoyltransferase  pyrB 35 kDa Q18CS8 0 0 1 2 1 3 
139 ATP synthase gamma chain  atpG 32 kDa ATPG_PEPD6 1 5 6 2 0 0 
140 ATP synthase subunit alpha  atpA 55 kDa ATPA_PEPD6  2 5 2 2 2 2 
141 ATP synthase subunit beta  atpD 50 kDa ATPB_PEPD6 7 2 4 3 1 3 
142 ATP synthase subunit delta  atpH 21 kDa Q180W9 2 2 2 2 2 2 
143 ATP-dependent DNA helicase RecG  recG 78 kDa Q182P8 1 3 4 1 0 0 
144 ATP-dependent zinc metalloprotease FtsH Ftsh 74  kDa Q181G0_PEPD6 1 3 4 2 3 2 
145 Bifunctional protein FolD folD 31 kDa FOLD_PEPD6 2 4 0 0 6 3 
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146 Bifunctional protein GlmU glmU 50 kDa Q181B4 0 0 2 2 0 0 
147 Biotin synthase biob 37 kDa Q18D35 2 5 0 0 0 0 
148 butyrate kinase buk 38 kDa WP_102822774.1 5 1 3 3 1 4 
149 Chorismate synthase  aroC 39 kDa Q187E5 1 4 2 2 0 0 
150 Cyclase family protein COG1878 24 KDa WP_003428771 0 0 2 4 3 2 
151 cysteine desulfurase  nifS 44 kDa WP_011861166.1 0 0 10 2 12 2 
152 cysteine synthase A WP_003436514.1 33 kDa WP_003436514.1  11 7 14 10 7 8 
153 Cysteine--tRNA ligase  cysS 54 kDa Q18CD5 7 3 2 1 2 3 
154 D-alanine--D-alanine ligase VanG 39 kDa Q186I2 2 2 2 2 0 0 
155 Dihydroorotase pyrC 38 kDa PYRC_PEPD6 2 2 2 3 2 4 
156 D-lactate dehydrogenase  ldhA 37 kDa Q188H7 4 5 6 7 0 0 
157 DNA gyrase subunit A gyrA 91 kDa Q18C90 1 2 6 5 4 4 
158 DNA gyrase subunit b gyrB 71kDa Q18C90 6 3 7 13 12 14 
159 DNA ligase  ligA 76 kDa Q180F3 2 2 5 2 0 0 
160 DNA mismatch repair protein mutS 109 kDa Q187T6 2 4 2 2 0 0 
161 DNA polymerase I polA 101 kDa Q18AY7 3 2 0 0 0 0 
162 DNA polymerase III PolC-type polC 162 kDa Q18BG8 4 1 3 6 2 3 
163 DNA polymerase III subunit alpha dnaE 136 kDa Q180P3  0 0 0 0 1 3 
164 DNA polymerase IV dinB 42 kDa Q18A91 0 0 6 3 0 0 
165 DNA replication and repair protein RecF  recF 42 kDa Q18C86 4 2 2 1 5 2 
166 DNA-binding protein HU hbs 10 kDa A0A031WHB1 4 7 2 6 0 0 
167 DNA-directed RNA polymerase subunit alpha  rpoA 35 kDa RPOA_PEPD6 2 2 2 3 2 1 
168 DNA-directed RNA polymerase subunit beta  rpoB 139 kDa Q18CF1 2 5 4 2 2 1 
169 Enamine/imine deaminase  yabj 14 kDa A0A031WH02 4 2 2 3 1 3 
170 Energy-coupling factor transporter ATP-binding protein EcfA2 ecfA2 32 kDa Q18CI9 1 3 0 0 0 0 
171 Enolase eno 46 kDa ENO_PEPD6 6 6 4 2 7 4 
172 enoyl-CoA hydratase/isomerase family protein  22 kDa EQG13789.1 3 2 3 1 3 4 
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173 flavodoxin family protein  18 kDa WP_009902172.1 2 4 0 0 0 0 
174 Fe-S cluster assembly scaffold protein NifU 16 kDa WP_003438275.1 0 0 0 0 4 3 
175 Formate--tetrahydrofolate ligase  fhs 60 kDa FTHS_PEPD6 10 12 12 15 19 9 
176 Fructose-1,6-bisphosphate aldolase fba 33 kDa Q188J1 6 6 12 3 2 1 
177 Glucose-6-phosphate isomerase pgi 51 kDa G6PI_PEPD6 2 5 4 2 2 1 
178 Glutamate--tRNA ligase  gltX 57 kDa Q18CD6 2 3 4 3 1 2 
179 Glyceraldehyde-3-phosphate dehydrogenase  gap 36 kDa Q181T9 4 2 1 2 3 4 
180 Glycine cleavage system H protein gcvH 14 kDa GCSH_PEPD6 2 1 3 6 2 4 
181 Glycine--tRNA ligase beta subunit  glyS 78 kDa SYGB_PEPD6 2 3 1 2 4 3 
182 Holo-[acyl-carrier-protein] synthase  acpS 14 kDa Q180W4 2 2 2 3 1 2 
183 Imidazole glycerol phosphate synthase subunit HisH hisH 23 kDa Q18C72 7 2 1 5 8 5 
184 indolepyruvate oxidoreductase subunit beta iorB 21 kDa Q181W6 3 2 5 1 4 2 
185 Inosine-5'-monophosphate dehydrogenase guaB 55 kDa A0A0H3N3T3 0 0 3 2 5 3 
186 Isoleucine--tRNA ligase  ileS 120 kDa Q182V2 5 1 4 6 3 4 
187 lactate utilization protein QCW_2161 24kDa QCW_2161 2 3 4 3 0 0 
188 Leucine--tRNA ligase  leuS 98 kDa Q182K8 2 2 2 3 2 4 
189 LexA repressor  lexA 23 kDa Q187P1 1 2 3 4 2 1 
190 Lrp/AsnC family transcriptional regulator  16 kDa WP_003421494.1 0 0 0 0 2 2 
191 lysyl-tRNA synthetase  LysS 58 kDa Q181F2 3 1 0 0 0 0 
192 Methionine--tRNA ligase metG 74 kDa Q181D9 2 3 1 2 4 5 
193 Methionyl-tRNA formyltransferase  fmt 34 kDa Q182S2 4 5 0 0 0 0 
194 N-acetylmuramic acid 6-phosphate etherase  murQ 33 kDa Q184N3 0 0 12 13 0 0 
195 NAD-specific glutamate dehydrogenase  gluD 46 kDa DHE2_CLODI 12 18 16 13 17 17 
196 NUDIX hydrolase  CD630_17650 23 kDa Q186X5 3 2 5 1 3 2 
197 Oligoendopeptidase F pepF 69 kDa A0A386FR43 4 5 0 0 0 0 
198 Orotate phosphoribosyltransferase  pyrE 21 kDa Q18CS5 4 2 3 4 2 1 
199 Peptide chain release factor 1 prfA 42 kDa Q180Y2 2 1 2 4 1 3 
 211 
 
200 Peptide chain release factor 3 PrfC 60 kDa A0A0A6PWC7 4 8 0 0 0 0 
201 Peptidyl-tRNA hydrolase  pth 21 kDa Q181A2 7 2 1 5 8 3 
202 Peptidylprolyl isomerase ppiB 19 kDa Q18D70 0 0 0 0 2 3 
203 phosphate propanoyltransferase  pduL 20 kDa Q183B8 5 6 4 2 2 2 
204 Phosphoenolpyruvate-protein phosphotranferase. ptsI 63 kDa Q183J1 4 3 2 0 3 4 
205 Phosphoglycerate kinase pgk 43 kDa PGK_PEPD6 1 2 6 5 4 4 
206 Phosphoribosylformylglycinamidine cyclo-ligase PurG 39 kDa Q18CW2 5 4 0 0 2 7 
207 Polyribonucleotide nucleotidyltransferase pnp 78 kDa Q18BI4 3 2 3 4 4 5 
208 Proline racemase  CD630_32370 36 kDa PRAC_CLODI 0 0 3 3 5 4 
209 Proline--tRNA ligase  proS1 49 kDa Q18CD2 2 1 2 4 1 2 
210 Protein RecA  recA 38 kDa Q18BJ4 1 4 3 2 1 5 
211 pyridoxamine 5'-phosphate oxidase family protein CD630_02790 15 kDa Q18D22 4 5 0 0 3 7 
212 Pyruvate kinase (PK) (fragment)  pyk 63 kDa Q180P2 1 2 6 5 4 4 
213 Pyruvate-flavodoxin oxidoreductase nifj 129 kDa Q183B6 7 8 2 8 3 4 
214 Redox-sensing transcriptional repressor Rex rex 23 kDa REX_PEPD6 2 1 2 4 1 3 
215 S-adenosylmethionine synthase metK 43 kDa Q18CL7 5 1 2 4 2 2 
216 Serine hydroxymethyltransferase  glyA 46 kDa GLYA_PEPD6 1 2 6 5 4 4 
217 Serine--tRNA ligase serS 49 kDa Q18C97 4 5 3 3 3 7 
218 Short-chain-enoyl-CoA hydratase (Fragment)  crt 17 kDa CRT_CLODI 4 2 7 1 3 4 
219 Sugar ABC transporter substrate-binding protein  23 kDa WP_009888534.1 3 2 0 0 2 2 
220 Tellurium resistance protein terD terD 21 kDa Q186I7 5 6 4 2 2 2 
221 Tellurium resistance protein terD1 terD1 22 kDa Q186J1 5 1 2 4 2 2 
222 Tellurium resistance protein terD2 terD2 23 kDa Q186J0 2 3 2 5 1 3 
223 thioredoxin family protein  6 kDa EQE71157.1 4 1 0 0 3 2 
224 Threonine--tRNA ligase  thrS 69 kDa Q189B8 1 2 6 5 4 4 
225 Transaldolase tal 37 kDa TAL_PEPD6 5 1 7 2 3 6 
226 Transcriptional regulator, LysR family CD630_26750 35 kDa Q183A9 2 3 1 2 4 2 
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227 Transcriptional regulator, LytR family CD630_06180 17 kDa Q189F8 4 1 2 1 3 4 
228 Transcriptional Regulator, marR family protein effr 22 kDa Q187W6 4 6 6 2 8 12 
229 Transketolase tkt 29 kDa A0A0H3N3X0 2 2 0 0 4 3 
230 Translation initiation factor IF-2 infB 70 kDa Q18BH4 4 4 3 2 2 2 
231 Triosephosphate isomerase tpI 27kDa Q181T6 5 2 0 0 4 5 
232 tRNA (guanine-N(1)-)-methyltransferase trmD 27 kDa Q18BC2 4 3 3 1 2 2 
233 tRNA modification GTPase mnmE 51 kDa Q181S7 2 4 4 3 2 4 
234 tRNA-2-methylthio-N(6)-dimethylallyladenosine synthase miaB 55 kDa Q187U6 1 4 5 3 2 4 
235 tRNA-specific 2-thiouridylase MnmA mnmA 41 kDa Q18BE2 7 4 2 3 3 4 
236 UDP-N-acetylglucosamine 1-carboxyvinyltransferase murA 45 kDa Q18CL1 9 4 4 3 2 4 
237 UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) 
pyrophosphoryl-undecaprenol N-acetylglucosamine transferase 
murG 40 kDa Q182Y6 0 0 2 4 4 3 
238 UDP-N-acetylmuramate--L-alanine ligase murC 56 kDa Q181B7 5 3 2 1 2 4 
239 UDP-N-acetylmuramoylalanine--D-glutamate ligase murD 50 kDa Q182Y7 0 0 5 1 7 11 
240 UvrABC system protein A uvrA 105 kDa Q180Q9 3 2 3 1 3 4 
241 UvrABC system protein B uvrB 76 kDa Q180R0 4 4 3 2 2 2 
242 UvrABC system protein C uvrC 70 kDa Q180Q8 4 2 1 2 3 4 
243 Valine--tRNA ligase valS 103 kDa Q180A1 3 4 2 2 0 0 
244 V-type ATP synthase alpha chain atpA 66 kDa VATA_PEPD6 2 1 4 4 4 3 
245 V-type ATP synthase beta chain atpB 51 kDa VATB_PEPD6 1 2 0 4 2 2 
246 XRE family transcriptional regulator  22 kDa WP_021370312.1 2 4 0 0 0 0 
247 hypothetical protein BER30_000919  BER30_000919  12 kDa OMK44041.1 4 4 4 1 0 0 
Uncharacterised and Hypothetical proteins 
248 hypothetical protein BM529_15905 BM529_15905 11 kDa OJT73147.1 0 0 0 0 2 3 
249 hypothetical protein QOI_2046  QOI_2046 10kDa EQI11398.1 2 3 0 0 5 3 
250 Uncharacterized protein CD630_02380 13 kDa Q18CX8 2 1 2 3 0 0 
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6.4 DISCUSSION 
Due to the increasing incidence of Clostridium difficile infection (CDI), several characterisation 
methodologies have been adopted to understand the detailed adaptive mechanisms of C. 
difficile. One such method is LC-MS/MS analysis of the C. difficile  proteome, which has been 
reported in several studies (Boetzkes et al., 2012; Chen et al., 2013; Chilton,et al., 2014; Chong 
et al., 2014; Jain et al., 2011, Jain et al., 2010; Lawley et al., 2009; Maaß et al., 2018; Moura 
et al., 2013). These studies highlighted several proteins associated with the adaptation of C. 
difficile within the gut environment. However, none of these studies investigated the 
proteome of C. difficile ribotype 002. Here, the whole-cell proteome of three CD002 strains 
from different geographical locations and time-lineages were investigated using the LC-
MS/MS mass spectrometry approach, to see if any differences existed between strains. 
C. difficile infection (CDI) is largely dependent on a range of virulence factors, including toxins, 
adherence factors, and motility factors. In the present study, the main virulence factors, toxin 
A and B were identified in the proteome of all investigated CD002 strains. Approximately, 17 
- 23% of C. difficile strains are capable of producing a third toxin, known as the binary toxin 
(Eckert et al., 2015). The exact role of binary toxin in C. difficile pathogenesis is still largely 
unknown, however, a number of studies have indicated that strains with this toxin cause 
severe CDI (Gerding et al., 2014). In the present study, no binary toxins were detected in any 
of the investigated strains, in line with the absence of binary toxins in CD002 reported in other 
studies (Eckert et al., 2015; Stubbs et al., 2000). Additionally, a global regulatory protein, 
CodY, which is found in many Gram-positive bacteria that monitors the nutrient sufficiency of 
the environment and regulates genes expression depending on nutrient availability was 
detected in all CD002 (Nawrocki et al., 2016). CodY binds to the DNA in the presence of GTP 
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and branched-chain amino acids to represses the transcription of genes including those 
involved in C. difficile toxin synthesis, and more recently it has been demonstrated to 
negatively regulate sporulation in two C. difficile ribotypes (012 and 027) (Nawrocki et al., 
2016).  All three strains were grown under the same conditions, the presence of CodY in the 
proteome can be attributed to stress and nutrient depletion in the media, as strains were 
continuously incubated for 64h on Columbia blood agar prior to proteome extraction.  
C. difficile spores are produced under stress conditions and are critical for transmission and 
establishment of an infection. The ability of spores to persist in the gut is attributed to their 
structure, which is made up of the exosporium, coat, cortex, membrane and core (Barra-
Carrasco et al., 2013). Recently, Theriot and colleagues demonstrated how spores within the 
small intestine of mice were able to germinate in the absence of antibiotic disruption(Theriot 
et al., 2016). Suggesting that other factors exist on the spore surface that may facilitate host 
colonisation. Proteomic and bioinformatics studies of the C. difficile spore have revealed that 
many proteins are included in the spore, however, the assignment of function to these 
proteins is still ongoing (Lawley et al., 2009; Phetcharaburanin et al., 2014; Pizarro-Guajardo 
et al., 2018). The most extensively studied are C .difficile spore coat proteins, cotA, cotB, 
cotCB, cotD, cotE and sodA (Hong et al., 2017; Permpoonpattana et al., 2013, 2011; Pizarro-
Guajardo et al., 2018). Indeed, CotE, a member of peroxiredoxin family, was recently 
demonstrated to interact with intestinal mucin promoting its degradation (prior to 
germination), contributing to colonisation and disease progression(Hong et al., 2017). 
Additionally, CotE expression increased the severity of CDI in a hamster model as animals 
dosed with spores lacking CotE exhibited significantly delayed symptoms of CDI, thus 
emphasising the contributory role of this protein to CDI (Hong et al., 2017).  
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In the present study, several spore-associated proteins were detected by LC-MS/MS analysis, 
including proteins associated with spore morphogenesis (sspA, sspB, spoIIIJ, spoIIGA, spoIVA, 
spoIIAB, spoVE & spoVG). Interestingly, CotE was identified in recent strains 71 (UK 2011-13) 
and 137 (Non-UK 2012-147) and absent in strain 174, belonging to the older lineage of strains 
(UK 2007-8). Whether the failure to detect this spore protein (CotE) in strain 174 means that 
it was not expressed or was degraded during the sample preparation process is unknown. 
Consequently, further investigation into the reproducibility of CotE expression in only recent 
CD002 strains is warranted, before speculating that the expression of certain spore proteins 
such as CotE in recent CD002 isolates may have facilitated the prevalence of this ribotype in 
recent years. Strains expressing CotE may succeed better in gut adherence, making a 
mechanical clearance from the gut lumen more difficult, thus spores persistence and re-
infection occur. Contrastingly, it is noteworthy that only three strains were investigated in the 
present study and therefore may not be wholly reflective of the spore proteins of other 
isolates within the recent lineages. 
The adhesion of intestinal pathogens to the host gastrointestinal tract is a crucial aspect of 
host colonisation, as it prevents them from being mechanically cleared (Hong et al., 2017). 
Several cell surface proteins coordinate adhesion of the bacterial cell into the gut, however, 
the mechanism is yet to be elucidated. Several cell surface proteins have been identified as 
been associated with C. difficile adherence. Some of these adhesins include cell wall surface 
proteins, surface layer proteins, and flagella. In the present study, several cell surface proteins 
(cwp20, cwp22, cwp66, slpA (77kDa) & cell wall binding repeat 2 family protein), previously 
demonstrated to contribute to adherence and colonisation, were identified in all strains. 
However, cell wall binding protein 2 (cwp2) was only expressed by recent CD002 strains 
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(strain 71 and 137). A mutant of this protein was recently demonstrated to impair adhesion 
of C. difficile  to mammalian cells in vitro  (Bradshaw et al., 2017) and it has previously been 
reported as being present in the spore coat (Lawley et al., 2009)and during high toxin 
production (Mukherjee et al., 2002). Despite the absence of this protein in Strain 174 (UK 
2007-8), in contrast to recent lineages (71 & 137), we cannot negate the fact that strains 
lacking the expression of this protein may be prolific in facilitating the production of other 
virulence-associated factors such as adhesion, toxin production and sporulation. Bradshaw 
and colleagues demonstrated how a mutant of this protein produced more toxin A(Bradshaw 
et al., 2017), as a result, the expression of this protein with recent lineages may not be a factor 
contributing to the recent prevalence of CD002.  
C. difficile strains are known to possess flagella for motility, however, their role in C. difficile 
adherence and colonisation, appears to be contentious and strain-dependent (Baban et al., 
2013; Dingle et al., 2011; Stevenson et al., 2015; Tasteyre et al., 2002). The two best 
characterised C. difficile flagellar proteins are FliC, the major flagellin structural monomer and 
FliD, the cap protein.  Mutations in FliC and FliD have been shown to increase adherence to 
intestinal epithelial cells in some strains(Baban et al., 2013) and toxin gene expression in C. 
difficile  630 strain (Stevenson et al., 2015). However, Dingle et al have shown that mutation 
in FliC and FLiD leads to lack of expression but does not affect adherence to intestinal 
cells(Dingle et al., 2011).In the present study, seven flagellar associated proteins were 
identified, with FliC and FliD being expressed by all investigated CD002 strains. Certain flagella 
proteins (fliW, flgC & flhA) involved in the assembly of C. difficile flagellum were expressed 
only by recent strains (71 and 137), and one putative flagellar core protein was expressed by 
only UK strains (71 & 174). Whether the expression of these flagellar proteins in recent CD002 
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strains has contributed to their prevalence is unknown. As a result, further characterisation 
of these proteins may be warranted to ascertain the contributory role of this protein in recent 
CD002 prevalence.  
Comparative proteomic analysis using LC-MS/MS analysis of the whole-cell proteome of three 
CD002 strains revealed similarities and differences that suggest minimal adaptation changes 
may have occurred over time. Additionally, the possibility that some proteins may have been 
degraded during the sample preparation process, suggests that some important proteins and 
differences between strains may have been missed during this analysis. As a result, further 
characterisation of the differences highlighted here is warranted as well as comparative 
genomic analysis studies, incorporating strains investigated in this study and even more 
recently isolated strains. 
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7 GENERAL DISCUSSIONS AND CONCLUSIONS 
Clostridium difficile (C. difficile) is the leading cause of healthcare-associated infections (HAIs) 
and an important public health threat (Planche & Karunaharan, 2017). C. difficile has been 
associated with substantial morbidity and mortality among individuals of all ages worldwide, 
even in the absence of the traditionally recognised risk factors (e.g., prior antimicrobial 
therapy, elderly and hospitalised patients) (Lessa et al., 2015). Efforts to reduce Clostridium 
difficile infections (CDI) (through antimicrobial stewardship programs, infection control 
measures and alternative preventative measures) have been successful, as demonstrated by 
UK CDI rates per 100,0000 population, which have fallen from 100.3 in 2007/08 to 24 in 
2017/18 (Public Health England, 2018). Despite this success, the epidemiology of CDI is 
constantly evolving and is characterised by the emergence of strains that cause severe 
disease. In addition, there has been an increase in the number of community-associated CDI 
cases, and a suggestion that animal and environmental reservoirs exist (Fawley et al., 2016; 
Rabold et al., 2018). The UK prevalence of C. difficile PCR ribotype 027 (NAP1) recently 
declined while other ribotypes emerged, including ribotype 002 (CD002). CD002 is also 
responsible for CDI in many countries across Europe, North America, Asia and Australia. The 
aim of this research was to identify phenotypic characteristics that may have contributed to 
the increased CD002 prevalence in the UK, by investigating the differences that exist between 
CD002 from different lineages (UK 2007-8, UK 2011-12 and Non-UK 2012-14) of CD002.  
Antimicrobial resistance in C. difficile has been shown to drive epidemiological change, and 
the emergence and expansion of new strains types(He et al., 2013). As part of this study, we 
sought to determine the antimicrobial susceptibility and resistance patterns of clinical isolates 
of CD002 using the agar incorporation method. The majority of CD002 isolates from different 
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time lineages were susceptible to many of the antimicrobial agents studied, including current 
CDI therapies; metronidazole, vancomycin and fidaxomicin. Consistent with previous studies, 
resistance to fluoroquinolones (particularly ciprofloxacin, MIC ≥ 8mg/L) was observed in all 
lineages of CD002. Investigations into the presence of resistance determinants against 
fluoroquinolones and rifamycins revealed previously reported amino acid substitutions in 
gryA (Thr-82-lle) and rpoB (Arg505Lys) genes. (Curry et al., 2009; O’Connor et al., 2008; 
Spigaglia et al., 2011; Spigaglia, 2016). Additionally, novel amino acid substitutions in these 
genes; gryA (Arg-98-Thr, and Asp-103-His) and rpoB (Leu509Phe) were identified. 
Furthermore, a high proportion of isolates in all CD002 lineages were reduced susceptible (≥ 
1mg/L) to beta-lactams (penicillin and ampicillin), but negative for β-lactamase activity assay. 
The overall data generated indicated common differences in the antimicrobial susceptibility 
and resistance patterns between different lineages of CD002. Therefore, it is unlikely that 
changes in antimicrobial resistance patterns might be a driver for the emergence of CD002 in 
the UK and in Europe. 
During the course of CDI, C. difficile sporulates and releases spores into the colonic 
environment. Recurrences due to relapses or re-infection has been reported in CDI (Barbut et 
al., 2000; Marsh et al., 2012; Oka et al., 2012), and it is suggested that C. difficile spores have 
mechanisms to efficiently persist in the host colonic environment, and therefore establish an 
infection following cessation of antimicrobial therapy. CD002 has been associated with 
increased sporulation frequency (Cheng et al., 2011). Thus, the sporulation capacities of 
CD002 from different lineages was investigated in the present study. Interestingly, greater 
sporulation capacities after 24h were demonstrated by recent CD002 (UK 2011-13 & Non-UK 
2012-14), in comparison to UK 2007-8. Additionally, the ability of purified CD002 spores to 
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adhere to human adenocarcinoma cells (Caco-2) at different stages of cell development was 
investigated.CD002 spores adhered more strongly to differentiated Caco-2 cells than 
undifferentiated Caco-2 cells, but the difference between lineages was not significant. Based 
on these findings, we hypothesise that recent CD002 strains are able to sporulate rapidly and 
persist within the colonic environment through spore surface properties that aid their 
adherence to intestinal epithelial cells. As a result, mechanical clearance is less efficient, 
consequently leading to a relapse of infection when the gut conditions become favourable. 
The possibility that these findings can be replicated in vivo, remains to be determined. 
Biofilms are thought to contribute to intestinal colonisation and recurrent CDI(Baines et al., 
2005; Crowther et al., 2014a; Plaza-Garrido et al., 2015; Soavelomandroso et al., 2017). 
Previous studies report the abundance of highly resistant spores harboured within C. difficile 
biofilms, which are dispersed in the later stages of biofilm development(Crowther et al., 
2014a; Dawson et al., 2012; Plaza-Garrido et al., 2015; Semenyuk et al., 2014). In the present 
study, biofilm formation was investigated in vitro using a simple microtitre plate assay, and 
recent isolates of CD002 (UK 2011-13 & Non-UK 2012-14) produced more biofilms compared 
to older isolates (UK 2007-8). The biofilm biomass correlated with the spore abundance in 
mature biofilms that was observed in the different lineages. These findings suggest that 
mucosal-associated biofilms may harbour CD002 spores, and thus allow spores to persist in 
the colon. This further supports the aforementioned hypothesis that spores of recent isolates 
may persist in the colonic environment and therefore contribute to recurrent CDI.  
 
The main virulence factors produced by C. difficile are two large clostridial toxins. Although 
controversial, Warny et al (2005) indicated that hypervirulent PCR ribotype 027 (toxinotype 
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III) produced quantitatively more of toxins A and B than a comparator toxinotype 0 group and 
therefore concluded that was why 027 caused more severe disease. Additionally, Baines et al 
(2008) reported an earlier (after 1 day) release of toxins by hypervirulent PCR ribotype 027 
strains, in comparison to other C. difficile strains. In the present study, no significant 
difference existed in the cytotoxin production between different lineages of CD002. 
Interestingly, detectable toxins were produced earlier in the growth cycle (at 12h) by the 
majority of CD002 strains, this was also observed with a ribotype 078 strain. Conversely, 
detectable toxins (1RU) were detected after 24h of in a ribotype 027 strain. This   suggests 
that strains of this ribotype could cause infections more readily, however, whether these 
characteristics are replicated in vivo, remains to be determined 
Another interesting observation was the higher maximum specific growth rate (µmax range 
0.76 - 0.92 h-1) demonstrated by more recent CD002 isolates (UK 2011-13 &Non-UK 2011-12) 
compared to the older group of isolates (UK 2007-8) (0.69 h-1), and hypervirulent ribotypes, 
027 and 078 (0.67 h-1, and 0.36 h-1)reported by Keighley et al (2015). This suggests recent 
CD002 may form vegetative cells faster, produce toxin earlier, sporulates rapidly, and 
therefore be better at causing disease and being transmitted or surviving therapy. 
Subsequently, the nutrient utilisation profile and competition for glucose in a single-stage 
fermenter by selected strains were investigated. Indeed, the findings in the present study 
indicated that strains of the recent lineages utilise more nutrient sources in comparison to 
strains of the UK 2007-8 lineage. This suggests that recent strains have more options of 
adaptability in response to nutrient availability within the gut, and this could select for their 
emergence. However, since recent studies revealed that C. difficile is an ecological generalist 
rather than a specialist (Jenior et al., 2017), strains with an expanded metabolic potential will 
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only be prolific in a favourable gut environment. In addition, CD002 strains utilised five carbon 
sources (D-ribose, L-xylose, L- arabinose, dihydroxy acetone, D-Arabinose and 2- deoxy- D- 
ribose) which were not utilised by hypervirulent C. difficile strains (RT 078 and RT 027), 
whether the ability to utilise these substrates facilitates the emergence of CD002 remains to 
be determined.  In the competition study, strains of different lineages, in two out of the three 
competing pairs, appeared to co-exist together rather than outcompete each other. 
Interestingly, a recent UK 2011-13 strain outcompeted a recent Non-UK 2012-14. Further 
investigations are required to clarify the significance of this observation for CD002 in vivo 
Analysis of the whole-cell proteome of one selected strain per lineage by LC-MS, revealed 
CotE, a spore coat protein only in recent CD002 isolates (71 (UK 2011-13) & 157(Non-UK 2011-
12). CotE was recently reported to aid intestinal colonisation and severity of disease in an 
animal model (Hong et al., 2017). This finding may explain why strains of this ribotype have 
been implicated in severe forms of CDI recently (Dauby et al., 2017; Wong et al., 2016). 
Further analysis is required to ascertain if the observations made in the present study are as 
a consequence of CotE being absent or defective in the investigated UK 2007-8 CD002 strain 
(174) or an artefact of sample preparation. Furthermore, comparative analysis of the whole 
proteome of three strains from the different lineages shows many similarities between strains 
that suggest a minimal adaptation of the proteome in CD002 has occurred over time. 
However, since only three strains were investigated, this may not be fully reflective of other 
CD002 strains. As a result, comparative proteomic analysis of the more CD002 strains is 
required before firm conclusions can be made.  
In conclusion, this study has enhanced our understanding of the potential factors that may 
have contributed to the recent emergence of strains of ribotype 002 in the UK. Although the 
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antimicrobial susceptibility patterns between lineages did not differ substantially, resistance 
to fluoroquinolones and reduced susceptibility to beta-lactams (such as penicillin and 
ampicillin) demonstrated by CD002, may have occurred as a result of selective pressure due 
to the continued use of these antimicrobial agents in the clinical setting. As a result, we cannot 
rule out the likely possibility that these antimicrobial agents could be facilitating the 
prevalence of this ribotype in recent years.  Additionally, the more recent isolates (Both UK 
and Non-UK) formed more biofilms, sporulated more rapidly, had a higher µmax, and a more 
expanded nutrient utilisation profile than the older UK isolates. These characteristics were 
found to be more prominent among strains originating from outside of the UK. Furthermore, 
CD002 strains were found to produce toxins earlier in their growth cycle, and selected strains 
were able to utilise certain substrates that had not been utilised by strains of the 
hypervirulent ribotypes (027 & 078). The increased sporulation, higher µmax, greater biofilm 
formation, abundance of spores in mature biofilms, and the utilisation of several nutrient 
substrates, demonstrated by recent C. difficile PCR ribotype 002, suggests that the may have 
a competitive advantage over other ribotypes, therefore increasing their prevalence in recent 
years. However, whether these factors, have a greater in vivo implication for this ribotype, 
remains to be determined. 
 
7.1  FURTHER WORK   
While significant progress has been made in characterising isolates of CD002 and identifying 
novel factors that may have contributed to the recent emergence of this ribotype, there are 
still major gaps that remain to be explored.  In order to build on the findings from the present 
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study, the following studies should be considered in more gut –reflective in vitro models or 
animal models of CDI;  
1. Examine the phenotypic characteristics of more recent isolates of CD002 in 
comparison to other emerging ribotypes (such as 005, 014/020 and 015), in order to 
establish if the factors identified in the present study gives CD002 a greater phenotypic 
advantage over other ribotypes. 
2. Investigate the CD002 spore structure in comparison to other emerging ribotypes to 
determine the role of exosporium, BcLA proteins and spore coat proteins, in 
adherence to intestinal epithelial cells. 
3. Investigate the role of trehalose (which was recently postulated to have an impact on 
the emergence of ribotypes 027, 078 and 017) and carbon sources that were only 
utilised by CD002 in the present study, on the emergence of CD002 and other 
emerging ribotypes (005, 014/020 and 015) 
4. Whole-genome sequencing of historic and recent isolates of CD002 to investigate 
mutational events within the genome that may have occurred over time to facilitate 
the prevalence of these strains. 
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APPENDICES 
a. Appendix 1 
1. Liquid media and buffers 
All buffers and liquid media used were prepared according to the manufacturer’s instructions. 
I. Schaedlers Anaerobic Broth-CM0497, Oxoid 
Formulation g/L 
Tryptone soya broth 10.0 
Special peptone 5.0 
Yeast extract powder 5.0 
Glucose 5.0 
Cysteine HCL 0.4 
Haemin 0.01 
Tris Buffer 0.75 
II. Brain Heart Infusion Broth -CM1135, Oxoid 
Formulation g/L 
Brain Infusion solids 12.5 
Beef heart infusion solid 5.0 
Preoteose peptone 10.0 
Glucose 2.0 
Sodium Chloride 5.0 
Di-Sodium phosphate 2.5 
 
III. Phosphate Buffered Saline- P4417, Sigma 
Depending on the required volume for use, one tablet was dissolved in 200 mL of 
water and sterilised prior to use. 
 
 
 262 
 
2. Solid Media  
I. Brazier’s CCEY agar- LAB160, LABM 
Formulation g/L  
Peptone Mix 23.0 
Sodium Chloride 5.0 
Soluble Starch 1.0 
Agar 12.0 
Sodium bicarbonate 0.4 
Glucose  1.0 
Sodium pyruvate 1.0 
Cysteine HCl 0.5 
Haemin 0.01 
Vitamin K 0.001 
L-arginine 1.0 
Soluble pyrophosphate 0.25 
Sodium succinate 0.5 
Cholic acid 1.0 
p-Hydroxyphenylacetic acid 1.0 
 
II. Schaedlers anaerobe agar- CM0437, Oxoid 
Formulation g/L  
Tryptone soya broth 10.0 
Special peptone  5.0 
Yeast extract  5.0 
Glucose  5.0 
Cysteine HCL 0.4 
Haemin HCL 0.01 
Tris Buffer 0.75 
Agar  13.5 
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III. Columbia blood agar - CM0331, Oxoid 
Formulation g/L  
Special peptone  23.0 
Starch 1.0 
Sodium Chloride 5.0 
Agar 0.01 
 
3. Media solution Used in the Cell culture 
I. For the culture of Vero cells, Dulbecco’s Modified Eagle’s medium (DMEM) (D6546, 
Sigma) was used. This medium was supplied in sterile 500mL bottles and stored at 4°C.  
Formulation g/L Formulation g/L 
Calcium Chloride  0.265 L-lysine HCI 0.146 
Iron (III) Nitrate 0.0001 L-methionine  0.03 
Potassium Chloride 0.4 L-serine 0.042 
Magnesium sulphate 0.09767 L-threonine 0.095 
Sodium Chloride 6.4 L-tryptophan 0.016 
Sodium hydrogen carbonate 3.7 L-tyrosine 0.10379 
Sodium dihydrogen phosphate 0.109 L-Valine 0.094 
Phenol Red Na 0.015 D-pantothenate ½ ca 4 
Pyruvate Na 0.11 Choline chloride 0.004 
D-glucose 4.5 Folic acid 0.004 
L-arginine HCI 0.084 myo-Inositol 0.0072 
L-cysteine  0.0626 Niacinamide 0.004 
L-glutamine 0.584 Pyridoxine HCI 0.004 
Glycine 0.03 Riboflavin 0.0004 
L-histidine HCI.H2O 0.042 Thiamine HCI 0.004 
L-isoleucine 0.105 
L-leucine 0.105 
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II. Eagles Minimal medium was used to culture Caco-2 cells (EMEM) (P04-08050, Pan 
Biotech). This medium was supplied in sterile 500mL bottles and stored at 4°C 
 
Components mg/L Components mg/L 
Calcium chloride x 2H2O  264.92 Nicotinamide  1.00 
Magnesium sulfate  97.67 Pyridoxal x HCl  1.00 
Potassium chloride  400.00 Riboflavin  0.10 
Sodium chloride  6800.00 Thiamine x HCl  1.00 
Sodium dihydrogen phosphate x H2O 140.00 NaHCO3  2,200.00 
D (+)-Glucose  1000.00 
Phenol red  10.00 
L-Arginine x HCl  126.00 
L-Cystine  24.00 
L-Glutamine  0.0 
L-Histidine x HCl x H2O  42.00 
L-Isoleucine  52.00 
L-Leucine  52.00 
L-Lysine x HCl  72.50 
L-Methionine  15.00 
L-Phenylalanine  32.00 
L-Threonine  48.00 
L-Tryptophan  10.00 
L-Tyrosine  36.00 
L-Valine 46.00 
D-Calcium pantothenate  1.00 
Choline chloride  1.00 
Folic acid  1.00 
myo-Inositol 2.00 
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b. Appendix 2 
Table 1. The relative hydrophobicity of all CD002 isolates. 
UK 2007-8 Relative Hydrophobicity (RH) % 
160 26.7 
161 8.9 
162 35.4 
163 18.9 
165 52.6 
166 21.3 
167 57.4 
168 16.5 
169 48.7 
170 31.5 
171 76.9 
172 67.8 
173 26.3 
174 31.0 
Mean 37.1 
UK 2011-13 Relative Hydrophobicity (RH) % 
39 59.9 
40 63.7 
53 48.6 
54 52.7 
66 63.6 
68 51.0 
71 53.3 
144 30.7 
145 71.4 
146 53.1 
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147 68.3 
148 67.1 
150 56.6 
151 43.9 
164 47.9 
154 68.8 
156 48.2 
157 83.6 
158 51.7 
159 60.9 
Mean 57.3 
Non- UK 2011-12 Relative Hydrophobicity (RH) % 
1 23.9 
4 52.5 
6 47.5 
126 64.1 
127 56.3 
128 40.2 
129 61.1 
130 62.4 
131 60.6 
132 55.6 
133 79.9 
135 72.4 
136 63.3 
137 2.2 
138 22.9 
139 152.0 
140 56.4 
141 38.9 
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142 22.6 
143 26.0 
155 17.2 
Mean 51.3 
 
